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This thesis examines the classification of death, and the use of probiotics to reduce 
and prevent infection-related mortality in children diagnosed with cancers. It comprises 
of three main parts. 
The first part describes a study that validated a consensus-based definition of 
treatment-related mortality (TRM) and cause-of-death attribution system. This took 
place in a single institution in Leeds, the UK outside the centre it was initially developed 
(Toronto, Canada). Two consultants and two clinical research associates 
independently classified deaths as TRM or “not treatment-related” according to an 
algorithm. When TRM occurred, reviewers applied the cause-of-death attribution 
system, and inter-relater reliability was then assessed. This study demonstrated that 
the classification and cause of death attribution systems can be implemented in 
different health care settings, but that further research is required for patients receiving 
palliative care. 
The second part of this thesis describes a systematic review and meta-analysis that 
investigated the efficacy and safety of probiotics in people with cancer. Probiotics 
appear safe to deliver and may reduce the incidence of diarrhoea and duration of fever, 
but, heterogeneity, unclear bias, and a lack of paediatric participants demonstrated 
uncertainty in these findings. Findings from this systematic review were used to 
develop a randomised-controlled feasibility study. 
The third part reports the first study undertaken to evaluate the feasibility of 
undertaking an randomised-controlled trial (RCT) to investigate the use of probiotics 
(Symprove) to prevent or reduce mucositis and infection in children with cancers in the 
UK. Evaluation suggested that a RCT is feasible, but further considerations are needed 
to address significant barriers to recruitment and adherence to the capture of data that 
were identified. Findings from this study have been used to develop a parallel 
biological sub-study that can be undertaken in a future RCT. 
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1 Introduction 
1.1  Background 
Childhood cancers are relatively rare accounting for less than 1% of cancer cases 
diagnosed in the UK between 2011-2013 (1) and survival of children diagnosed with 
cancers have  increased during recent decades (2). Before the 1950s, most children 
diagnosed with cancers did not survive. Sixty years later, 5-year survival is reported to 
be approximately 80% in developed countries (3). 
This success is mostly credited to the development of treatment protocols which have 
progressed to include multi-modal and combination therapies, treatment stratification 
according to prognostic factors, and improved supportive care strategies. Recently, 
personalised interventions developed to target tumour biology have also been shown to 
improve survival in malignant conditions further. For example, imatinib a tyrosine 
kinase enzyme inhibitor (TKI) is now used to target the PCR-ABL translocation 
mutation between chromosomes 9 and 22 in Philadelphia positive chronic myeloid 
leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Prior to the use of TKIs, 
patient with these specific mutations received combination chemotherapy regimens 
which achieved a complete response rate of 45-90% with few long term survivors (4). 
However, a trial in children with good-risk Philadelphia ALL reported that 4-year overall 
survival was 75 % (95% confidence interval (CI) 61%–84·9%) for those receiving 
imatinib and 56% (95% CI 36%–72%) for those who did not receive imatinib (p=0·06) 
(5). Because of these findings, children with Philadelphia positive ALL now have the 
option of receiving imatinib as part of first-line treatment. 
However, despite the improvement of survival rates, it is estimated that 20 % of 
children diagnosed with cancers die (6). Between 2015 and 2017, 236 children died 
from cancers in the UK alone (7, 8) and it is reported as the second most cause of 
death of children in developed countries (9). An estimated 80,000 children worldwide 
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 Lack of improvement in anti-cancer treatment efficacy. Several tumour types 
are disproportionately unaffected by the development of modern medicine. For 
example, diffuse intrinsic pontine gliomas (DIPGs) still have dismal outcomes: 
1-year overall survival of less than 40% (10). Sadly, this has not improved 
during recent decades. 
 Toxicity from treatments utilised. Despite improved supportive care strategies, 
toxicity from treatment is still a significant cause of mortality.  
 
Identifying the cause of death in children with cancer is vital in enabling the analysis of 
existing data while directing future research appropriately for different cancers. 
Unfortunately, there are no universally validated methods to distinguish deaths caused 
directly by disease from deaths which occur due to toxicities. For cancers with poor 
survival, outcomes may require research to focus on curative strategies whilst cancers 
with good survival outcomes, but have a significant proportion of deaths from toxicity of 
interventions may require greater focus on supportive care interventions.  
Death not directly due to cancer has been termed “treatment-related mortality” (TRM) 
and causes include infection, bleeding, and organ dysfunction (11). Infection is 
recognised as a leading cause of morbidity in TRM and poses a significant risk in 
patients diagnosed with malignant haematological conditions (16). 
 Therefore, the research undertaken for this thesis will be addressed in two parts: 
 The first part will focus on how the reporting of cause of death in children 
diagnosed with cancer can be improved to enhance current interventions and 
direct future research.  
 The second part of this thesis will research a novel intervention which could be 
used to reduce infection-related mortality (IRM) a significant cause of cancer 
deaths that are not related to the disease. 
1.2 Classification of death 
1.2.1 The diagnosis and management of childhood cancers 
The management of cancers involves a multi-disciplinary team (MDT) approach  
including haematologists, oncologists, surgeons and other allied health-care 
professionals. 
Types of management can be broadly grouped into 2 components: 
 Treatment directed at cancer (with or without curative intent), which may include 
the use of surgery, chemotherapy, immunotherapy and radiotherapy  
- 17 - 
 Treatments to support patients through interventions, including the 
management of toxicities, nutritional, psychological, and spiritual support. 
Most patients are treated with curative intent, despite a predicted ‘poor’ outcome. For 
example, only 20% of children diagnosed with a metastatic rhabdomyosarcoma will 
survive longer than 5 years (12). Oncologists typically commence potentially curative 
treatment knowing that 80% of children treated will not survive.  
Sometimes, a decision to proceed with non-curative treatment occurs at the time of 
diagnosis. For example, only 40% of children diagnosed with a diffuse intrinsic pontine 
glioma (DIPG) of the brain stem will survive longer than one year, and only 10% 
survive longer than 3 years (13). Patients with this diagnosis receive 6 weeks of 
radiotherapy. This treatment helps relieve symptoms and may prolong survival but will 
not cure the child.  
Other non-curative treatments may involve the use of certain chemotherapies. For 
example, low-dose oral etoposide may be delivered with the aim of reducing symptoms 
and prolonging and improving quality of life in children with relapsed sarcoma (14). 
All children diagnosed with cancer will require interventions to manage complications of 
therapies delivered (known as supportive care). Management may involve preventative 
strategies (e.g. the delivery of co-trimoxazole in immunosuppressed children diagnosed 
with ALL to prevent Pneumocystis jiroveci), interventional strategies (e.g. the use of 
platelets for a patient who has developed thrombocytopenia as a direct consequence of 
bone marrow suppression caused by chemotherapy), or treatment for long term effects 
(for example psychological therapy in a young adult who received cancer treatment as 
a child). Other supportive care interventions may include:  
 Management of oncological emergencies: e.g. treating a child who has 
developed tumour lysis syndrome following a diagnosis of ALL, 
 Care of central venous access devices,  
 Management of infiltration and extravasation: e.g. chemotherapy accidentally 
delivered to subcutaneous tissue due to a faulty central venous catheter, 
 Nutritional intervention: for example, delivery of enteral feeds via a nasogastric 
tube for excessive weight loss, 
 Management of mucositis: e.g. delivery of pain relief for oral mucositis (damage 
to the mucosal barrier of the gastrointestinal system), 
 Management of nausea and vomiting: e.g. use of antiemetics to prevent 
nausea and vomiting when delivering highly emetogenic chemotherapy drugs,  
- 18 - 
 Management of fluids and electrolytes: e.g. delivery of potassium supplements 
to treat hypokalaemia resulting from the development of chemotherapy-induced 
diarrhoea, 
 Management of late effects: e.g. endocrine support following cranial 
radiotherapy, 
 Social and financial support. 
Curative strategies and supportive care implemented has resulted in improved survival 
(15). Further improvements may come from focussing on why children with cancer die; 
understanding which deaths are due to a failure of the anti-cancer therapy, and which 
are from the toxicities of therapy. 
1.2.2 Causes of death in children diagnosed with cancers 
The second most common cause of death in children globally, is cancer (13). Two 
hundred and fifty-seven children died of cancers in the UK between 2012-2014. This 
accounted for 23 cancer deaths per million children under the age of 14 (15). Twenty-
five  per cent of  all cancers classified as CNS tumours were diagnosed in children and 
contributed to 35% of deaths by the end of 2016, whilst conversely, 31% of children 
were diagnosed with leukaemias, and these accounted for 23% of deaths (16). Three 
per cent of deaths in children diagnosed with CNS tumours had infection listed as one 
of the causes of deaths whilst twenty-seven per cent of children who died from 
leukaemias had infection listed as one of the causes of death. The UKALL2003 trial 
which occurred between 2003 and 2011 reported 249 deaths, of which 75 were due to 
infection-related mortality (IRM) (17). These findings highlight the burden of infection-
related mortality particularly in malignant haematological conditions (16) 
1.2.3 Classification of death 
The increasing success of cancer-directed interventions due to increasing intensity is 
associated with a higher number of deaths due to toxicities arising from or 
complications of the therapies delivered (18). As previously described, death due to 
cancer is termed ‘disease-related’ or ‘disease-progression’. Death not directly due to 
cancer has been termed ‘treatment-related mortality’ (TRM). Causes of TRM deaths 
include infection, bleeding, and organ dysfunction (11). Because strategies are 
required to address disease-related and TRM differently, it is incumbent to attribute the 
cause of death correctly. 
1.2.3.1 Case study: Disease-progression  
An 8-year child diagnosed with a diffuse intrinsic pontine glioma receives 6 weeks of 
conventional radiotherapy. Whilst this child initially appears to improve, after a few 
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months, their initial presenting symptoms worsen. The child becomes increasingly 
drowsy and unresponsive. Because of tumour progression and its impact on the brain 
stem, the child subsequently dies. 
1.2.3.2 Case study: TRM 
An 4-year old child  diagnosed with B-cell ALL has commenced induction therapy. This 
includes the delivery of dexamethasone, intrathecal methotrexate, vincristine and 
asparaginase. A bone marrow aspirate performed 8 days after the start of treatment 
demonstrates an excellent response to treatment with no evidence of disease. On day 
15 of induction therapy, the child becomes febrile. A full blood count reveals the child is 
neutropenic. Despite the delivery of intravenous antibiotics, the child develops septic 
shock and subsequently dies.  
The delivery of dexamethasone in combination with vincristine, asparaginase and 
intrathecal methotrexate resulted in bone marrow suppression exposing the child to 
overwhelming infection. This, alongside other factors, including initial bone marrow 
suppression due to disease, contributed to the cause of death; this death would be 
classified as TRM. 
1.2.4 Reporting of TRM  
As previously highlighted, TRM is still a significant cause of death in children diagnosed 
with cancer. Infection, particularly in children diagnosed with malignant haematological 
conditions, is thought to be one of the leading causes of TRM and is termed infection-
related mortality (IRM). 
However, despite this systematic reviews by Ethier et al, and Thai Tran et al (19, 20) 
highlighted a paucity of reporting of TRM. The study by Ethier et al reported that only 
6.3% of the included studies examined reported the definitions or incidence of TRM, 
whilst the study by Thai Tran et al reported that only 16% of 64 identified studies 
reported TRM.  These studies demonstrate how a lack of consistent reporting has 
made analysis and comparison of TRM and IRM difficult. Improving the harmonisation 
of definitions and recording of TRM will enable more reproducible reporting of causes 
of death as well as comparisons between trials.  
1.2.5 Justification for the identification of TRM and disease-progression 
In order to focus research efforts to improve survival further, knowing why children with 
cancer die; understanding where the deaths are through a failure of the anti-cancer 
therapy, and where they are from the toxicities of therapy, may allow us to direct 
research to the areas of highest need. 
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Diagnostic groups identifying disease-progression as a significant cause of death 
would benefit from strategies and research focused on improving curative outcome. For 
example, a study undertaken by Loeffan et al reported that out of 267 patients 
diagnosed with brain tumours 2.1% had died from TRM whilst 28.8% had died from 
disease-progression.  This study highlights how pertinent it is to focus research on 
curative intent rather than on supportive care strategies for those diagnosed with CNS 
tumours (21). 
Conversely, conditions identifying TRM as a significant cause of death would require 
strategies and research that would enable improved supportive care. For example, 
TRM is a significant cause of death in children with standard-risk ALL, despite its better 
overall survival (22). A significant number of TRM deaths identified are recognised as 
IRM. This highlights the need to focus on research and strategies on improving 
supportive care (for example, preventing infections). 
To improve survival and reduce TRM and IRM in children with cancer the review of the 
literature undertaken for this thesis has highlighted the need for a uniform definition of 
TRM and classification of death in children with cancer which could be initially applied 
in the UK and high-income countries. A new classification system was developed and 
validated by Alexander et al in 2015 (23) in Toronto, Canada.  However, this system 
had not been validated outside the centre it was developed. 
1.3 Infection-related mortality 
1.3.1 Infection, mucositis and probiotics 
As previously introduced infection is a well-recognised cause of treatment-related 
mortality that occurs as a direct consequence of interventions delivered. The 
relationship of gastrointestinal mucositis, the breakdown and inflammation of the 
gastrointestinal lining is also known, but there is a lack of strategies to prevent infection 
that may develop from mucositis. 
This section will, therefore, introduce and explore the relationship between infection 
mucositis and the gastrointestinal microbiome. It will then introduce the use of 
probiotics. Probiotics have previously been investigated in various paediatric conditions 
affecting the gastrointestinal system, but there is a lack of research investigating its use 
in children with cancer. The final part of this section then presents and justifies the 
need to investigate the use of probiotics in cancer therapy as a novel intervention to 
prevent and reduce mucositis and infections. 
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1.3.2 Infection 
Infection is a leading cause of morbidity in TRM and poses a significant risk in patients 
diagnosed with malignant haematological conditions (16). Bone marrow suppression 
and damage to the mucosal barrier of the gastrointestinal system may occur following 
delivery of chemotherapy, immunotherapy or radiotherapy, and may also occur in bone 
marrow disease (17), affecting the child’s ability to fight infection.  
The UKALL 2003 trial reported 117 TRM deaths out of 3126 enrolled patients. Of these 
deaths, 64.1% were attributed to infection, constituting 2.4% of all included patients 
(18). In the USA, 63 (6.9%) out of 901 enrolled patients on the BFM-93 and AML-BFM 
98 USA trials died of infection (16). This significant burden of death prompted the 
National Institute for Health and Care Excellence (NICE) to create national guidelines 
on the management of febrile neutropenia (19). Key recommendations include delivery 
of a beta-lactam monotherapy (e.g. piperacillin/tazobactam) within one hour of 
presenting with a temperature >38oC and confirmed or suspected neutrophil count of 
less than 0.5 x109/L. Emerging concerns regarding the use of antibiotics and evolving 
microbial resistances are resulting in considerations of other preventative and 
treatment strategies and have, therefore prompting further exploration. 
1.3.3 Mucositis 
Mucositis is the inflammation and ulceration of the gastrointestinal mucosal lining that 
can occur in children diagnosed with cancer. It may be caused by radiotherapy or 
cytotoxic agents that affect DNA synthesis (particularly S-phase specific agents 
including cytarabine, methotrexate, actinomycin D, cisplatin, doxorubicin, daunorubicin, 
etoposide and mitoxantrone) (24). 
Mucositis can occur in any part of the gastrointestinal system from the mouth to the 
anus. Symptoms range from mild erythema to widespread ulceration. Development of 
mucositis can, therefore, cause pain, nausea, malabsorption, malnutrition, diarrhoea, 
and increased risk of local and systemic infections (25, 26). 
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1) Radiotherapy or cytotoxic exposure to the mucosal lining resulting in DNA 
damage and release of free radicals. 
2) Activation of transcription factors, which results in the upregulation of 
proinflammatory cytokines causing mucosal destruction. 
3) Signal amplification, which may exacerbate or prolong mucosal injury. 
4) Ulceration.  
5) Healing and gradual restoration of the flora (27).  
The gold standard for the diagnosis of mucositis is by biopsy of the gastrointestinal 
mucosal lining. However, children typically require an endoscopy under general 
anaesthesia for this investigation, which is associated with significant risk, mainly as 
children are immunosuppressed and susceptible to complications, including severe 
infections and bleeding. Therefore, children with suspected mucositis are diagnosed 
clinically and graded according to the severity of reported symptoms using validated 
assessment scales such as the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) (28) and the WHO guidelines for adverse 
events reporting (29, 30) summarised in table 1. 
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Table 1: Summary of sources and how mucositis is graded 0 (no symptoms) to grade 5 (death related to mucositis toxicity
Name of scale and source  Grade 0 
(None) 
Grade 1 (Mild) Grade 2 (Moderate) Grade 3 
(Severe) 
Grade 4 (Life 
threatening) 
Grade 5 (Death) 
Mucositis scale, 
CTCAE version  v5.0 (31) 
- Asymptomatic or 
mild  symptoms; 
intervention not 
indicated 
Moderate pain; not 
interfering with oral 










Death related to toxicity 
Oral Mucositis Scale, 
World Health Organization 
(32) 
None Oral soreness 
and erythema 
Oral erythema and 
ulcers: solid diet 
tolerated 
Oral ulcers; 




Acute Radiation Morbidity 
Scoring Criteria,  
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1.3.4 The relationship between mucositis and infection  
The relationship between mucositis and febrile neutropenia is recognised, and the term 
‘febrile mucositis’ is increasingly used (34). Patients with mucositis are believed to be 
most vulnerable to bacterial translocation from the gastrointestinal tract during stage 4 
of the Sonis hypothesis, following damage to the epithelial lining of the mucosa and 
inflammatory amplification (35). 
Studies have demonstrated the relationship between mucositis and febrile neutropenia 
(36). Mucosal damage which can occur following treatment with certain drugs (e.g. 
methotrexate),acts as a portal for the pathogen to enter the body. This, alongside 
neutropenia and immunosuppression, leaves the child in a particularly vulnerable state 
and at an increased risk of developing bacteraemia and sepsis. A study of adult 
patients diagnosed with multiple myeloma or non-Hodgkin’s lymphoma demonstrated a 
higher incidence of fever with severe mucositis when compared to those with less 
severe or no mucositis (68% vs 47%, difference 21%, p=0.004) (26). This relationship 
has consequently resulted in the term ‘febrile mucositis’ to reflect the different causes 
of fever in mucositis is now being used (25). However, studies investigating mucositis 
and infection in paediatric cancer patients are limited. A review of guidelines 
investigating the management of oral mucositis in children undergoing stem cell 
transplantation highlighted the epidemiology of mucositis is poorly understood, and that 
further observational studies and consensus-based approaches are required to 
understand and to develop appropriate risk stratification tools. It also stated further 
studies are required to investigate preventative measures for the development of 
mucositis (21).  
1.4 The prevention and management of mucositis 
Management of mucositis involves treatment once symptoms have developed. This 
includes the use of analgesia, loperamide to reduce diarrhoea, and delivery of nutrition 
using both enteral and parental routes.  
Currently, there are no widespread preventative interventions for mucositis. 
Therapeutic strategies to manage mucositis include supportive strategies previously 
described alongside the delivery of antibiotics for potential severe infection.  
Research into strategies to prevent febrile mucositis has been undertaken to 
investigate the use of probiotics to prevent or reduce mucositis in people with cancer. 
(31). 
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1.4.1 Probiotics  
Probiotics according to the World Health Organisation and United Nations Food and 
Agriculture Organization (FAO) are defined as “live micro-organisms which, when 
administered in adequate amounts, confer a health benefit on the host” (37). The most 
common strains used in probiotics belong to the genera Lactococcus and 
bifidobacterium (38). Health benefits attributed to probiotics include improved 
gastrointestinal flora, reduction in serum cholesterol, prevention of cancer, and reduced 
incidence of irritable bowel diarrhoeas (39). 
Systematic reviews and meta-analyses have demonstrated potential benefits of the use 
of probiotics in a range of conditions. A review by Zhang et al (40) suggested 
administering probiotics prenatally to pregnant mothers and postnatally to children 
could reduce the risk of atopy (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.57-
0.89). A review by Aceti et al (41) states probiotics have an overall preventative effect 
for necrotizing enterocolitis (NEC) in preterm infants. They demonstrated probiotics 
prevented NEC in very-low-birth infants (RR 0.47, 95 % CI 0.37-0.62). There have 
been numerous systematic reviews published investigating the use of probiotics for 
gastrointestinal symptoms. A Cochrane systematic review by Goldenberg et al (42) 
concluded there was moderate-quality evidence suggesting probiotics confer a 
protective effect in preventing antibiotic-associated diarrhoea (AAD) in children (RR 
0.46, 95 CI 035-0.61). Nevertheless, they noted the reporting of serious adverse events 
(SAE) in debilitated or immune-compromised children with underlying risk factors, 
including the development of probiotic associated infections, particularly from central 
venous catheter use. They recommended probiotic use should be avoided in paediatric 
populations at risk of adverse events. Another review by Szajewska and Kolodiej (43) 
suggested the probiotic Lactobacillus rhamnosus GG reduced the risk of AAD in adult 
and paediatric patients (RR 0.49, 95% CI 0.29-0.83). However, subgroup analysis 
revealed a risk reduction in only paediatric participants (RR 0.48, 95% CI 0.26-0.89). 
For adults, risk reduction occurred only in those receiving antibiotics as part of their 
Helicobacter pylori eradication therapy (RR 0.26, 95% CI 0.11-0.59). However, the 
quality of the included studies was recorded as moderate to low.  
Gastrointestinal symptoms can occur in cancer patients receiving treatments. 
Chemotherapy and radiotherapy-induced diarrhoea is typically reported as an adverse 
event and is associated with fluorouracil, capecitabine, and irinotecan-based cancer 
regimes. It is estimated 20-45% of all chemotherapy patients experience severe 
diarrhoea (30). Radiotherapy is believed to potentially alter bacterial flora and affect the 
intestinal motility and vascular permeability of mucosal cells (44). Chemotherapy is 
thought to alter the composition of intestinal flora and therefore affect the metabolism of 
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intestinal enzymes vital for gut integrity. Changes to the gut flora may impact the gut 
defence barrier, immune function, and absorption of vital nutrients (45). Radiotherapy 
or chemotherapy-induced diarrhoea may interrupt or even stop treatment, impair the 
quality of life and prolong hospital stay of patients with cancer, potentially increasing 
health economic burdens too (46). 
There has been interest in the role of probiotics in chemotherapy and radiotherapy 
associated diarrhoea. A previous systematic review and meta-analysis investigating the 
efficacy and safety of use of probiotics in people with cancer by Redman et al was 
published in 2014 (47). It proposed probiotics may reduce the severity and frequency of 
diarrhoea in patients with cancer following a review of 11 randomised-controlled trials 
(RCTs). Meta-analysis of 4 RCTs investigating the frequency of CTC grade >2 
diarrhoea found that participants receiving probiotics showed a significant reduction in 
frequency when compared to the control group (OR 0.32, 95% confidence interval (CI) 
0.13-0.79), and this may also have been the case with grade > 3 diarrhoea (OR 0.72, 
95% CI 0.41-1.25). It suggested that in the probiotic groups soft/ semi-solid stools may 
occur more commonly (OR 0.46, 05% CI 0.04-5.64) and reduce the need for anti-
diarrhoeal medicine (OR 0.63, 95% CI 0.13-0.79). Safety analysis of 17 studies and 
1530 cancer patients revealed 105 adverse events (AE) in 756 people consuming 
probiotics and 145 AE in 774 people not consuming probiotics. Adverse events 
included bacteraemia/ fungaemias, infections, gastrointestinal symptoms, high blood 
pressure, and raised intracranial pressure. Five case reports of the 756 cases 
describing the consumption of probiotics reported bacteraemia/ fungaemia/ blood 
culture growth. Whilst these findings are encouraging it also highlights the need to re-
assess the safety of probiotics in people with cancer. 
Because probiotics contain bacteria which are believed to modify the gastrointestinal 
microbiome its relationship with the human microbiome and cancer therapy is now 
explored further. 
1.5 The Human Microbiome 
Humans are inhabited by a large number of microorganisms, and it is estimated that 
approximately 37 trillion cells inhabit the human microbiome. The ratio of microbial to 
human cells is reported to be 3:1 (48). 
Microorganisms present in the human microbiome include bacteria, viruses, fungi and 
protists. Microorganisms residing within the microbiome have different functions (49). 
The human microbiome incorporates all microorganisms residing within or on any 
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human tissue or biofluid such as the skin, gastrointestinal system, uterus, and seminal 
fluid.  
For the purpose of this thesis, the term ‘microbiome’ will refer to the gastrointestinal 
(gut) microbiome; and the gastrointestinal system will be the focus for the prevention 
and reduction of mucositis and infection. 
1.5.1  The microbiome in infancy and childhood 
Previously, it was hypothesised that the foetus is sterile, that colonisation of the 
microbiome occurs during delivery and birth, and that the mode of delivery (vaginal vs 
caesarian section) is a crucial modifiable factor impacting the development of the gut 
microbiome (50). However, recent studies have proposed that microorganisms colonise 
the amniotic fluid, umbilical blood cord and placenta, suggesting that colonisation of the 
infant occurs in utero (51, 52). 
It is believed the presence of a healthy microbiome in term infants in the absence of 
infection or inflammation supports the proposition that not only do microorganisms 
colonise the foetus prior to delivery but that they may also contribute to the 
physiological development of the healthy foetus (53, 54). 
During the first year of life, it was hypothesized that the gut microbiome changes from 
one  representing maternal influences in utero to one consistent with that found in 
adults (50),although how this takes place is not fully understood. Some studies have 
reported Bifidobacteria bacteria are the most prevalent organisms of the 
gastrointestinal microbiota in breast-fed infants (55, 56) whilst other studies report they 
are only present in a small proportion of infants (57). One study reported a smaller 
proportion of Bifidobacteria bacteria and a higher proportion of aerobic bacteria in the 
gastrointestinal microbiota of formula-fed infants compared to infants who were 
breastfed (58). Other studies reported no differences (59). 
An older study by Bezirtzoglou E. et al (60) proposed that at birth, the microbiota is 
typically aerobic and the most prevalent bacteria is Enterobacteriaceae phylum. Shortly 
after birth, the gastrointestinal microbiome becomes anaerobic, resulting in the growth 
of bacteria such as Bifidobacterium - thought to be the dominant bacterium genus in 
the first months of life. During weaning and introduction of solid food, a more adult-like 
microbiome develops between the ages of six months and one year, and the gut 
microbiome is subsequently dominated by Firmicutes and Bacteroidetes (60). 
Dysbiosis (the disruption of the microbiome) in infancy and childhood is believed to be 
associated with an increased risk of immunological diseases such as asthma, type 1 
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diabetes, and celiac disease and metabolic diseases, e.g. obesity and type 2 diabetes 
(50).  
Scientists have also been interested in the state of the microbiome before, during and 
following a cancer diagnosis. In recent years it has been proposed that changes to the 
microbiome can influence the development of toxicity (i.e. infection) and response to 
interventions (61). 
1.5.2 The microbiome and its impact on cancer therapy 
The term pharmacomicrobiomics is used to describe how the microbiota can affect 
drug metabolism and toxicity. Pharmacomicrobiomics is believed to determine the 
toxicity versus the efficacy of chemotherapy in different individuals (53). 
A ‘balanced’ microbiome is believed to enhance therapeutic effects and reduce toxicity 
by manipulating how an individual responds to chemotherapy regimens and is based 
on an evaluation of the individual’s microbiome (62). 
It is believed the gut microbiota impacts an individual’s response to chemotherapy 
through its relationship with the immune system (63). The microbiota is thought to 
contribute to the metabolism of chemotherapy and production of toxic metabolites, 
therefore altering the microenvironment and indirectly impacting how an individual 
metabolises chemotherapy. One study proposed the bacterial metabolism of bacterial 
vitamin B6, B9, and ribonucleotide can strengthen or weaken the effects of the 
chemotherapy drug 5-fluorouracil (5-FU) (64). A further study proposed disruption of 
bacterial deoxynucleotide pools can amplify 5-FU-induced autophagy and apoptosis 
(65). 
The gut microbiota is impacted by multiple factors during chemotherapy. This includes 
diet, surgical intervention, supportive care interventions (i.e. antibiotics), and 
chemotherapy. A negative impact can result in dysbiosis, which can impair the 
symbiotic relationship of the microbiota and the individual, causing adverse side effects 
(i.e. diarrhoea) and thereby weakening the efficacy of the chemotherapeutic 
intervention (66).  
The microbiota can also influence the host’s response to chemotherapy through 
modulation of the immune system. It is believed the interaction of the adaptive and 
innate immune system and the gut microbiota can regulate immunomodulation (66). 
Chemotherapy is thought to cause bacterial translocation through damage to the 
gastrointestinal mucosal epithelium, which causes systemic infections and exposure to 
pathogens and leads to priming of the adaptive immune system, thereby impacting how 
an individual responds to chemotherapy (67, 68). 
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 It has also been proposed bacterial translocation and T-helper 17 cell activation may 
increase the efficacy of cyclophosphamide in mice with a ‘healthy’ gut microbiota when 
compared to mice raised in a sterile environment (69). Mice with depletion of gram-
positive bacteria (i.e. commensal bacteria) due to vancomycin were found to have a 
reduced therapeutic response to cyclophosphamide when compared to the control 
group [(70). Intraluminal myeloid cell activation is thought to enhance the action of 
oxaliplatin (71). However, the impact of the human gut microbiota on 
cyclophosphamide has not been investigated. 
A study by Zieglar et al 2019 (72) evaluated the impact of a prophylactic antibiotic 
(levofloxacin) to prevent febrile neutropenia when compared to broad-spectrum beta-
lactam (BSBL) antibiotics on the gut microbiome in patients with haematological 
malignancies (72). In sixty patients the gut microbiome of patients with BSBL exposure 
had significantly reduced diversity when compared to those without (median, 
interquartile range (IQR), 3.28 [1.73 to 3.71] vs 3.73 [3.14 to 4.31]; p = 0.01). Patients 
receiving levofloxacin were found to have increased gut microbiota diversity when 
compared to those not receiving it (median IQR, 3.83 [3.32 to 4.36] vs 3.32 [2.35 to 
4.02]; p = 0.03). Levofloxacin exposure was also associated with a trend towards a 
lower risk of the dominance of non-Bacteroidetes genera compared to those without 
levofloxacin exposure (3 [14%] vs 15 [38%]; p = 0.051). All this suggests gut 
microbiome interacts with chemotherapy delivered; supportive care strategy deliveries 
could lessen toxicity experienced by a patient in current and future courses of 
chemotherapy. There is a need to investigate how the gut microbiota could be 
manipulated to reduce infections and therefore, potentially reduce mortality (72). 
1.6 Summary 
In summary, the survival of children diagnosed with cancer has improved during recent 
decades. Earlier diagnoses, improved curative treatment and supportive care 
strategies have reduced overall mortality. However, death attributed to treatment-
related mortality, particularly infection-related mortality from increased toxicity of 
intensive treatment strategies, is still a significant concern.  
Treatment-related mortality (TRM) is poorly defined and reported in studies. Increased 
accuracy and reporting of TRM and infection-related mortality (IRM) will harmonise 
results, enabling better comparisons of clinical trials. 
 Despite the recognised relationship between mucositis and febrile neutropenia, there 
are no widely used preventative or therapeutic interventions for febrile mucositis. 
Exploration of possible strategies may result in reduced TRM due to infections. 
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This chapter has highlighted and presented two critical areas of research within this 
topic that require further exploration: 
1) The need for a uniform definition of TRM and disease-progression for the 
classification of death in children with cancer, applicable in high-income 
countries. 
2) The need for preventative and treatment strategies to reduce TRM in children 
diagnosed with cancers, potentially through the modification of the microbiome 
to reduce mucositis, bacterial translocation and bloodstream infection. 
As infection is a significant and leading cause of TRM, this thesis will focus on the 
reporting of classification of death and on the use of probiotics to reduce and prevent 
infection and mucositis in children with cancer. 
Therefore, the research undertaken for this PhD intends to:  
 Investigate and validate a newly developed definition of TRM through the use of 
a classification tool and cause of death attribution system  
 Investigate the use of probiotics in gastrointestinal mucositis by updating a 
systematic review and meta-analysis published in 2012 (47)  
 Use the findings of the review to conduct a feasibility study investigating the use 
of probiotics in children with cancer at who are at risk of or who have previously 
developed mucositis.  
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2 Validation of a classification system for treatment-related mortality in 
children with cancer 
2.1 Introduction 
The previous chapter introduced key concepts around childhood cancers, including 
mortality, classification of death, and how supportive care strategies can be used to 
prevent and reduce morbidity and mortality. It demonstrated that despite advances in 
medical research and in the management of patients, death is still a concerning and 
significant outcome in children diagnosed with cancer. Treatment-related mortality 
(TRM) is one major cause of death, but it is poorly defined and understood. 
As previously described varying definitions of TRM are used; identifying the cause of 
death (treatment-related mortality vs disease-progression) is necessary to identify 
where to focus research, strategies and interventions. Systematic reviews performed 
by Ethier MC et al (20) and Tran Thet al (19) identified significant heterogeneity in TRM 
definitions used in randomised therapeutic trials. This inspired a global collaboration 
led by Lillian Sung from Toronto in Canada to develop and validate a consensus-based 
classification tool for ascribing death as a TRM (figure 1) alongside further specifics of 
causes of death (table 2) (23). 
The tool is intended for use by clinical research assistants (CRA), a term used to 
describe non-medically qualified professionals who work with clinical trial data capture 
and entry. Etiological categories, e.g. infection or haemorrhage, were derived from the 
International Statistical Classification of Diseases and Related Health Problems (ICD)-
10 and Common Terminology Criteria for Adverse Events (CTCAE) v4.0. The 
classification system developed was validated by a retrospective case review of 30 
cancer patients who died between 2003 and 2012 by 2 independent blinded medical 
and CRA reviewers. Reliability for the TRM classification was deemed to be almost 
perfect between the medical and CRA reviewers who had been involved in developing 
the system (kappa=0.92, 95% confidence interval 0.78-1.00). 
An ideal classification system for treatment-related mortality should be applicable 
across different countries, treatment protocols, and health care settings. It is therefore 
essential to attempt to further validate the proposed classification tool and attribution 
system in a different treatment centre. Therefore, this chapter describes the efforts to 
further validate the consensus-based definition of treatment-related mortality and 
cause-of-death attribution system at Leeds Teaching Hospital, UK, with a group of 
individuals who were not involved in the development of the system. 
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This study aimed to evaluate the reliability of the newly developed consensus-based 
definition of TRM and explore the use of the cause-of-death attribution system at a 
regional paediatric oncology centre in Leeds, England. 
2.2 Methods  
This study was approved by the University of Leeds School of Medicine Ethics 
committee (Ref: MREC15-118) (appendix 1.1) and did not require NHS ethics 
approval. Eligible patient records were those of patients treated for malignancy or who 
underwent a haematopoietic stem cell transplant (HSCT) for a non-malignant diagnosis 
at Leeds Children’s Hospital (Leeds, UK) while aged 18 years or younger at diagnosis. 
Five cases were excluded as patients had died following relapse after the age of 18, or 
the medical records could not be located. All included patients died between 2014 and 
2016. Data from the clinical records  were anonymised and presented in a different 
random order for each assessor. Thirty patient records were included. Each set of 
records was presented twice, once with information from 2 weeks prior to death, once 
with the information extending back to 4 weeks prior to death, leading to a total of 60 
assessments being made. Four participants were identified to review the case notes; 
the two CRAs were a data analyst (AF) and research nurse (JT), and the two senior 
clinicians were a consultant paediatric oncologist and consultant paediatric 
haematologist (AG and SK).  
The study was undertaken on a single afternoon. After reading a participant information 
leaflet (appendix 1.2) and signing a consent form (appendix 1.3), participants received 
a 10-minute educational presentation explaining how to use the system, and how the 
study would be undertaken. The reviewers then independently classified each death 
according to the algorithm (fig. 1). For cases assessed as TRM, the reviewers were 
asked to apply the cause-of-death attribution system (table 2) to identify a primary 
cause of death. Following the completion of the assessments, a moderated group 
discussion was undertaken with notes recorded by two facilitators being used to 
supplement the themes of the discussion. 
Inter-relater reliability was assessed using the Kappa statistic (k). Criterion validity was 
assessed by assuming classification by the Consultants as the gold standard. Group 
consensus classification between and within the CRAs and Consultant group was 
evaluated using the Cohen’s kappa statistic, and across all individuals using the Fleiss’ 
kappa statistic. The strength of agreement was defined as slight (0.00-0.20), fair (0.21-
0.40), moderate (0.41-0.60), good (0.61-0.80) and very good (0.81-1.00) (73). A 
numerical code was used to combine agreement/disagreement between the individual 
consultants (TRM was recorded as “0”, and non-TRM outcomes were recorded as “1” 
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in Excel). If individual disagreement was noted when calculating inter-relater reliability 
between the CRAs and consultants, the outcome was recorded as “2”.  Based on the 
previously published study (23), we decided to include 30 cases for analysis.  A sample 
size of 27 deaths determined whether k was good (i.e., ≥0.61), with a power of 0.80, 
and two-sided α of 0.05, and assuming that treatment-related mortality accounted for 
20% of deaths (6). A further 30 cases would be reviewed if validity was inadequate 
(defined a priori as k<0.6). Calculation of the k statistic was completed using the R 
studio irr package, and bootstrap with 2000 iterations was used to calculate 95% 
confidence intervals (74). Comparison of the cause of death was qualitative, and to 
provide further insight reviewers participated in a discussion of the use of the algorithm 
and cause of death attribution system. 
2.2.1 Inter-relater reliability 
This study was designed to include reviewers of different job roles to demonstrate that 
the TRM classification tool can be used by individuals with varying clinical experience 
and skills. Analysis of results, therefore compared agreement of outcomes recorded 
using the algorithm in figure 1. Reliability of the study was dependent on the amount of 
‘disagreement’ or error that occurred. The extent of agreement between the reviewers 
was termed ‘interrater reliability’.  Inter-relater reliability of the CRAs and of the 
consultants was assessed using the Kappa statistic (k). This is a statistic that 
measures the degree of agreement between independent reviewers. It is more 
accurate and reliable than percentage agreement calculation of reviewers as it factors 
in the proportion of agreement which may occur due to chance.  
Calculation of the k statistic was completed using the R studio irr package and 
bootstrap method (see below) (74). The relevant software packages “lpsolve” and “irr” 
required to calculate k statistics were downloaded. Cohen’s kappa (for two raters) and 
Fleiss kappa (an adapted Cohen’s kappa for 3 or more raters) formulas were used to 
calculate the appropriate k statistic (73). The Fliess kappa also allows each rater to rate 
different items, while Cohen's kappa assumes that both raters are rating identical 
items. Therefore, the fliess kappa should be be used when raters responsible for rating 
one subject are not assumed to be the same as those responsible for rating another 
(75).  
As the irr package does not include methods to calculate confidence intervals, this had 
to be ‘bootstrapped’ into R studio.  
2.2.2  Bootstrapping  
“Statistical Bootstrapping” is a method used to calculate measures of estimation (for 
example, variance, confidence intervals and prediction errors) of a population from a 
- 34 - 
sample (76). As only one k statistic can be calculated from one study sample, a 
bootstrap sample is created using the sampling with replacement method (a result 
within the population can be used more than once). As an element can be repeated 
more than once it ensures that all unique outcomes are considered with resampling. 
This is then repeated a large number of times (typically 1000 or more), and an average 
k statistic is calculated for each bootstrap sample (also known as bootstrap estimates). 
Once a sufficient number of bootstrap estimates are calculated, the central limit 
theorem (77)  can be applied to assume that the bootstrap estimates are reflective of 
the population. The distribution of bootstrap estimates is then used to calculate the 
measure of variance or in this case, confidence intervals.  A code was imputed into R 
studio to resample the results of the study, and this was bootstrapped 2000 times to 
calculate the bootstrap estimates (95% confidence intervals).  
2.2.3  Qualitative analysis 
Comparison of the cause of death attribution system was qualitative. Following the 
review of the clinical records, reviewers then participated in a discussion of the use of 
the algorithm and cause of death attribution system. 
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Table 2: Cause-of-death attribution system. 
 
Cause-of-death Probable cause of death Possible cause of death 
Infection A.1 Clinically or 
radiographically documented 
infection with associated 
microbiologically documented 
organism 
1. Clinically or radiographically 
documented infection without 
associated microbiologically 
documented organism. 
Haemorrhage B.1 Acute symptomatic 
intracranial haemorrhage 
shown by imaging or 
pathology. 
B.2 Acute symptomatic 
pulmonary haemorrhage 
shown by imaging or 
pathology. 
B.3 Acute symptomatic 
bleeding resulting in 
hypotension, urgent 
transfusion or fluid bolus. 
2. Acute symptomatic 
pulmonary haemorrhage not 
shown by imaging or 
pathology 
Thrombosis C.1 Acute symptomatic 
intracranial thrombosis or 
embolism shown by imaging 
or pathology. 
C.2 Acute symptomatic 
pulmonary thrombosis or 
embolism shown by imaging 
or pathology. 
C.3 Acute symptomatic 
hepatic thrombosis or 
embolism shown by imaging 
or pathology. 
3. Acute symptomatic 
pulmonary thrombosis or 
embolism not shown by 
imaging or pathology. 
Cardiac D.1 Acute symptomatic 
arrhythmia excluding sinus 
tachycardia or bradycardia 
shown by ECG. 
D.2 Acute symptomatic 
cardiac dysfunction defined by 
ECG, cardiac imaging or 
pathology. 
4. Acute symptomatic 
arrhythmia excluding sinus 
tachycardia or bradycardia not 




E.1 Acute allergic reaction, 
anaphylaxis with symptomatic 
bronchospasm, oedema, 
angioedema, or hypotension. 
E.2 Worsening symptomatic 
graft versus host disease. 




syndrome or cytokine-release 
5. Stable graft-versus-host 
disease. 
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Cause-of-death Probable cause of death Possible cause of death 
syndrome. 
Metabolic F. Clinically diagnosed tumour 
lysis syndrome with cardiac 
arrhythmia, seizure, or 
creatinine concentrations 
greater than 3 times the ULN. 
 
CNS G.1 Acute symptomatic CNS 
necrosis shown by imaging or 
pathology 
G.2 Acute symptomatic 
encephalopathy shown by 
imaging or 
electroencephalography 
G.2 Acute symptomatic 
hydrocephalus or raised 
intracranial pressure shown 
by imaging, pathology, or 
measurement of intracranial 
pressure 
G.4 Seizure lasting at least 30 
minutes within 48 hours of 
death 
6.1 Acute symptomatic CNS 
necrosis not shown by 
imaging or pathology 
6.2 Acute symptomatic 
encephalopathy not shown by 
imaging or 
electroencephalography 
6.2 Acute symptomatic 
hydrocephalus or raised 
intracranial pressure not 
shown by imaging, pathology, 
or measurement of 
intracranial pressure 
6.4 Seizure between 5 and 30 
minutes within 48 hours of 
death 
Respiratory H. Acute symptomatic 
respiratory distress with 
ventilator support 
7. Acute symptomatic 
respiratory distress without 
ventilator support 
Gastrointestinal system I.1 Acute symptomatic bowel 
disease resulting in necrosis, 
obstruction or perforation 
shown by imaging or 
pathology 
I.2 Acute, clinically diagnosed 
hepatic dysfunction 
associated with conjugated 
bilirubin concentrations 
greater than 10 x ULN, 
ammonium concentrations 
greater than 2.5 x ULN, or 
international normalised 
greater than 2.5 times the 
ULN 
I.3 Acute, clinically diagnosed 
pancreatitis with 
haemorrhage, peritonitis, 
necrosis or haemodynamic 
instability (evidenced by 
hypotension, urgent 
transfusion, fluid bolus, or 
vasopressers 
 
8.1 Acute symptomatic bowel 
disease resulting in necrosis, 
obstruction or perforation not 
shown by imaging or 
pathology 
8.2 Acute, clinically diagnosed 
hepatic dysfunction 
associated with conjugated 
bilirubin concentrations 
greater than 1.5 and less than 
10 x ULN, ammonium 
concentrations greater than 
1.5 and less than 2.5 x ULN, 
or international normalised 
greater than 1.5 but less than 
2.5 times the ULN 
 
Renal system J. Acute kidney injury with 
dialysis or renal replacement 
therapy (planned or received) 
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Cause-of-death Probable cause of death Possible cause of death 







ULN: upper limit of normal   ECG: electrocardiography 
CNS: central nervous system   
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2.3  Results 
2.3.1 Summary of results 
Twenty patients included in the review were diagnosed with solid tumours, and 10 were 
diagnosed with malignant haematological conditions (summarised in table 5). Thirty-
three per cent of total deaths were classified as TRM. Ten per cent of patients 
diagnosed with solid tumours and 80% of patients diagnosed with malignant 
haematological conditions were classified as TRM. Reliability of classification was 
almost perfect between CRAs and consultants, with a k statistic of 0.86 (95% 
confidence interval 0.72-0.97). There was also almost perfect agreement between 
CRAs (k=0.96, 95% confidence interval 0.87-1.00) and consultants (k=0.85, 95% 
confidence interval 0.67-0.97), a summary of the results is shown in table 3. Table 6 
summarises the percentage agreement and bias index. The CRAs disagreed only in 
one case, whilst the consultants disagreed on 2 cases. There were 3 disagreements 
when results of CRAs were compared with the consultant’s decisions. This will be 
discussed further in this chapter. 
2.3.2 Demographics 
Age of identified patients ranged from less than 1 to 17 years, and 57% (17) were 
male. 67% (20) were diagnosed with solid tumours, and 33% (10) were diagnosed with 
malignant haematological conditions. Collectively, sarcomas were the most frequent 
solid tumour diagnosed (12 cases, 40% of total), followed by CNS tumours (9 cases, 
30% of total). 27% (8 cases) of these patients had presented with metastatic disease at 
diagnosis. All patients with malignant haematological conditions were diagnosed with 
leukaemia. 40% (12 cases) of patients had either received a transplant or presented 
with relapsed disease. A summary is enclosed in table 5. 
2.3.3 Classification of treatment-related mortality  
Ten deaths (33%) were identified as TRM by at least one reviewer. Three (15%) of 
patients diagnosed with solid tumours and 80% (8 cases) of patients diagnosed with 
malignant haematological conditions were classified as TRM. Reliability of classification 
was very good between CRAs and consultants, with a k statistic of 0.86 (95% 
confidence interval 0.72-0.97, with disagreement on 3 deaths). There was also very 
good agreement between CRAs (k=0.96, 95% confidence interval 0.87-1.00, 
disagreement on one record) and between consultants (k=0.85, 95% confidence 
interval 0.67-0.97, disagreement on two deaths) (tables 3).  
When the 2 and 4-week data were examined, there was a single difference between 
the assessments of each of the four assessors.  
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2.3.4 Cause of death attribution system  
Table 5 summaries the diagnoses of those whose deaths were classified as TRM and 
the causes according to the cause of death attribution summarised in table 2. 
All reviewers unanimously agreed on the cause of death of 3 cases (J, V, AA). 
Reviewers failed to agree on the primary cause of death in 7 cases (M, X, Y, Z, AB, AC 
and AD).  
Infection was the most common cause of death attributed in 6 of the 10 patients with 
treatment-related mortality (V, X, Y, Z, AA and AB). However, reviewers failed to 
unanimously agree on the primary cause in 4 of these cases (X,Y, Z and AB). 
The next most common cause of death attributed was haemorrhage (M, X, Y, AC), 
followed by immunomediated (J, AC, AD). Respiratory (Y,Z) and renal (AD) were other 
causes attributed.  
Reviewers failed to agree on the cause of death attribution when there were multiple 
factors which contributed to the death of a patient; one example involved a patient 
diagnosed with standard-risk B-cell ALL who developed febrile neutropenia and 
gastrointestinal haemorrhage (case X). Reviewers struggled to attribute the cause of 
death for case AD (cause of death on death certification was recorded as multi-organ 
failure), and both CRAs did not list a cause. 
2.3.5 Post-review discussion  
The reviewers agreed that the TRM algorithm was straightforward to use and that it 
would be beneficial to have a standardised tool and attribution system to use in trials.  
Questions highlighted in completing the review included how to address the patients 
who may die from TRM whilst receiving palliative care and particularly how the 
algorithm could be used as part of palliative care study. 
In one particular case, a patient (case D) was taking palliative etoposide following a 
diagnosis of relapsed ALL and developed a febrile illness. Another question raised was 
how to define the end of treatment in cancer patients. This question arose because a 
child (case V) who had completed treatment for standard risk AML died of 
overwhelming pneumococcal septicaemia 6 months after the end of treatment. It is 
important to note the child had not been re-vaccinated at this point. Suggestions of 3 
months after the end of treatment for standard patients, 12 months post-transplant for 
high-intensity therapies, or following revaccination were proposed. Another case the 
reviewers felt was important to highlight was how to classify the death of somebody 
who dies during surgical intervention. This question was raised following the case 
review of a patient (case M) who presented acutely with signs of raised intracranial 
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pressure and large mass noted on CT. The patient died on the operating table whilst 
receiving a surgical intervention.  
The case the reviewers found most challenging to categorise involved a patient who 
died of multi-organ failure following an HSCT (AD). Both CRAs, in particular, felt it was 
difficult to attribute one organ system to the cause of death, and both independently 
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Table 3: Summary of kappa statistic and 95% confidence intervals of independent reviewers, consultants, CRAs and between CRA and 











*calculated using the Fleiss kappa statistic (between 4 reviewers). 




Total k (95% 
confidence 
interval) 
4 weeks k (95% 
confidence 
interval) 
2 weeks k (95% 
confidence interval)  
Independent 
reviewers * 
0.92 (0.83-0.98) 0.91 (0.76-1.00) 0.92 (0.79-1.00) 
Consultants ** 0.85 (0.67-0.97) 0.85 (0.59-1.00) 0.84 (0.59-1.00) 
CRA ** 0.96 (0.87-1.00) 0.85 (0.59-1.00) 0.85 (0.60-1.00) 
CRA vs 
consultants** 
0.86 (0.72-0.97) 0.87 (0.66-1.00) 0.86 (0.67-1.00) 
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Table 4: Diagnosis of included patients results of classification by reviewers 
Case Diagnosis  CRA 1 CRA 2 Consultant 
1 
Consultant 2 
A Germ cell CNS tumour Not TRM Not TRM Not TRM Not TRM 
B Diffuse intrinsic pontine 
glioma (DIPG) 
Not TRM Not TRM Not TRM Not TRM 
C Thalamic astrocytoma Not TRM Not TRM Not TRM Not TRM 
D Relapsed B-cell ALL Not TRM Not TRM Not TRM Not TRM 
E Spinal cord 
glioblastoma 
multiforme  
Not TRM Not TRM Not TRM Not TRM 
F Metastatic Ewing’s 
sarcoma  
Not TRM Not TRM Not TRM Not TRM 
G Metastatic Ewing’s 
sarcoma 
Not TRM Not TRM Not TRM Not TRM 
H Metastatic 
rhabdomyosarcoma  
Not TRM Not TRM Not TRM Not TRM 
I Philadelphia positive 
ALL 
Not TRM Not TRM Not TRM Not TRM 
J AML prior to HSCT TRM TRM TRM TRM 
K Metastatic 
rhabdomyosarcoma  
Not TRM Not TRM Not TRM Not TRM 
L Soft tissue 
myoepithelial 
carcinoma  
Not TRM Not TRM Not TRM Not TRM 
M ATRT TRM TRM Not TRM TRM 
N Metastatic Ewing’s 
sarcoma 
Not TRM Not TRM Not TRM Not TRM 
O High risk 
neuroblastoma 
Not TRM Not TRM Not TRM Not TRM 
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P Osteosarcoma Not TRM Not TRM Not TRM Not TRM 
Q DIPG Not TRM Not TRM Not TRM Not TRM 
R Osteosarcoma Not TRM Not TRM Not TRM Not TRM 
S High risk 
neuroblastoma 
Not TRM Not TRM Not TRM Not TRM 
T Malignant melanoma 
of the CNS 
Not TRM Not TRM Not TRM Not TRM 
U Metastatic Ewing’s 
sarcoma 
Not TRM Not TRM Not TRM Not TRM 
V AML TRM TRM TRM TRM 
W Epithelial sarcoma  Not TRM Not TRM Not TRM Not TRM 
X ALL TRM TRM TRM TRM 
Y T-cell ALL TRM TRM TRM TRM 
Z B-cell ALL TRM TRM TRM TRM 
AA B-cell ALL TRM TRM TRM TRM 
AB Ependymoma  TRM TRM Not TRM TRM 
AC T-cell ALL TRM TRM TRM TRM 
AD B-cell ALL post HSCT TRM TRM TRM TRM 
   
Abbreviations 
CNS central nervous system   HSCT haematopoietic stem cell 
transplantation (HSCT) 
AML acute myeloid leukaemia 
DIPG diffuse intrinsic pontine glioma 
ALL acute lymphoblastic leukaemia   ATRT atypical teratoid rhabdoid tumour  
  
- 45 - 
Table 5: Summary of the cause of death attribution by reviewers for deaths classified as TRM.  
Bold font=probable causes of death 
  
Case Diagnosis  CRA 1 CRA 2 Consultant 1 Consultant 2 
J  AML prior to 
HSCT 
Immunomediated  Immunomediated  Immunomediated  Immunomediated  
M ATRT Acute symptomatic intracranial 
haemorrhage 
Acute symptomatic intracranial 
haemorrhage 
NR Acute symptomatic intracranial 
haemorrhage 
V AML Infection Infection Infection Infection 
X B-cell ALL  Acute symptomatic intracranial 
haemorrhage 
Acute symptomatic intracranial 
haemorrhage 
Infection Infection 
Y T-cell ALL Respiratory Infection Acute symptomatic 
intracranial haemorrhage 
Infection 
Z B-cell ALL Respiratory Infection Respiratory  Infection 
AA B-cell ALL Infection Infection Infection Infection 
AB Ependymoma  NR Infection NR Infection 
AC T-cell ALL Worsening symptomatic graft versus 
host disease. 
Worsening symptomatic graft 
versus host disease 
Worsening symptomatic 
graft versus host disease 
Acute symptomatic pulmonary 
haemorrhage 
AD B-cell ALL post 
HSCT 
“Unclear” “Difficult case” Worsening symptomatic 
graft versus host disease 
Acute kidney injury 
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Table 6: Results of percentage agreement and bias index of reviewers. 
 
 Result 
Percentage agreement 93.3% 
Bias index 0.03 
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2.4 Discussion  
To the best of our knowledge, this study is the first revalidation of the standardised 
definition of treatment-related mortality and cause of death attribution system for 
paediatric cancer patients (23). It demonstrates that the system is reliable and 
establishes its validity in an alternative centre and health care system with different 
treatment protocols.  It can be used after minimal training, with “very good” agreement 
between assessors irrespective of discipline (Fleiss kappa 0.92, 95% CI 0.83-0.98). 
The study confirms the observations of the development group and shows that 
information from two weeks prior to the death of a patient is sufficient to attribute death 
to either TRM or disease consistently.  
2.4.1 Strengths of the study  
Criterion validity and almost perfect agreement between CRAs and consultants were 
demonstrated using the k statistic. However, using a measure of inter-rater agreement 
as a measure of reliability should be done cautiously. The use of the k statistic with 
dichotomous outcomes (e.g. dead or alive) is more reliable when compared to the use 
of non-dichotomous outcomes which require finer discriminations and are subject to 
different interpretation, as was the case in this study. Reliability in cases which require 
more information can be improved with appropriate training. To increase the reliability 
of agreement in this study, a participation information leaflet (appendix 1.2) was 
produced along with a short presentation. Despite this attempt to increase reliability 
between reviewers, external factors can also influence decision making. This may 
include previous experience, level of clinical expertise, and interpretation of the training 
delivered. 
2.4.2 Agreement 
As previously discussed in the methods, use of the k statistic is believed to be more 
reliable than using percentage agreement, as the k statistic factors in the possibility of 
agreement occurring to chance (73). However, the presumed proportion of random 
agreement included in the analysis, assumptions about intra-rater independence, and 
other factors, may result in potential underestimation of agreement between reviewers. 
It is, therefore, useful to compare the results of the k statistic with the percentage 
agreement statistic. Whilst the percentage agreement statistic does not factor 
agreements occurring due to chance and may over-inflate the agreement; it is a useful 
statistic to use when raters have adequate knowledge and training and are less likely to 
guess decisions (78). The k statistic is useful when there is more likely to be confusion 
in decision making and therefore, potentially a more significant proportion of 
- 48 - 
agreements occurring due to chance. For this study, using both statistics gives greater 
credibility to the conclusions drawn.   
Other inter-reliability agreements which could have been used include the intraclass 
correlation coefficient, person r, the contingency coefficient, and Krippendorff’s alpha. 
However, the use of some of these agreement statistics may be difficult to interpret 
with non-exchangeable observers and may result in the extreme under or 
overestimation of inter-rater agreement (78). 
2.4.3 Limitations of the study 
Although consultants were considered gold-standard in this study, it was identified that 
even experienced clinicians might disagree on the cause of death when using the 
algorithm. Whilst the initial study [7] asked the consultants to discuss and resolve any 
differences in how each death was classified; this was not undertaken in this study as 
this was more reflective of how the classification tool would be used in a clinical setting. 
Consultants disagreed on the classification of death in two cases. This may have 
occurred due to the individual consultant’s clinical experience or previous contact with 
the patients concerned. Even though the cases were anonymised and randomised, the 
consultants may have recognised the patient due to their involvement in the delivery of 
clinical care. The differences identified highlights how the TRM classification tool would 
never have perfect agreement between reviewers irrespective of experience, or clinical 
and scientific knowledge. 
In this study, reviewers attributed death to one primary probable, or possible, cause. 
Whilst developing the study protocol, we decided to limit the number of causes of death 
for simplicity. However, reviewers found it challenging to identify only one cause of 
death, and to distinguish between probable and possible causes.   
Since the development of this study, a standard operating procedure TRM web-based 
tool has been published (https://www.sungresearch.com/trm-training-manual/) and 
includes working examples. Use of this tool when delivering the training package 
should help clarify how to use the cause-of-death attribution system and minimise 
misunderstanding. Currently, the web-based tool is available in English. Having the tool 
available in other languages could potentially reduce confusion and improve 
harmonisation across clinical trials. 
2.5 Other considerations  
The dichotomous definitions (TRM and cancer-deaths) and semantic interpretations of 
the classification (what type of deaths are included under each definition) have been 
previously explored. What these definitions do not identify is a third group of deaths 
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that can occur in cancer patients; deaths due to non-cancer causes (or ‘other natural’). 
During the participant discussion after the study, the participants highlighted the death 
of patient not included in the study. This particular patient had completed treatment for 
Hodgkin’s lymphoma and attended the clinic for a routine follow up 3 months later. The 
family was involved in a road traffic accident on the way home, and the patient 
subsequently died in hospital. Whilst such a cause of death is uncommon, it is still not 
appropriately addressed by the use of the terms TRM and cancer-deaths. Under the 
current classification, this death would have been defined as TRM death, which is 
misleading. This could be addressed in a number of ways; firstly, by clearly defining the 
end of treatment in cancer patients or by adding a third type of death - ‘other natural’. 
The occurrence of death due to natural causes, when compared to treatment-related 
deaths, will increase with time following the end of treatment. Not defining an end of 
treatment date when using the algorithm may contribute to over-inflation of deaths 
reported as TRM. The chosen definition would need to consider the probability of death 
occurring to natural causes or late effects of cancer therapies. Creating a third group 
could potentially reduce the over-reporting of TRM deaths and therefore increase the 
accuracy of the data. However, as previously discussed, this may complicate the use of 
the tool when implementing the system across the world in translation. 
Other limitations of the tool include incorrect classification due to inaccurate or 
incomplete information documented in the medical records or due to use of different 
types of records (for e.g. computer-based vs handwritten records). Currently, the tool 
can only be implemented in high-income and possibly middle-income countries due to 
reduced availability of interventions, medical care and due to issues with follow up.  
2.5.1  Cause of death attribution system 
During the discussion, reviewers stated they felt the cause of death attribution was 
easy to follow. However, reviewers failed to agree on the cause of death in 6 of the 10 
TRM episodes (X, Y, Z, AB, AC, AD) summarised in table 5. In 5 cases (X, Y, Z, AC, 
AD) death involved complications of multiple systems, and therefore reviewers were 
unable to agree on the primary cause of death. In 2 cases (M, AB) reviewers disagreed 
on the classification of death (TRM vs cancer-death). Case AD was felt to be a 
particularly difficult case for the reviewers, and both CRAs did not attribute a cause of 
death. Interpretation of the attribution system was felt to require more subjective 
interpretation when compared to the dichotomous decision making of the classification 
tool.  Discrepancies may be attributed to a number of external factors including 
previous experience, clinical expertise and interpretation of clinical documentation of 
the reviewers.  
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Although the tool was developed with the intention of widespread use by CRAs of 
varying levels and experience, it may require users to meet specific requirements of 
expertise or experience. This study showed discordance between consultants (deemed 
gold standard for criterion validity). In this study, the consultants disagreed in 5 cases 
(M, Y, Z, AB, AD), whilst CRAs disagreed on 3 cases (Y, Z, AB). Differences between 
the consultants may be attributed to their qualification (consultant haematologist and 
consultant oncologist), which may result in differing views of supportive care, or 
previous involvement with some patients. 
Reviewers’ understanding and interpretation of the cause of death attribution system 
could possibly be improved further by dedicating more time and expanding in greater 
detail on the use of the cause of death attribution system. Another possibility involves 
potentially refining the cause of death attribution system. This could include having the 
option of listing multiple causes of death (with or without ranking) or refining the current 
options. For example, rather than having ‘respiratory’ and ‘infection’ as 2 separate 
entities ‘respiratory infection’ could be listed as a subcategory. However, this would 
increase the information in the cause of death attribution table, potentially making it 
more challenging to navigate and translatable to different health-care settings and 
languages.  
2.5.2 Challenges and areas for future development  
Our study highlighted specific challenges with the system as it currently exists, both 
with the classification of TRM and the attribution of a specific cause of death. 
Fundamentally, this approach defines deaths as either ‘treatment-related’ or ‘cancer 
related’. This gives rise to a semantic challenge; “treatment-related mortality” implies 
that deaths that come under this term occur directly because of the therapies delivered. 
However, the classification system also classifies deaths occurring prior to the 
commencement of anti-cancer therapy, which are not directly attributable to cancer (for 
example, tumour lysis syndrome in high-count leukaemia) as cases of TRM.  This clash 
of language and “common sense” may confuse users of the classification tool, for 
example, case M in which a patient presented acutely with signs of raised intracranial 
pressure and died on the operating table.  
A more profound challenge to this system addressed the philosophical distinction 
between assigning deaths into one of two categories; cancer or treatment-related. 
There is a convincing argument that a third category of death should be attributable, 
“other non-cancer death”, for those who die of an event or illness external to their 
malignancy. This problem is particularly evident if the current system is to be used after 
the completion of treatment. For example, a patient dies as a passenger in an air traffic 
accident 4 years after treatment for a localised Wilms tumour. Under the current 
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system, this death would be classified as TRM, even though the death would be 
unrelated to the child’s cancer diagnosis. 
Conversely, it is also important to note how a diagnosis of cancer may be included in 
‘non-cancer deaths’. For example, a patient may commit suicide some years after the 
completion of treatment because of the psychological effects of their diagnosis or 
treatment. Any modification of the system would need to be sensitive to these potential 
issues.  
We have further identified the need to refine the approach to categorising cause of 
death in cancer patients receiving care without intent to cure. This is particularly 
important if the system is applied in ‘routine’ settings, assessing deaths in the palliative 
setting rather than in the original setting of use within a curative trial. Increasingly, 
individuals destined not to be cured are living for lengthier periods due to participation 
in clinical trials/studies. This group of patients currently have all deaths classified as 
“not treatment-related mortality” as clinicians would have either specified progressive 
disease or that cancer therapy has no curative intent. This algorithm may fail to identify 
a significant group of patients who may die of causes amenable to better supportive 
care whilst receiving palliative care. For example, a patient can die of overwhelming 
sepsis whilst receiving palliative etoposide for refractory neuroblastoma. This could be 
addressed by modifying the algorithm for this type of use. Another proposal includes 
using a separate classification tool for patients on palliative care trials (figure 2), 
although this should be further developed in conjunction with palliative care physicians 
and researchers. The counter-argument to this suggested change is the risk of adding 
complexity to a simple, effective tool which can be used by people of different skills 
from different health care settings globally. It would also have similar issues with 
interpretation as with the original algorithm. 
Reviewers failed to agree on a primary cause of death in 6 episodes and probable and 
possible causes in 4 cases. Differences in the cause of death allocated could be 
attributed to the reviewers’ previous experience, clinical expertise and interpretation of 
the clinical records, particularly in light of potential previous direct clinical involvement 
with the cases under review. Currently, the tool is intended for use by any CRA. 
However, it may require users to have a certain level of experience or clinical expertise, 
and agreement may be reduced amongst CRAs who are new to the role.  
Understanding and interpretation of the system as proposed for attribution of a specific 
mechanistic cause of death could potentially be improved by dedicating more time 
during the presentations and using the newly developed web-based training tool. 
Alternatively, the cause of death attribution system could be further refined.
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Figure 2: Proposed classification of TRM in children receiving non-curative 
therapy (NCT) only. 
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2.6 Conclusions 
This study has demonstrated the reproducibility and criterion validity of the TRM 
classification system. This supports the hypothesis that the classification system can 
be implemented quickly and effectively in different health care settings, thereby 
improving the consistency and accuracy of outcome reporting in clinical trials. The TRM 
classification system will be of immense value in the evaluation of deaths in the 
palliative setting. We propose the addition of a separate classification tool in patients 
on palliative trials. 
Criterion validity was further established using the newly developed classification of 
TRM, demonstrating almost perfect agreement between CRAs and consultants k= 0.86 
(95% CI 0.72-0.97) using a simple presentation and participation information leaflet. I 
believe the classification and cause of death attribution system could be implemented 
in different health care settings. This would help improve the consistency and accuracy 
of outcomes in clinical trials. Exploration for the use of the classification tool in patients 
receiving palliative intervention should be considered, with the possibility of refining the 
classification system for this group of patients.  
Reviewers did not agree on 6 of the causes of death attributed to TRM. This may have 
been due to external factors, including previous experience and clinical knowledge. 
However, reliability can be improved by refining the training delivered to improve 










- 54 - 
3 Systematic review and meta-analysis investigating the efficacy and safety of 
probiotics in people with cancer. 
So far, this thesis has introduced key concepts regarding childhood cancers, including 
mortality, classification of death, and how supportive care strategies can be used to 
prevent and reduce morbidity and mortality.  
The previous chapter reported on the validation of a classification system for treatment-
related mortality for children diagnosed with cancer. Infection as a cause of death was 
identified as the most common cause of mortality from TRM: 6 out of the 10 patients 
who died from deaths due to TRM were attributed to infection.  
Despite extensive research into the use of antibiotics, antiviral and antifungal 
supportive care strategies, infection-related mortality (IRM) is still a leading cause of 
TRM in children diagnosed with cancers. 
Recent evidence has explored the relationship between mucositis and febrile 
neutropenia and this thesis has reported how currently there is no standard 
preventative or therapeutic intervention for febrile mucositis.  
This, therefore led to the development of the next part of this thesis; exploring the use 
of probiotics as a novel strategy to reduce or prevent mucositis and infection in children 
with cancer. 
This chapter has investigated the use of probiotics in gastrointestinal mucositis by 
reporting a systematic review and meta-analysis undertaken to investigate the efficacy 
and safety of probiotics.  
3.1 Background 
Probiotics are defined as “live micro-organisms which, when administered in adequate 
amounts, confer a health benefit on the host” according to the World Health 
Organisation and United Nations Food and Agriculture Organization (FAO) (37). The 
most common strains belong to the genera Lactococcus and Bifidobacterium (38). 
Health benefits attributed to probiotics include the reduction of the severity of antibiotic-
associated diarrhoea in paediatric patients (42), necrotising enterocolitis in premature 
infants (79) and the incidence of radiation-induced diarrhoea (80) (81). 
Chemotherapy and radiotherapy-induced diarrhoea is a common adverse event. 
Radiotherapy is believed to potentially alter bacterial flora and affect the intestinal 
motility and vascular permeability of mucosal cells (44). Chemotherapy is thought to 
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alter the composition of intestinal flora and therefore affect the metabolism of intestinal 
enzymes vital for gut integrity. Changes to the gut flora may impact the gut defence 
barrier, immune function and absorption of vital nutrients (45). It is estimated that 20-
45% of all chemotherapy patients experience severe diarrhoea (30). Radiotherapy or 
chemotherapy-induced diarrhoea may interrupt or even stop treatment, impair the 
quality of life and prolong hospital stay of patients with cancer, also potentially 
increasing health economic burdens (46).  
There have been multiple studies investigating the role of probiotics in reducing 
chemotherapy and radiotherapy associated diarrhoea. A rigorous systematic review 
and meta-analysis investigating the efficacy and safety of use of probiotics in people 
with cancer by Redman et al were published in 2014 (47). It proposed that probiotics 
may reduce the severity and frequency of diarrhoea in patients with cancer following 
the review of 11 randomised-controlled trials (RCTs). A meta-analysis of 4 RCTs found 
that participants receiving probiotics, when compared to the control group, showed a 
significant reduction in the frequency of CTC grade ≥ 2diarrhoea ( odds ratio (OR) 0.32, 
95% confidence interval (CI) 0.13-0.79), and possibly grade ≥ 3 diarrhoea (OR 0.72, 
95% CI 0.41-1.25). It suggested that in the probiotic groups soft/semi-solid stools may 
occur more commonly (OR 0.46, 95% CI 0.04-5.64) and reduce the need for anti-
diarrhoeal medicine (OR 0.63, 95% CI 0.13-0.79). Between-study heterogeneity of 
results was noted. This was attributed to the different treatments, strain, doses and 
duration of probiotics alongside comorbidities, cancers and interventions delivered.  
Safety analysis of 17 studies and 1530 cancer patients revealed 105 adverse events 
(AE) in 756 people consuming probiotics and 145 AE in 774 people not consuming 
probiotics. Adverse events included bacteraemia/fungaemias, infections, 
gastrointestinal symptoms, high blood pressure and raised intracranial pressure. Five 
case reports of the 756 cases describing the consumption of probiotics reported 
bacteraemia/fungaemia/blood culture growth. The use of probiotics in 
immunosuppressed patients is one of the most concerning adverse outcomes and 
requires further investigation. At the time of completion of the review by Redman et al 
(47) 10 trials were identified as ongoing, and few studies included children.  
This review, therefore, aimed to update the systematic review and meta-analysis by 
Redman et al (47), to explore the previous heterogeneity and update the assessment 
of safety for the use for the use of probiotics in people with cancer. 
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3.2 An introduction to Systematic reviews 
A systematic review is a methodological overview of primary research that focuses on 
a research question. Evidence is selected, synthesized and appraised according to a 
pre-specified eligibility criterion with the intention of minimising bias and heterogeneity 
by using precise, systematic methods. There are different ways of undertaking a 
systematic review, including the Cochrane method (82) or the Centre of Reviews and 
Dissemination (CRD) (81). A comprehensive systematic search of databases should 
take place following the identification of a question. The quality of the included studies 
should be assessed using an objective assessment tool to assess methodological 
quality as recommended by CRD (81) and the high-quality standards of the Cochrane 
collaboration (103). The review may include a narrative analysis or a meta-analysis; a 
statistical technique used to combine results across the included studies. Reporting 
and dissemination should be undertaken using methods recommended by the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
(115). 
3.2.1 Why perform a systematic review? 
Health care professionals are overwhelmed with large volumes of data that are difficult 
to manage. A systematic review is an efficient method to integrate and synthesize data 
across populations and subgroups to provide results for evidence-based decision 
making. Meta-analysis can be used to increase statistical power and precision of 
estimates of results from individual studies. Pre-defined eligibility criteria reduce bias, 
whilst an assessment of methodological quality identifies inherent biases in the primary 
studies and therefore improves the accuracy of conclusions drawn by the review. 
3.2.2 Why perform this systematic review? 
The systematic review was undertaken by Redman et al in 2014 (47) identified 10 
ongoing clinical trials, and enough time had passed to undertake an update. A meta-
analysis with more pooled studies would increase the statistical power and accuracy of 
point estimates and identify potential adverse complication. In addition to this, further 
subgroup analysis could be used to identify potential risk factors for 
complications/infection. The findings from this review were then used to identify areas 
of research which require more focus.  
3.2.3 How to identify the evidence to be included in a systematic review 
Undertaking a comprehensive search to identify relevant studies is necessary to 
minimise bias in the review process. The search strategy should be transparent and 
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recorded in a way that enables it to be replicated and evaluated to ascertain the same 
findings. A variety of sources can be searched to identify relevant data. These include: 
 Searching electronic databases (e.g. PubMed and SCOPUS). 
 Identifying key studies from reference lists from relevant studies. 
 Searching relevant resources, key journals and conference proceedings. 
 Directly contacting research authors and experts. 
 Searching the references of included citations. 
Undertaking narrow searching can introduce bias into the review process as it may 
exclude relevant data that is not in that source. For example, limiting searches to the 
use of electronic databases can introduce bias as they typically only identify published 
journal articles. This can result in publication bias as this type of database is unlikely to 
highlight studies that have not been published. Therefore, more comprehensive 
searches are necessary to limit the impact of publication bias. This may include 
searches for reports, abstracts or papers in other databases which includes conference 
reports or the search of grey literature. 
Furthermore, limiting searches to certain languages can introduce language bias. Most 
journals in databases, such as MEDLINE and EMBASE, are only reported in 
English. Language bias can be overcome by including databases reporting journals 
from other languages.  However, despite these issues, there are no agreed 
requirements for what an acceptable number of databases is to search.  
3.2.4 Screening process 
Screening of identified titles and abstracts commences once the search has been 
completed. Using one reviewer to undertake this poses a significant risk of selection 
and information bias. Having two reviewers independently screen titles/abstracts of 
identified studies to confirm inclusion and exclusion according to the inclusion criteria 
will reduce bias and increase the relevant number of studies identified for use in a 
systematic review. Disagreements between the independent reviewers can be resolved 
through mutual discussion or referred to a third independent reviewer. 
3.2.5 Qualitative analysis 
It is essential to undertake a critical appraisal of included studies by exploring the 
reporting and methodological qualities of a study. This is because the quality of a study 
can impact findings. Trials deficient in reporting and methodological quality can impair 
the accuracy of conclusions drawn due to high risk of bias. For example, if qualitative 
analysis demonstrated that two of three RCTs included in pooled statistical analysis 
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were of poor methodological quality (for example poor study design/implementation), it 
can infer uncertainty on any conclusions (i.e. statistical significance) drawn. 
Using robust, validated tools specific for differing study designs ensures more 
objective, qualified assessment on findings. Examples of validated tools include The 
Cochrane Risk of Bias Assessment tool for RCTs (83), Risk of Bias in Non-randomised 
Studies of Interventions (ROBINS-I) for non-randomised studies (84) and the Loke 
method to assess the quality of studies investigating adverse effects (85). 
3.2.6 Quantitative analysis 
Systematic reviews may or may not include statistical analysis. These can be 
undertaken and reported in a variety of ways, such as findings reported from individual 
studies, pooled analysis from multiple studies (also known as a meta-analysis) or a 
pooled analysis of data from individual participants from multiple studies (also known 
as individual participant data). The systematic review protocol should report the 
strategy for data-synthesis a-priori to reduce reporting bias. 
3.2.7 Pooled analyses 
Pooled analysis of data increases the statistical power by increasing the total number 
of participants. This reduces random error, narrows confidence intervals (interval 
estimate that may include the true value for a population for a certain percentage, e.g. 
95%) and precision intervals (the range of which the point estimate will fall in future 
studies for a certain percentage, e.g. 95%). 
Meta-analyses are typically undertaken using two statistical models; fixed-effect and 
random-effect models. Fixed-effect models usually weight the results from each study 
according to the number of participants included and only factor variability of results 
reported between studies. Random-effect models adjust for between-study and within-
in study variability. Whilst both approaches are similar, some argue using a fixed-effect 
model enables small studies to influence the estimate, whilst using a random-effect 
model models between-study variability, thereby reporting a more accurate statistic. 
3.2.8 Heterogeneity  
Studies included in systematic review and meta-analysis will have some variability in 
study outcomes, and this is known as heterogeneity. Types of heterogeneity include 
clinical heterogeneity (variability in participants, interventions and outcomes), 
methodological diversity (variability in study methodology and risk of evaluation) and 
statistical heterogeneity (variability of intervention effects being evaluated).  
Variations between studies may result in differences in observed intervention effects 
because of random error or differences in studies. Heterogeneity can be explored by 
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visually inspecting a forest plot for the variability of effect reported between studies and 
poor overlap between confidence intervals suggests statistical heterogeneity. 
Calculating chi-squared can suggest whether heterogeneity occurred because of 
chance. The I-sq statistic defines the percentage of heterogeneity that can be attributed 
to between-study difference rather than chance. I-sq values of 30-60%, 50-90% and 
greater than 75% suggest there is moderate, substantial and considerable 
heterogeneity respectively. 
It is essential to identify statistical heterogeneity because reasons for variability 
between studies should be considered. Studies included in the pooled analysis with 
substantial differences can result in misleading meta-analysis results which can be 
overinflated. A subgroup meta-analysis using specific study characteristics can be 
undertaken to adjust for this. 
3.3 Methodology 
This review was undertaken followed a prespecified protocol registered on 
PROSPERO (the international register of systematic reviews): CRD 42016050252 
October 2016 (13).  
3.3.1 Aims 
This review aimed to update the Redman et al (47) systematic review and meta-
analysis safety analysis of the use of probiotics in people with cancer assessment. 
It investigated the quality of identified randomised controlled trials and analysed 
quantitative outcomes, including the occurrence of invasive infection, duration of 
diarrhoea, and length of hospital stay from identified studies. 
The review also investigated the safety of using probiotics in patients with cancer by 
investigating reported adverse events. 
3.3.2 Inclusion criteria 
Designs of studies eligible for efficacy analysis included randomised-controlled trials of 
people diagnosed with cancer who received probiotics as an intervention. Outcomes 
assessed included antibiotic-associated diarrhoea, gastrointestinal infection, mucositis 
or any adverse event. Non-randomised studies and case reports were also included 
within the safety analysis. 
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3.3.3 Identification of trials  
Database searches of MEDLINE, EMBASE, and Allied and Complementary Medicine 
(AMED) without language limitations were undertaken with the following search 
strategy: 
((cancer OR malignancy OR malignant OR oncology OR oncological OR transplant OR 
leukaemia tumour OR tumour OR chemotherapy OR radiotherapy) AND (probiotic OR 
lactobacillus OR saccharomyces)) AND (infection OR sepsis OR diarrhoea OR fungal)) 
A simplified search strategy was used for the following search engines:  the Cochrane 
Central Register of Controlled Trials, Literatura Latino-Americana e do Caribe em 
Ciências da Saúde, Database of Abstracts of Reviews of Effects, American Society of 
Clinical Oncology, International Society of Paediatric Oncology, Multinational 
Association of Supportive Care in Cancer, International Cancer Research Portfolio, 
National Cancer Institute Clinical Trials, National Cancer Research Institute, Current 
Controlled Trials and CenterWatch. 
3.3.4 Study selection 
Study selection and data extraction were conducted in 2 stages: 
 Two reviewers independently assessed the title and abstract of the studies for 
possible inclusion (H.H, M.R). Inclusion or exclusion was verified by assessing 
the full text of potentially included studies. 
Discrepancies between the raters were addressed, and those unresolved were referred 
to an independent assessor (R.P). 
 Data was extracted by a researcher using a standardised form (H.H) which was 
independently checked by a second person (M.R). When further information 
was required, the author of the paper was contacted. 
The study selection process and data extraction were piloted using a sample of 100 
papers in order to check that the correct papers would be identified, interpreted and 
analysed. The pilot study was used to refine the inclusion criteria to ensure it could be 
applied consistently, and that correct data were extracted.  
3.3.5 Risk of bias and quality assessment of included studies  
The Cochrane risk of bias tool was used to assess the risk of bias of included RCTs 
(83). 
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The Loke method was used to assess the quality of studies investigating adverse 
effects (85). Items were identified as “unclear risk of bias” when studies did not specify 
the relevant information. 
3.3.6 Data synthesis 
Where possible, comparable data were pooled using the Mantel-Haenszel method for 
dichotomous data and inverse variance model for continuous data as recommended in 
“Systematic reviews: CRD's guidance for undertaking reviews in health care” (86). This 
was undertaken using random-effect meta-analyses to supply an average estimate of 
effects, with their associated 95% confidence interval (CI) and 95% prediction interval 
(PI)  (87). Results were displayed in forest plots. I-sq was used to evaluate between-
study heterogeneity. An I-sq of >50% was deemed to represent significant 
heterogeneity (86). Funnel plots were planned to be used to assess for bias. However, 
there were insufficient data to undertake this. The analysis was undertaken using the 
‘metafor’ package in R-studio (74) . 
3.3.6.1 Subgroup analysis 
It was not possible to undertake any subgroup analysis due to marked heterogeneity of 
included studies. Subgroup analyses were intended to assess age of patients, type of 
probiotics, mode of delivery, and underlying cancer therapy based on radiotherapy or 
chemotherapy interventions. 
3.4 Results  
We identified 8015 unique articles, of which 98 were selected for full-text review, with 
10 RCT and 8 additional safety papers added in this update (see Figure 3). This 
resulted in a total of 21 studies included in the efficacy analysis and 25 studies in the 
safety analysis. Indications for excluding articles following full-text review are 
summarised in Figure 3.  
3.4.1 Efficacy analysis 
Table 7 summarises characteristics of the RCTs included in the efficacy analysis. 
Studies were conducted in 14 different countries, of which China was the most 
common. Eleven studies included surgical interventions, 9 studies included 
radiotherapy, and 7 studies included chemotherapy interventions. Sixteen studies used 
probiotics with more than one strain of bacteria, and 11 studies included 3 or more 
strains of bacteria. Eighteen studies included Lactobacillus strains, of which there were 
12 different species. Fifteen studies included Bifidobacterium strains, of which there 
were 7 different species. Only 2 of the 21 studies included paediatric patients.  
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3.4.2 Risk of bias assessment 
Findings of the risk of bias assessment identified that most items were assessed as 
unclear (up to 45% in each domain) due to a lack of reporting of methods in both the 
reports and published protocols (table 8). The highest risk of bias was noted when 
assessing performance bias (29%). Most of the studies reported as high risk specified 
that participants but not personnel were blinded to the intervention delivered, which 
could potentially have affected how outcomes were assessed. Lowest risk of bias was 
found when investigating attrition bias and sequence generation (62% and 52% 
respectively); most studies clearly specified methods used. Risk of bias assessments 
are summarised in table 8 and figure 4. 
3.4.3 Meta-analysis 
Pooled analysis demonstrated that probiotics reduced the incidence of diarrhoea in 
patients with cancer [odds ratio (OR) = 0.52, 95% CI 0.34-0.78, 95% PI 0.30-0.92, I-sq 
36.9%, 5 studies, figure 5], and duration of pyrexia [standardized mean difference 0.64 
days, 95% CI 053-0.77, I-sq 0.01%, 5 studies, figure 6]. Probiotics may also reduce the 
severity of diarrhoea, for example Common Toxicity Criteria grade 2 diarrhoea 
[OR=0.67, 95% CI 0.15-2.98, PI 0.07-6.55, I-sq 76.9%, 3 studies],  grade 3 and 4 
diarrhoea [OR=0.51, 95% CI 0.12-2.2, PI 0.03-9.08, I-sq 92.5%, 4 studies, figure 7], the 
incidence of septicaemia [OR=0.39, 95% CI 0.13-1.17, PI 0.05-3.05, I-sq 76.4%, 5 
studies], and central line infections [OR=0.50, 95% CI 0.15-1.71, PI 0.09-2.7, I-sq 
62.9%, 3 studies] but these results are very heterogenous and uncertain. Due to the 
marked heterogeneity of reporting in included studies we were unable to perform 
subgroup analysis on intervention, strain, dose of probiotic and age. 
3.4.4 Safety of probiotics 
Demographics of the 25 studies (N = 2,242) included in the safety analysis are 
summarised in Table 9 at the end of this chapter. An estimated 237 AEs events 
occurred in those consuming probiotics and 314 AEs in those not consuming 
probiotics. However, most studies did not specify how AEs were reported; for example, 
it is unclear whether two separate AEs recorded as ‘sepsis’ or ‘pneumonia’ occurred 
independently or from the same episode. No deaths attributed to probiotics were 
identified in the update. In the initial review, 2 deaths were reported in probiotic groups, 
but these were not attributed to the intervention delivered. Five case reports were 
identified during the initial review of probiotic associated infections, and no further case 
reports or probiotic associated infections were identified in the update, with one cohort 
study explicitly reporting an absence of probiotic associated infection. 
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3.4.5 Loke method for quality assessment for the reporting of adverse 
events 
Quality assessments of studies included for safety analysis are reported in Table 10 at 
the end of this chapter. As described in the initial review definitions of adverse events 
were inconsistently reported. Some were defined according to CTCAE or NCI-CTC, 
whereas others did not state how the definition was determined. 
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3.5 Discussion 
3.5.1 Summary of main results 
This update found 10 new RCTs and 8 further studies reporting AEs of probiotics in 
people with cancer, giving a total of 21 studies for efficacy analysis and 25 studies for 
safety analysis. There was marked heterogeneity of the strain, dose, and duration of 
probiotic used and age, cancers and anti-cancer therapies under study.  It was not 
possible to undertake subgroup analysis to explore between-study heterogeneity 
further.  
3.5.2 Strengths of this systematic review and meta-analysis 
This review was performed in accordance with standards published by the Centre of 
Reviews and Dissemination(81). A comprehensive search strategy of 14 databases 
was undertaken, and this included a grey literature search. We created general 
inclusion criteria to identify different study types.  Two reviewers performed abstract 
screening independently and cross-checked decisions to minimise bias. Although the 
data extraction was completed by one person, data from included papers and full-text 
exclusions was verified by a second reviewer. The Cochrane Risk of Bias was used for 
the randomised-controlled trials to assess biases as a measure of intervention effect, 
and the Loke method was used to assess the quality of studies investigating adverse 
effects. Where possible meta-analysis was undertaken to calculate pooled effects to 
strengthen findings further.  
3.5.3 Comparisons with other reviews  
The systematic review undertaken by Redman et al (47) reported that there was 
insufficient evidence to claim probiotics are effective and safe. Meta-analyses 
undertaken demonstrated that probiotics significantly reduce the incidence of CTC 
grade > 2 diarrhoea and may reduce the incidence of CTC grade > 3 diarrhoea, daily 
bowel movements, and the need for anti-diarrhoeal medication. The review suggested 
that an effect on faecal bacteriological composition may be found, but this needs to be 
examined in further trials alongside analysis of ongoing studies before drawing any 
conclusions.  
The updated systematic review undertaken for this thesis concluded there is still 
insufficient evidence to determine that probiotics are effective and safe in people with 
cancer. A meta-analysis demonstrated that probiotics might reduce the incidence of 
diarrhoea, duration of pyrexia and may reduce incidence of septicaemia and central 
line infection. However, these results should be interpreted cautiously because of the 
heterogeneous nature of included studies and the lack of studies with a clear low risk of 
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bias. It was not possible to perform subgroup analysis, particularly in children, to 
investigate this further. Our review reported that probiotics may be a rare source of 
infection but that no deaths have been attributed to their consumption. However, the 
variability of definitions used and reporting of adverse events means conclusions 
cannot be drawn with confidence. There was still insufficient evidence to investigate the 
effect on faecal bacteriology, highlighting the need for further research. 
A further systematic review (88) was identified during the screening process but was 
not eligible for inclusion. It reported that patients receiving chemotherapy or radiation 
therapy demonstrated changes in intestinal microbiota, particularly, a decrease 
in Bifidobacterium, Clostridium species, Faecalibacterium prausnitzii, and increase 
in Enterobacteriaceae and Bacteroides, which may increase the risk of developing 
mucositis, and that probiotics significantly reduce the incidence of diarrhoea. However, 
these conclusions were drawn from studies which included pre-clinical models, and the 
methodology for how the systematic review was undertaken was not reported. Whilst 
our systematic review did not identify sufficient data to undertake a meta-analysis of 
the faecal composition of stool samples in clinical trials, and it has identified the need 
for further trials to explore this further. 
3.5.4 Limitations of this systematic review and meta-analysis 
3.5.4.1 Risk of bias assessment of trials 
Domains of risk of bias were mostly reported as unclear due to limited reporting of 
methods undertaken. The highest risk was identified when assessing selection and 
detection bias. Whilst aspects of these biases may not be relevant, e.g. whether 
participants were blinded to the episodes of diarrhoea, most studies did not report 
sufficient information about methods undertaken, e.g. whether personnel were blinded 
from allocation of randomisation. This may have undermined the randomisation 
process, resulting in biased and inflated effect estimates. Selection bias can be 
reduced by implementing allocation concealment. Accuracy of the assessment of bias 
could be improved by more transparent reporting in studies and protocols. Reporting of 
studies can be improved by using the Consolidated Standards of Reporting Trials 
(CONSORT)(89). This is an evidence-based set of recommendations for the reporting 
of RCTs enabling better transparency and appraisal of studies, thereby potentially 
reducing bias.   
3.5.4.2 Quality assessment for the reporting of adverse events 
The Loke method (85) for the quality assessment of safety of probiotics (Table 10) 
identified that studies are still unclear on definitions, measure, and reporting of adverse 
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events. Definitions of adverse events may vary according to country and health care 
provisions.  
Currently, no consistent definitions are used in the reporting of adverse events and 
other outcomes. Uniformity of outcome reporting can be improved using the Core 
Outcome Measures in Effectiveness Trials (COMET) initiative (90) in which a 
standardised set of outcomes (i.e. adverse events)  represent the minimum measured 
and reported in clinical trials. We were unable to perform subgroup analysis due to the 
number of studies using different strains and doses of probiotics, age groups, 
treatment, and reporting of different outcomes. Using the proposed COMET initiative to 
agree on a standardised set of outcomes would enable improved accuracy when 
undertaking further updates, potentially reducing between-study heterogeneity. 
3.5.4.3 Efficacy of probiotics  
There remain insufficient studies to assess the true effect of probiotics in people with 
cancer. Meta-analysis suggests probiotics may be beneficial, but further studies are still 
required, particularly in children. The updated meta-analysis was unclear if probiotics 
can reduce the severity of grade 2 diarrhoea [OR=0.67, 95% CI 0.15-2.98, PI 0.07-
6.55, I-sq 76.9%, 3 studies] or Grade 3 and 4 diarrhoea [OR=0.51, 95% CI 0.12-2.2, PI 
0.03-9.08, I-sq 92.5%, 4 studies]. Pooled analysis did demonstrate that those treated in 
the probiotic group had a reduced incidence of diarrhoea [odds ratio (OR) = 0.52, 95% 
confidence interval (CI) 0.34-0.78, PI 0.3-0.92, I-sq 36.9%, 5 studies] and reduced 
duration of pyrexia [standardized mean difference 0.64 days, 95% CI 0.53-0.77, 5 
studies]. It was unclear if probiotics can reduce the incidence of septicaemia [OR=0.39, 
95% CI 0.13-1.17, PI 0.05-3.05, I-sq 76.4%, 5 studies] or central line infections 
[OR=0.5, 95% CI 0.15-1.71, PI 0.09-2.7, I-sq 62.9%, 3 studies].  
Marked heterogeneity was demonstrated by the high I-sq results and wide prediction 
intervals. Prediction intervals represent an estimate of where the effect will fall in future 
observations. Wide prediction interval, therefore, demonstrates a greater variability of 
estimated treatment effects in future studies.  This could be attributed to clinical 
diversity, e.g. the use of different strains and doses of probiotics, cancer diagnoses and 
interventions delivered, methodological diversity, e.g. differing study designs and 
statistical heterogeneity, e.g. the varying outcome effects reported in studies. 
There were insufficient data reported in the studies identified to undertake an updated 
pooled analysis of daily bowel movements, use of anti-diarrhoeal medication, and 
faecal bacteriological comparison. It was not possible to undertake any subgroup 
analysis due to the marked variability of study designs, probiotic strain dose, age and 
outcomes reported, and the small numbers of studies in each subgroup. Again, using 
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the COMET initiative to create a standardised set of outcomes would enable more 
accurate meta-analysis and therefore potentially more accurate conclusions. 
3.5.4.4 Safety analysis 
Twenty-five studies (N = 2,242) were included in the updated safety analysis 
summarised in table 10 at the end of this chapter. It is unclear how many individuals 
sustained adverse events as reporting varied between studies. Some studies reported 
on individual events rather than people sustaining an adverse event, and it is unclear 
how this may overlap (for example some studies reported on the incidence of 
septicaemia, incidence of pneumonia and UTIs - making it challenging to identify the 
number of individuals, or indeed if the same episode of illness was counted in two 
categories). An estimated 237 AEs events occurred in those consuming probiotics and 
314 AEs in those not consuming probiotics. Of the 8 studies identified during the 
updates, there were no deaths attributed to probiotics. In the initial review, 2 deaths 
were reported in probiotic groups, but this was not attributed to the intervention. There 
were 5 case reports identified during the initial review of associated probiotic infections. 
Some studies did not report on bacterial isolates from positive blood cultures identified 
(in both probiotic and control groups). Therefore, it cannot be concluded with 
confidence that there were no probiotic-associated infections, or that adverse events 
sustained cannot be attributed to probiotics consumed, due to the heterogeneity of 
malignancies and treatment regimens. As adverse events were also not clearly or 
uniformly defined in identified studies, it cannot be determined if all relevant data were 
appropriately identified, recorded or documented. As previously explained, this could 
be improved using methods such as the COMET initiative in future studies. 
3.6 Conclusion 
This systematic review update demonstrates that there is still insufficient evidence to 
conclude that probiotics are effective and safe in people with cancer. Meta-analysis has 
demonstrated that probiotics may reduce the incidence of diarrhoea, duration of 
pyrexia and may possibly incidence of septicaemia and central line infection. However, 
these results should be interpreted cautiously because of the heterogeneous nature of 
included studies and the lack of studies with a clear low . It was not possible to perform 
subgroup analysis, particularly in children, to investigate this further. Probiotics may be 
a rare source of infection, but no deaths have been attributed to their consumption. 
However, the variability of definitions used and reporting of adverse events means 
conclusions cannot be drawn with confidence. Further harmonisation of reporting of 
clinical trials using strategies such as the COMET initiative and CONSORT checklist 
would enable greater precision and confidence in conclusions drawn.  
- 68 - 
 
Figure 3: Summary of the screening process. 
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Table 7: Characteristics of included RCTs for efficacy analysis 
Bold: studies identified during update, RT, Radiotherapy; CHT, chemotherapy. 
Study first 
author  
Country of study  Study Probiotic administered 
Sadahiro 
 
Japan Surgery Bifidobacteria.  
 
Delia Italy Surgery, RT VSL#3 
Four strains of Lactobacilli (L. casei, L. plantarum, L. acidophilus, 
and L. delbruekii subsp. bulgaricus), 
Three strains of Bifidobacteria (B. longum, B. breve, and B. 
infantis),  




Canada RT Double strain Bifilact® probiotics (Lactobacillus acidophilus LAC-
361 and Bifidobacterium longum BB-536) 
 
Ekert Austrailia CHT Co-trimoxazole and synerlac (Lactobacilli preparation) 
Kotzampas
si 
Greece Surgery Four probiotics: Lactobacillus acidophilus LA-5, Lactobacillus 
plantarum, Bifidobacterium lactis and Saccharomyces boulardii 
 
Liu ZH China Surgery Lactobacillus plantarum, Lactobacillus acidophilus-11 
and Bifidobacterium longum-88  
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Study first 
author  
Country of study  Study Probiotic administered 
 
Liu Z China Surgery Three PRO bacteria composed of Lactobacillus 
plantarum  (CGMCC No.1258), Lactobacillus acidophilus and 
Bifidobacterium longum every day 
 
Mego  Slovakia CHT Each capsule contained 10 lyophilized probiotic strains 
including Bifidobacterium breve HA-129 (25%), Bifidobacterium 
bifidum HA-132 HA (20%), Bifidobacterium longum HA-135 
(14.5%), Lactobacillus rhamnosus HA-111 (8%), Lactobacillus 
acidophilus HA-122 (8%), Lactobacillus casei HA-108 
(8%), Lactobacillus plantarum HA-119 (8%), Streptococcus 
thermopilus HA-110 (6%), Lactobacillus brevis HA-112 
(2%), Bifidobacterium infantis HA-116 (0.5%)  
 
Yang China Surgery  Bifidobacterium longum, Lactobacillus 
acidophilus and Enterococus faecalis 
 
Zhang  China  Surgery B longum, L acidophilus and Enterococcus faecalis 
 
Castro [14]  Brazil  RT  Lactobacillus casei shirota and Bifidobacterium breve  
Chitapanaru
x [22]  
Thailand  RT  Lactobacillus acidophilus, Bifidobacterium bifidum (Infloran®)  
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Study first 
author  
Country of study  Study Probiotic administered 
Delia [23]  Italy  RT  VSL#3 (Lactobacillus casei, Lactobacillus plantarum, Lactobacillus 
acidophilus, Lactobacillus delbrueckii subsp. Bulgaricus, 
Bidobacterium longum, Bifidobacterium breve, Bifidobacterium 
infantis, Streptococcus salivarius subsp. thermophilus)  
Germain 
[13]  




Italy  Surgery  Lactobacillus johnsonii, Bifidobacterium longum (with maltodextrin)  
Giralt [12]  Spain  RT ± CHT  Lactobacillus casei DN-114 001, Streptococcus thermophilus, 
Lactobacillus delbrueckii subsp. Bulgaricus  




Finland  Adjuvant CHT following 
surgery  
Lactobacillus rhamnosus  
Sharma 
[27]  
India  RT + CHT  Lactobacillus brevis  
Urbancsek 
[28]  
Hungary  RT  Lactobacillus rhamnosus  
Wada [29]  Japan  CHT  Bifidobacterium breve strain Yakult (BBG-01)  
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Table 8: Risk of bias for included randomised controlled trial for efficacy analysis, judged according to Cochrane risk of bias assessment 
tool (82) 











Blinding of participants 
and personnel 
(performance bias) 








Sadahiro Low risk Low risk Unclear Low risk Low risk Unclear 
Delia Higher risk Unclear Unclear Unclear Unclear Unclear 
Demers  Higher risk
  
Higher risk Low risk Low risk Low risk Low risk 
Ekert,  Higher risk Higher risk Unclear Unclear Unclear Unclear 
Kotzampa
ssi 
Lower risk Low risk Unclear Low risk Low risk Low risk 
Liu ZH Lower risk Unclear Higher risk Higher risk Low risk Unclear 
Liu Z Unclear Low risk Higher risk Unclear Low risk Unclear 
Mego  Low risk  Low risk Low risk Unclear Unclear Higher risk 
Yang Low risk Low risk Low risk Unclear Low risk Unclear 
Zhang  Unclear Unclear Higher risk Unclear Unclear Unclear 
Castro 
[14]  
Low risk Low risk Low risk Unclear Higher risk Unclear 











Blinding of participants 
and personnel 
(performance bias) 









rux [22]  
Unclear Unclear Low risk Low risk Low risk Low risk 
Delia [23]  Unclear Unclear Low risk Unclear Low risk Unclear 
Germain 
[13]  
Low risk Higher risk Low risk Low risk Unclear Unclear 
Gianotti 
[24]  
Low risk Low risk Low risk Low risk Unclear Unclear 
Giralt [12]  Unclear Unclear Low risk Low risk Low risk Low risk 
Liu [25]  Low risk Unclear Higher risk Unclear Low risk Unclear 
Osterlund 
[26]  
Low risk Unclear Higher risk Higher risk Low risk Unclear 
Sharma 
[27]  
Low risk Low risk  Unclear Unclear Unclear Unclear 
Urbancsek 
[28]  
Unclear Unclear Unclear Higher risk Low risk Higher risk 
Wada 
[29]  
Higher risk Higher risk Higher risk Higher risk Low risk Low risk 
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Figure 4: Bar chart demonstrating of Risk of Bias results  
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 Figure 5: Forest plot summarising for the incidence of diarrhoea  
 
 Favours probiotic                                                                                      Favours control  
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Figure 6: Forest plot summarising the duration of pyrexia (days) 
 




- 77 - 
Figure 7: Forest plot summarising grade >3 and 4 diarrhoea 
 
 Favours probiotic                                                                  Favours control
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Table 9: Studies included for safety analysis 





 Probiotic administered Adverse event 
Ekert,  RCT Total 68 
Intervention: 35 
Fracon: 33  
Control: 34 
Co-trimoxazole and Synerlac 
(Lactobacilli preparation). 
 
Intervention group (Co-trimoxazole and 
Synerlac)  
5 x fevers >38 C appearing for the first time, 2 
positive blood cultures,5 x fevers 
 >38 C appearing for the first time, 2 positive 
blood cultures.  
No issues regarding tolerance to treatment 
observed 
FRACON group: 
5 x fevers >38 C appearing for the first time, 5 
positive blood cultures, 19 (? episodes) 
vomiting & nausea, 7 refusal to take medication, 
9 dose reductions, 5 changed to alternate 
regimens  
Control group:  
 14 fevers >38 appearing for the first time, 8 
positive blood cultures. 
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Kotzampassi RCT  Total 164 
Probiotic: 80 
Control:80 
Four probiotics: Lactobacillus 
acidophilus LA-5, Lactobacillus 
plantarum, Bifidobacterium 




24 (28.6%) major complications, 10 (11.9%) any 
infectious complications,  
2 (2.4%) pneumonia, 6 (7.1%) surgical site 
infections, 4 (4.8%) bacteraemias 
6 (7.1%), severe sepsis, 1(1.2%) anastomosis 
leakage,1(1.2%) need for mechanical ventilation 
Isolates- Acinetobacter 3 (3.7 %), Pseudomonas 
aeruginosa 2 (2.3 %), methicillin-resistant 
Staphylococcus aureus 1 (1.2 %). 
Control group: 
 39 (48.8%) major complications, 23 (28.7%) any 
infectious complications, 9 (11.3%) pneumonia, 
16 (20%) surgical site infections, 8 (10%) 
bacteraemia,  
8 (10%) severe sepsis, 4 (5%) anastomosis 
leakage, 7 (8.8%) and need for mechanical 
ventilation, 1 patient sustained a pulmonary 
embolism 
Isolates- Acinetobacter 8 (10.0 %), 
Pseudomonas aeruginosa 4 (5.0 %), methicillin-
resistant Staphylococcus aureus (MRSA) 3 (3.8 
%). 






and Bifidobacterium longum-88  
 
Probiotic group: 
41 (55%) septicaemia, 4 (5%) central line 
infection, 3(4%) pneumonia, 2 (3%) UTI, 11 (15%) 
incidence of diarrhoea 
5.82 days+/-1.98 SD duration of post-operative 
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pyrexia 
Escherichia coli:  Blood 3, Central lines 1, 
sputum 1 
Staphylococcus aureus:  Blood 1, Central lines 
1, sputum 2 
Klebsiella pneumoniae:  Blood 0, Central lines 0, 
sputum 1 
Aeruginosum: Blood 0, Central lines 1, sputum 1 
Control group: 
 41 (73%) septicaemia, 12 (16%) central line 
infection, pneumonia 10 (13%),  
UTI 10 (13%), 29 (22%) incidence of diarrhoea, 
6.68 days+/-2.29 SD duration of post-operative 
pyrexia  
Escherichia coli:  Blood 7, Central lines 3, 
sputum 3 
Staphylococcus aureus:  Blood 3, Central lines 
3, sputum 2 
Klebsiella pneumoniae:  Blood 0, Central lines 0, 
sputum 0 
Aeruginosum: Blood 0, Central lines 2, sputum 0 
Liu Z RCT  Total: 150 
Probiotic: 66 
Control: 68  
Three PRO bacteria composed 
of LP (CGMCC No.1258), LA-11 
and BL-every day 
 
Probiotic group: 
39 (59%) septicaemia, 7 (11%) central line 
infection, 6 (9 %) pneumonia  
2 (3%) UTI, 16 (24%) incidence of diarrhoea 
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35 (51%) abdominal distention, abdominal 
cramping 15 (23%)  
6.02 days+/-1.68 SD duration of post-operative 
pyrexia 
Escherichia coli:  Blood13, Central lines 0, 
sputum 1 
Staphylococcus aureus:  Blood 1, Central lines 
1, sputum 1 
Klebsiella pneumoniae:  Blood 0, Central lines 0, 
sputum 1 
Aeruginosum: Blood 0, Central lines 1, sputum 0 
Control group: 
60 (88%) septicaemia, 6 (9%) central line 
infection, 8 (12%) pneumonia  
9 (13%) UTI, 31 (46%) incidence of diarrhoea, 
6.98 days+/-2.22     SD duration of post-operative 
pyrexia  
Escherichia coli:  Blood 6, Central lines 1, 
sputum 2 
Staphylococcus aureus:  Blood 2, Central lines 
1, sputum 2 
Klebsiella pneumoniae:  Blood 0, Central lines 0, 
sputum 1 
Aeruginosin: Blood 1, Central lines 0, sputum 0 
Mego  RCT Total: 46 
Probiotic: 23 
Each capsule contained 10 
lyophilized probiotic strains 
including Bifidobacterium 
Probiotic group:  
Diarrhoea grade 1: 5 (21.7%), diarrhoea grade 
2:4 (17.4%), diarrhoea grade 3: 0, diarrhoea 
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Control: 23 breve HA-129 
(25%), Bifidobacterium 







(8%), Lactobacillus casei HA-




(6%), Lactobacillus brevis HA-
112 (2%), Bifidobacterium 
infantis HA-116 (0.5%).  
 
grade 4: 0, enterocolitis: bloating: 2 (8.7%) 
Control group: 
Diarrhoea grade 1: 8 (34.8%), diarrhoea grade 2: 
2 (8.7%), diarrhoea grade 3: 0 (13%), diarrhoea 
grade 4: 1 (4.3%) enterocolitis: 2 (8.7%), 
bloating: 4 (17.4 %) 
Mego Cohort  N=60 E. faecium M-74 14 patients (100%) with infectious fever 
30 infectious episodes 
14 (47%) microbiologically documented 
infection (episodes) 
10 (33%) fever of unknown origin 
Blood stream: 5 Coagulase-negative 
staphylococcus, 1 Escherichia coli, 1 Klebsiella 
pneumonia, 2 Corynebacterium sp, 1 
Pseudomonas aeruginosa, 1 Stenotrophomonas 
maltophilia. 1 Citrobacter sp. 
Urinary tract: 1 Enterococcus faecalis, 1 
Escherichia coli. 
No Probiotic associated infections or 
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bacteraemia. 
 









4.77 days +/- 1.79 SD duration of pyrexia, 
bacteraemia: 3 (10%) 
Wound infection 1 (3.33%), pneumonia: 3 (10%), 
UTI: 2 (6.67%) 
Incidence of diarrhoea: 8 (26.7%), abdominal 
distention: 9 (30%) 
Control:  
4.80 days +/- 2.34 SD duration of pyrexia, 
bacteraemia: 9 (30%), wound infection 1 (3.33%), 
pneumonia: 5 (16.7%), UTI: 2 (6.67%), incidence 
of diarrhoea: 16 (53.3%), abdominal distention: 
13 (43.3%) 
Zhang  RCT  Total: 60 
Probiotic: 30 
Control: 30 




Bacteraemia: 2 (6.7%), septicaemia: 1 (3.3%), 
pneumonia: 1 (3.3%), intra-abdominal abscess: 
2 (6.7%), surgical site infection: 1 (3.3%) 
anastomotic leak: 0, intestinal obstruction: 3 
(10%) 
Control:  
Bacteraemia: 9 (30%), septicaemia: 8 (26.7 %), 
pneumonia: 4 (13.3%), intra-abdominal abscess: 
1 (3.3%), surgical site infection: 4 (13.3%), 
anastomotic leak: 2 (3.3%), intestinal 
obstruction 6 (20%) 
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Abd El-Atti 
[30]  
Case report  1  Multispecies  0 AE  
Bellette [31]  Case report  1  Colotium (ADVITEC)—Culture 
showed growth of Candida 
pelliculosa, Candida krusei, A. 
corymbiferaand Aspergillus flavus.  
Appendicitis and liver abscesses  
Cesaro [32]  Case report  1  Saccharomyces boulardii  Saccharomyces cerevisiae fungaemia  
Chitapanarux 
[22]  
 RCT  63 (placebo = 31; 
probiotics = 32)  
Lactobacillus 




0 AE  
Delia [23]  RCT  482 analysed 
(placebo = 239; 
probiotics = 243)  
VSL#3 (multispecies)  0 AE  
Giralt [12]  RCT  85 (placebo = 41; 
probiotics = 44)  
Lactobacillus casei DN-114 
001, Streptococcus thermophiles 
and Lactobacillus delbrueckii 
subsp. bulgaricus  
0 AE  
Henry [33]  Case report  1  Saccharomyces boulardii  
(Perenterol)  
Saccharomyces cerevisiae found on blood cultures  
LeDoux [34]  Case report  1  Lactobacillus acidophilus but not 
clear if additional organisms  
Persistent Lactobacillus acidophilus bacteraemia on 
serial blood cultures for 3 days  
Liu [25]  RCT  100 analysed 
(placebo = 50; 
probiotics = 50)  
Lactobacillus plantarum, 
Lactobacillus and Bifidobacterium 
longum  
0 AE  
Malkov [35]  Case series  10  Bacillus oligonitrophilus KU-1  5 potential AE- Sicchasia (patient withdrew), blood 
pressure rise ×3 (patients' probiotics paused), ICP 
gain  
Mehta [36]  Case report  1  Unclear but did Lactobacillus acidophilus on blood cultures—though 












contain Lactobacillus acidophilus  not clear to tell if symptomatic  
Naito [37]  RCT  202 analysed 
(group without 
probiotics = 102; 
group with 
probiotics = 100)  
Lactobacillus casei  126 AE in group without probiotics; 80 AE in group 
with probiotics – unclear how many individuals 
these were distributed over. Wide range of 
gastrointestinal and urinary symptoms - unable to 
differentiate from malignancy (transitional cell 
carcinomas) or chemotherapy  
Oggioni [38]  Case report  1  Bacillus subtilis spores 
(Enterogermina)  
Blood cultures positive for B. subtilis  
Osterlund [26]  RCT  148 (group 
without probiotics 
= 97, group with 
probiotics = 51)  
Lactobacillus rhamnosus GG  No probiotic = 2 of 51; probiotic = 9 of 97 all cases 
of neutropenic infection (but no growth of 
Lactobacillus in blood cultures)  
Sharma [27]  RCT  188 analysed 
(placebo = 95, 
probiotic = 93)  
Lactobacillus brevis CD2  Placebo group = (7 × grade II dysphagia, 6 × grade 
II nausea and vomiting) + 1 died after developing 
grade IV neutropenia and sepsis; probiotic group = 
1 × grade II dysphagia; 1 × developed acute 
myocardial infarction after 4 weeks of anticancer 
therapy - all attributed to chemotherapy by authors  
Urbancsek 
[28]  
RCT  205 (placebo = 





Placebo = 2 × GI problems (mild to moderate), 1 × 
labial oedema; probiotic = 3 × GI problems (mild to 
moderate)  
Wada [29]  RCT  40 (placebo = 22; 
probiotic = 18)  
Bifidobacterium breve strain Yakult 
(BBG-01)  
0 AE  
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Table 10: Summary of Loke quality assessment of adverse events of studies identified during the update (85)  








AE stated?   












Categories of AE 
reported 










I H Jurk 
et al 
RCT Y Spontaneous  Unclear Y New fever 
Positive culture 





at entry into 
study 













G et al 
RCT Y Prospective 
monitoring 











Need for mechanical 
ventilation 
Y Exact definitions 
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Liu ZH, 
Huang 
MJ et al 














Liu Z, Li 
C et al 




Side effects of 
probiotics 







c et al 
















ova et al  




Side effects of 
probiotics 
Y According to 
Primary 
endpoint of this 











any grade of 
diarrhea, 
N 








any grade 3 or 4 
toxicity or SAE 
related toxicity. 
Y Yang, 
Y Xia et 
al 
RCT Y Routine Unclear Y Infection 
Fever 
Neutropenia  







staphylococci was the 
most frequent. Four 
patients experienced 




septic shock with a 
need of vasoactive 
support. There were 
no treatment-related 
deaths. Only two 
patients (14%) had 
mild diarrhoea (grade 





grade 2 and one 
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4 Mucositis and infection reduction with liquid probiotics in children with 
cancer: a randomised-controlled feasibility study (The MaCROS study) 
 
4.1 Introduction 
The systematic review reported in the last chapter demonstrated there were insufficient 
studies to assess the true effect of probiotics in people with cancer, particularly in 
children. Meta-analysis suggested that probiotics may be beneficial, but further studies 
were still required. 
This chapter outlines and justifies the decision to undertake a randomised-controlled 
feasibility trial (the MaCROS study). The aim of this study was to explore the feasibility 
of conducting a randomised controlled trial (RCT) to investigate whether the use of 
probiotics could prevent or reduce mucositis and infection in children diagnosed with 
cancer. Participants in the feasibility study included children diagnosed with cancer 
receiving chemotherapy that may cause mucositis. The participants taking probiotics 
were compared to those taking a placebo supplement. Results are reported in following 
chapter (part 2) and is reported according to the CONSORT 2010 statement for 
feasibility and pilot studies (89). 
4.2 Part 1: Setting up the MaCROS study 
4.2.1 The rationale for undertaking a feasibility study 
Randomised control trials (RCTs) are prospective studies that measure the effect of a 
treatment or intervention. RCTs are considered the gold standard for evaluating the 
effect of an intervention because they reduce selection bias through the random 
allocation of patient characteristics in a two-arm intervention (91).  However, RCTs 
sometimes fail. Some reasons why an RCT may not work include: 
 Researchers may be interested in a research question, but this may not be of 
interest to the patient with the relevant condition  
 There could be difficulties implementing the protocol 
 There could be a problem implementing allocation concealment, randomisation 
and blinding successfully 
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 It may not be possible to recruit enough participants to the study to achieve 
adequate statistical power 
 Patients may struggle to adhere to the requirements of participation 
Due to the costly and time-consuming nature of RCTs, it is crucial to identify any 
potential issues prior to conducting the study. These issues can be identified by 
undertaking a feasibility study. A clinical trial feasibility study is a research method for 
determining whether it is appropriate to undertake a larger study.  Feasibility studies do 
not investigate primary outcomes but appraise important and essential parameters 
required to undertake a large adequately powered study such as an RCT.  
4.2.2  Why is this feasibility study required? 
The systematic review and meta-analysis presented in chapter 3 highlighted the need 
for further studies to investigate the use of probiotics in people with cancer, particularly 
in paediatric patients. Undertaking an RCT to explore this further would be very costly. 
Therefore, a feasibility study (the MaCROS study) was developed to investigate 
whether such an RCT could be undertaken successfully. 
4.2.3 Approach to developing the MaCROS study 
It was determined that a pragmatic clinical trial, rather than an explanatory trial would 
be more appropriate for the MaCROS study. Whilst an explanatory trial evaluates the 
efficacy of an intervention in an idealised setting, a pragmatic trial evaluates the 
intervention in everyday clinical setting for its  applicability i.e. ‘does this intervention 
work in real life?’(92). 
The primary aim of this study was to explore the feasibility of undertaking a large and 
adequately powered RCT. For this reason, the secondary endpoints reported (for 
example the incidence of diarrhoea between the probiotic and placebo arm) were not 
adequately powered. These findings should, therefore, be interpreted with caution. 
4.2.4 Developing the MaCROS study protocol 
Once the primary aim of the MaCROS study was decided, the study protocol was 
designed to capture the necessary information whilst meeting the guidance of: 
 the CONSORT 2010 statement for feasibility and pilot studies (89), 
  ethical guidance issued by the Health Research Authority (HRA) (93), 
 National Institute of Health Research (NIHR) (94)  
 Leeds Teaching Hospital Trust research and innovation guidance (95).  
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The protocol was developed with expert input. This included health care 
professionals such as senior clinicians, dieticians and play therapists, senior 
academics and the University of Leeds ethics team and sponsors.  The final 
version of the protocol can be viewed in appendix 2.1. 
4.2.5 Deciding which probiotic to use in the MaCROS study 
The systematic review undertaken prior to the development of this study identified 
significant heterogeneity between the type of probiotic strains used in the different 
studies, and that there was a particular lack of information about the strains used in 
paediatric studies. For the MaCROS study, a number of factors were considered prior 
to deciding which type of probiotic to use: 
 Bacterial diversity: probiotics with more than one strain of bacteria were identified to 
reflect the bacterial diversity of the gastro-intestinal tract better. 
 Mode of ingestion: children may struggle with swallowing tablets. A liquid option 
was sought, as this also gave the option of delivery via nasogastric tubing. 
 The probiotic company’s previous experience with research: as the MaCROS study 
was intended as a double-blind randomised controlled trial, it was preferred to have 
a company with previous experience of undertaking clinical trials and randomisation 
and supplying a placebo. 
Following these criteria, the probiotic company Symprove was identified. 
4.2.6 Symprove liquid probiotic 
Symprove (Symprove Ltd, Farnham, Surrey, UK) is a liquid probiotic that contains four 
strains of bacteria with a total of 109 colony forming units: 
 Lactobacillus rhamnosus NCIMB 30174, 
  Lactobacillus plantarum NCIMB 30173, 
  Lactobacillus acidophilus NCIMB 30175, 
  Enterococcus faecium NCIMB 30176 
 In a water-based suspension of barley extract. Symprove is classified 
as a food supplement under EU law. It is hypothesised that suspension 
of the barley extract in water provides acid protection and a nutrient 
source for the bacteria when compared to freeze-dried probiotic 
formulations. Therefore a greater number of bacteria survives the transit 
through the human gastrointestinal system. This results in a higher 
number of probiotic bacteria to colonise in the colon (96). The 
- 93 - 
colonisation of bacteria from a probiotic supplement is believed to 
increase the secretions of anti-inflammatory cytokine interleukins (IL) 
such as IL-10 and IL-8, T-regulatory cells, and reduce interferons. These 
inhibit the development of oral and intestinal inflammation, and therefore 
mucositis (97).The use of Symprove in RCTs has been investigated in 
conditions affecting the gastrointestinal system, including inflammatory 
bowel disease, irritable bowel syndrome and diverticular disease. 
4.2.6.1 Symprove in adults  
Data suggests that Symprove reduces intestinal inflammation in patients with ulcerative 
colitis (96), and the frequency of diarrhoea and mucorrhoea in patients with diverticular 
disease (98). Another RCT demonstrated that the use of Symprove resulted in lower 
symptom severity in participants with irritable bowel syndrome (IBS) when compared to 
placebo (99).  
4.2.6.2 Symprove in paediatrics 
Symprove has been approved for use in children under EU law, and Symprove 
encourages the use of the liquid probiotics in paediatrics. However, dosing varies in 
younger children (20ml for those under the age of 4 and 0.5ml/kg for children aged 
between 4-8 years). There have been no paediatric clinical trials investigating the use 
of Symprove. Therefore the MaCROS study was the first trial exploring the use of 
Symprove in children with cancer. It was believed the liquid and flavoured formulations 
would improve compliance in children compared to tablets or freeze-dried formulations. 
As the use of Symprove has been investigated in other gastrointestinal disorders, it 
was  an appropriate intervention to explore in children with cancer who are at risk of 
developing mucositis. 
4.2.6.3 Safety of Symprove 
Liquid probiotics have been reported as safe in previous studies (n=197 patients), and 
there have been no reports of unexpected serious adverse events attributed to 
Symprove (96, 99). However, consumption may be associated with nausea and reflux 
(99). As previously reported, in rare cases probiotics can be associated with infections 
in immunocompromised patients. 
4.2.7 Patient information leaflets 
The patient information leaflets designed were tailored to meet the requirements of 
children, teenagers and young people who were to participate in the study. Children 
and young people under the age of 16 may not have competence to understand a 
study, whilst young people above the age of 16 years are presumed to have 
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competence. Therefore, the leaflets were designed to reflect the different levels of 
understanding in children. Leaflets were created for the following ages: 
 Children under the age of 10 
 Children and teenagers aged 10-16 years 
 Teenagers aged 16-18 years 
 Parents/guardians of participants 
Images used in the patient information leaflets were taken from Shutterstock (100). 
4.2.7.1 Children under the age of 10 
This patient information leaflet was designed with the intention of making the 
information engaging and relevant to young children. The Give a Duck charity donates 
a “Chemo Duck” to every child diagnosed with cancer in Leeds (101). Chemo Duck is a 
soft toy that represents experiences that a child diagnosed with cancer may go 
through. Chemo Ducks have central lines, a bandana for hair loss and hospital attire. 
This soft toy is given with the intention of alleviating the fears and anxiety children may 
have by introducing them to the concepts of cancer treatment (appendix 2.2) through 
play therapy. 
4.2.7.2 Children and teenagers aged between 10 and 16 
This leaflet was designed to deliver the relevant information in an engaging and 
relevant way for children and teenagers of this age range. Information was delivered 
using language that can be understood with engaging pictures taken from Shutterstock 
(appendix 2.3). 
4.2.7.3 Teenagers and young adults aged between 16-18 
As participants of this age range are expected to consent for themselves, the 
information leaflet was almost identical to the leaflets designed for parents and 
guardians. The only difference was language i.e. ‘you’ vs ‘your child’ (appendix 2.4). 
4.2.7.4  Parents and guardians 
This leaflet was designed to deliver the necessary information for parents and 
guardians to enable informed consent (appendix 2.5). 
4.2.8 Consent of children and young people in clinical trials 
There are a number of legal and ethical issues to consider when approaching children 
and young people to participate in research. The requirements for consent in these 
cases will depend on the type of study occurring and where in the UK it is taking place 
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(for example, Scotland or the rest of the UK). Clinical trials can be classified as clinical 
trials of an investigational medicinal product (CTIMP) or Non-CTIMP. 
4.2.8.1 Clinical Trials of an Investigational Medicinal Product (CTIMP)  
A CTIMP is a clinical trial that evaluates the safety or efficacy of a drug (known as an 
Investigational Medicinal Product or IMP) or obtains other relevant information such as 
how it is absorbed and metabolised. 
Young people above the age of 16 are presumed to be capable of giving their own 
consent to participate in CTIMPs.   
Children under the age of 16 are prohibited from giving consent to participate in a 
CTIMP and consent must be given on behalf of a child/ young person by: 
 A parent or someone with parental responsibility 
 A personal legal representative (only when someone with parental responsibility 
cannot be contacted prior to the proposed inclusion of a child/young person 
because of the urgent nature of treatment) 
 A professional legal representative or a nominated person who is independent of 
the study 
Children and young people should participate in decision making and be given 
information about the trials which is understandable to them. 
4.2.8.2 Non-CTIMP trials  
Non-CTIMP trials which do not involve an IMP as defined by the Medicines and 
Healthcare products Regulatory Agency (MHRA), do not fall within the requirements of 
the Medicines for Human Use (Clinical Trials) Regulations 2004. In England, Wales or 
Northern Ireland there is no statute which governs a child’s right to consent in non-
CTIMP trials and because of this both common law (derived from judicial decisions) 
and case law (collection of past legal decisions written by courts and tribunals) are 
considered and applied. Common law presumes that young people above the age of 
16 are typically competent to give consent to treatment. Case law proposes that if a 
young person has sufficient understanding of the law to understand what is proposed 
and weigh up the information to reach a decision, he or she can give consent to 
treatment – for example, Gillick competence [ref]. In the absence of law related 
explicitly to non-CTIMP research, it is assumed that these principles also apply to 
consent for research in those under 16 years of age. Young people who are under the 
age of 16 who are competent to understand and weigh information to reach a decision 
do not need consent from a parent/responsible person. 
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It is good practice to involve families in the decision-making process whilst respecting 
the privacy of the young person. Therefore, parents of young people under the age of 
16 were asked to give consent unless the young person explicitly stated they do not 
want this (appendix 2.6). All children and young people under the age of 16 were given 
the opportunity to assent (appendix 2.8). It is also good practice to supply information 
about the study (93). Competent young people above the age of 16 were required to 
give their own consent (appendix 2.7). 
The MaCROS study was classified as a non-CTIMP clinical trial. To reflect the good 
practice that is recommended by the HRA, parental or guardian consent was required 
on behalf of all young people under the age of 16 unless there was an explicit request 
from the young person, and the young person was offered the opportunity to sign an 
assent form. 
The consent and assent forms covered the necessary information for all aspects of the 
study. This included seeking permission to share information with the GP (appendix 
2.9), storage of information and data after the study closed, dissemination of 
information and permission to be approached to participate in an interview (appendix 
2.18). 
4.2.9 Developing the patient diaries 
The patient diaries were developed with the intention of capturing data to address the 
aims and objectives of the feasibility study. Where possible, validated questionnaires 
were identified and used to capture this information. For example, the Bristol Stool 
Chart (102) was used to describe stool consistency, and the Children’s International 
Mucositis Evaluation Scale (ChIMES) (103) was used to describe oral mucositis. 
Currently, there is no validated tool to assess gastrointestinal mucositis in adults and 
children. Because of this, some questions were adapted from other validated tools 
such as ChIMES to answer questions about nausea and vomiting, and other features 
of gastrointestinal mucositis. Once the questions required to capture the necessary 
data were formulated, they were applied to a patient-friendly diary with the aim of 
making them easy to understand and quick to use.  
Participants or their parents/guardians had the option of completing one of two diaries: 
 A paper booklet 
 An online diary that could be accessed using a web-app 
Prior to the start of the MaCROS study, patients and parents within the department 
were asked to review the two types of diaries and provide feedback on what required 
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changing. Questions asked in the paper booklet and the online diary were identical and 
included questions to assess nausea, vomiting, diarrhoea, pain and oral mucositis.   
4.2.9.1 Validated measurements tools used in the patient diary 
The use of validated tools to capture information is vital for undertaking a randomised 
controlled trial. These tools may use subjective reporting (e.g. self-reporting) or proxy-
subjective reporting by the parents of participants. Self-reporting has been increasingly 
recognised as the gold standard for collecting information on subjective information in 
paediatric haematology and oncology patients. This includes health-related quality of 
life and symptom burden questions. Reporting by a health care professional may not 
appropriately reflect symptoms that may be distressing to the patient. For example, 
whilst the visible appearance of an oral ulcer may be correctly reported by a health 
care professional, the same tool can under-report other unobservable symptoms, for 
example, nausea or pain. Previous studies have reported that clinicians may under-
report the prevalence and severity of subjective symptoms when compared to patient 
self-reporting (104). 
Subjective symptom reporting by parents on behalf of their children is known as ‘proxy 
reporting’. Previous studies have reported fair to moderate agreement between 
children and parent-proxy reporting. This suggests that parent-proxy reporting may not 
accurately reflect the child’s perspective (105).  
A few subjective mucositis scales have been developed and validated for oral 
symptoms in adults. These include Patient-Reported Oral Mucositis Symptom scale 
(PROMS) (106) and the Oral Mucositis Weekly Questionnaire - Head and Neck 
cancers (OMWQ-HN) (107). In paediatrics, the Children’s International Mucositis 
Evaluation Scale (ChIMES) can be used by children aged 8 and above to assess 
symptoms of mucositis (103), with validated parent-proxy reporting for children under 
the age of 8. ChIMES focuses on the functional elements using simple questions and 
pictures of facial expressions that may reflect symptoms that the child experience.  
However, there are no validated subjective reporting tools to assess gastrointestinal 
mucositis. Therefore, in the MaCROS study, tools that had been validated to assess 
oral mucositis were modified to enable assessment of gastrointestinal mucositis (108). 
A modified version of ChIMES was used to capture all necessary information, adding 
closed questions with multiple-choice options, and the Bristol stool chart to describe 
stool consistency using pictures.  
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4.2.9.2 Web-app 
A web-app was developed for children, young adults and their parents/guardians to 
use, in order to increase the likelihood of compliance with reporting symptoms. The 
web-app is an electronic version of the paper diary. This is described in further detail in 
appendix 2.10.  
Traditionally, the capture of self-reported information has been obtained from the use of 
paper patient diaries, questionnaires, or face to face encounters. However, paper 
diaries have the risk of participants completing data for multiple days at once, which 
can result in reporting and recall bias. They can also be misplaced, resulting in missing 
data. Electronic methods for self-reporting are increasingly used in research because 
some believe it can improve compliance, increase the amount of information which is 
provided by the patient, and has a higher acceptance rate by respondents (109). Whilst 
recall bias can occur with both paper and electronic diaries, the use of push 
notifications in electronic apps is thought to reduce this because they act as a reminder 
to the participants. As a result, the participants will be prompted to complete the 
relevant section when the information is required (110). 
4.2.10 Data collection and analysis: protection and confidentiality 
In the MaCROS study, data was collected using: 
 Paper (e.g. clinical notes, consent forms, patient diaries) 
 NHS electronic records 
 Internet and software (web-app, encrypted audio recordings) 
Some data was sensitive and had patient-identifiable and sensitive information. 
Because of this, methods to preserve and protect the anonymity of participants were 
implemented.  
Data with identifiable patient information was accessed only on an NHS password-
protected computer. Data transferred to the University of Leeds servers were 
anonymised, so that patient information was unidentifiable. Only the direct care team 
and researchers directly involved in the study had access to participants' personal 
data. Monitors and auditors from NHS R&D offices and regulatory inspectors may also 
require access to patients' clinical notes to verify or cross-check information. This 
information was provided in the information sheet to parents and participants aged 16 
years and over, and only participants and legal guardians who signed the consent form 
were included in the study. Individuals who had access to participants' personal data 
were required to have an appropriate professional background and access to direct 
care. 
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4.2.10.1 Paper records 
Consent forms/ participants diaries were stored in a locked filing cabinet in Martin Wing 
(offices for the paediatric haematology/oncology department) in LTHT. Only members 
of the research team had access to this filing cabinet. Written clinical records were 
accessed on the ward by a healthcare professional who was also a member of the 
research team (H.H). Data collected from written clinical records were transferred to an 
excel sheet that was accessed only on an NHS password-protected computer. 
Participants who chose to decline to participate in the MaCROS study were invited to 
complete an anonymous questionnaire explaining why they chose not to take part in 
the study. Once transcribed, the anonymous questionnaires were destroyed. 
Participants were required to avoid mentioning any personally identifiable information.  
4.2.10.2 Data collection and analysis: electronic records 
Information was collected at Leeds Teaching Hospital trust on NHS password-
protected computers. 
An electronic database was created using a spreadsheet to store the patient's name, 
NHS number, unique randomisation number, age, sex, diagnosis/chemotherapy/course 
of treatment, sex and any relevant clinical information pertaining to hospital admissions 
(e.g. duration of stay, neutrophil count, blood culture results). Once this was completed, 
a duplicated spreadsheet was created, and the name, NHS number, and randomisation 
number were removed, leaving only the anonymised patient data. 
Results (without any personally identifiable data) were emailed to the chief investigator 
(HH) using the encrypted and password protected NHS.net email account computer. 
Information was then transferred to a database on the university M drive, a secure, 
password-protected, University of Leeds server. Data was analysed only on an NHS 
computer. 
Strategies to ensure data protection of recorded interviews were also implemented. 
Only encrypted University of Leeds or NHS audio recorders were used, and it was 
required that participants do not refer to any patient identifiable data. The information 
was then transcribed onto a word document (identifiable only by the randomisation 
number). Once the transcribing was completed, the audio recording was deleted. 
4.2.10.3 Web-app use: security and data protection 
Data provided by participants in the web-app was identified only by their unique 
identification number, and there was no identifiable personal information. Information 
was downloaded to an excel spreadsheet and was accessed and analysed only on an 
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NHS password-protected computer. No identifiable data from the web-app was kept 
locally on laptops or computers. 
The web-app was hosted by Amazon Web Services, one of the world’s best providers 
with a high level of security. 
4.2.10.4 Long-term data storage 
As a PhD research project, raw datasets need to be held for a minimum period of 5 
years after completion due to University regulations. The data, with consent forms, may 
also be needed for further follow-on studies evaluating longer-term outcomes. As such, 
the data will be stored for a total of 10 years. If appropriate, future studies would be 
submitted for their own ethical approval.  
 
4.2.11 Patient and public involvement   
Patient and Public Involvement (PPI) in research is described as research carried out 
with input from members of the public (in this case, patients). It is increasingly 
recognised that using PPI  in the early stages of a study can optimise the impact and 
relevance of research (111). Feedback received from PPI early in the study design was 
used to identify and address issues that may impact the participant’s experience, and 
consequently, their recruitment.  Feedback from PPI can be used to revise aims, 
objectives, data collection and collection of outcome measures. 
In the MaCROS study, PPI included children, teenagers and young people who are 
patients at the paediatric haematology and oncology department and/or their parents or 
guardians. Several children, young people, and their parents were approached to give 
feedback on the consent forms, PILs and patient diaries. This was to ensure they were 
easy to understand, and clearly explained participants’ potential involvement in the 
study. Feedback involved: 
 Parents giving feedback on the study aims and objectives 
 Whether they would consider participating in a future study 
 Voting for their preferred study short name acronym (MaCROS was the most 
popular) 
 Giving feedback on the patient information leaflets and diaries that have been 
developed 
- 101 - 
We planned to use the feedback from patients and families to make changes which 
would make participation more engaging and user-friendly. However, the feedback 
received was positive, and no changes were needed. 
4.2.12  Healthcare professional involvement 
A play specialist (N.B) contributed to the revisions of the patient information leaflet for 
young children. Most suggestions focused on altering the wording and formatting to 
make the leaflet more engaging. All suggestions by N.B were included in the final 
version of the patient information leaflet. Furthermore, a dietician (E.W) with research 
experience within the topic of mucositis in oncology patients (112) highlighted the need 
to add a section about confidentiality in the patient information leaflets.  
The study proposal was presented at the Experimental Cancer Medicine Centre 
meeting in January 2018, and the local Haematology and Oncology department at 
Leeds Teaching Hospital Trust. Queries and feedback were considered during 
revisions of the protocol prior to the submission of ethical review. 
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4.3 Part 2: Methodology  
4.3.1  Introduction to the MaCROS study methodology 
The previous sections discussed the justifications and the approach for developing the 
MaCROS study. The following section provides an overview of the study methods. 
Greater detail is provided in the MaCROS study protocol included in appendix 2.1.  
4.3.2 Aim 
This study aimed to evaluate the feasibility of an RCT investigating the efficacy of liquid 
probiotics in preventing or reducing mucositis and infection in paediatric oncology 
patients undergoing treatment regimes likely to cause mucositis. 
4.3.3 Objectives 
The primary objectives of this study were to determine: 
1) Whether it is feasible to recruit children to a study when they are diagnosed with 
cancer and are at risk of developing mucositis 
2) The completion rates of participants taking the liquid probiotic/placebo for 2 weeks 
3) The completion rate of the symptom diary (paper/web-app) by participants or legal 
guardians recording the symptoms of nausea, vomiting, diarrhoea, oral mucositis 
and abdominal pain from the start of chemotherapy up until 21 days 
4) Provide preliminary information on the health economics surrounding the costs and 
benefits of the intervention 
Secondary objectives included: 
1) Evaluation of the research protocol: by exploring the barriers and facilitators of 
the primary and secondary outcomes, and whether the protocol is pragmatic 
2) Barriers to complying with the protocol 
3) Evaluation of the outcomes intended to be assessed in an RCT. This could 
have included, but was not limited to, the incidence, severity and duration of 
diarrhoea and infection in both groups; the incidence of nausea, vomiting, oral 
mucositis; use of analgesia; and evaluation of hospital admissions. 
4.3.4 Methods 
The MaCROS study was registered prior to commencement (ClinicalTrials.gov 
Identifier: NCT03785938 (active), IRAS PROJECT ID: 246313, CPMS ID: 40800). The 
MaCROS study protocol, PILs and consent forms for the parents/responsible carers of 
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the children participating in the study and children aged 16-18 years old are enclosed 
in appendices 2.1-2.8.  
4.3.4.1 Trial design 
This was a single-centre double-blind randomised-controlled feasibility study.  
4.3.4.2 Study setting 
This study took place at Leeds Teaching Hospital Trust, (LTHT) Leeds UK between 
May and November 2019.  
4.3.4.3 Participants 
Participants were recruited from the Paediatric Haematology and Oncology Department 
(inpatient and outpatient settings). 
4.3.4.4 Eligibility criteria for participants  
Patients treated on paediatric cancer protocols, receiving chemotherapy, or on 
regimens that were likely to cause mucositis. Examples of protocols are included in 
appendix 2.1. 
4.3.4.4.1 Exclusion criteria 
 Patients who had already started the course of chemotherapy 
 Patients receiving radiotherapy or surgery alone 
 Patients who had taken probiotic supplements in the month prior to starting their 
next course of chemotherapy 
 Patients with confirmed immunodeficiency 
4.3.4.5 Target recruitment 
The recruitment target was between 20 and 40 patients over a six-month period. As 
this was a feasibility study, a power calculation was not required. 
4.3.4.6 Ethical review 
This protocol was approved by the UK National Health Service (NHS) Ethics 
Committee process (REC ref: 19/YH/0005, appendix 2.11) and MHRA who confirmed 
that in this study, probiotics are classified as a supplement and that this would be 
classified as a Non-CTIMP study (appendix 2.12).  
4.3.4.7  Consent 
Consent on behalf of children under the age of 16 was taken from their parents/legal 
guardian. Children under the age of 16 were invited to complete an assent form 
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(appendix 2.8). Children aged 16-18 years old with capacity were required to supply 
their own consent. 
4.3.4.8  Interventions 
Participants were required to commence the blinded liquid probiotic or placebo 
enterally; either orally, via nasogastric tube, or gastrostomy; from the first day of their 
chemotherapy/pre-stem cell transplant chemotherapy conditioning. They were required 
to take this daily for 14 days. The dose prescribed varied according to age groups: 
 Under the age of 4:  20 mL once a day 
 4-8 years of age: 0.5mls/kg once a day 
 Above the age of 8: 1ml/kg once a day 
4.3.4.9  Randomisation: type 
Simple randomisation was used due to the small number of participants recruited.  
4.3.4.10  Randomisation: implementation 
This was undertaken by the trials pharmacist at LTHT. 
4.3.4.11 Allocation concealment 
Healthcare professionals (except the trials pharmacist) and participants were blinded to 
the randomisation allocation.  
4.3.4.12  Blinding 
Patients, healthcare professionals (except the pharmacy department) and the research 
team were blinded to the type of intervention delivered (intervention or placebo). 
Packaging for both groups was identical, and this was completed by the liquid probiotic 
company. 
4.3.4.13 Data collection 
4.3.4.13.1 Patient diary 
The diary included questions to assess nausea, vomiting, diarrhoea, pain and oral 
mucositis (using a modified version of the ChIMES (103)). Either the participant or legal 
guardian was requested to fill in the diary, daily, for a minimum of 21 days. If possible, 
the same person was required to fill in the diary throughout the 21 days. They were 
given the option to complete a paper diary (appendix 2.16) or use a web-app which 
was secure and accessible only by the participant's randomisation number, which was 
issued by the trials pharmacist (www.macrosstudy.com). 
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4.3.4.13.2 Investigation of febrile episodes/infection 
Clinical records, including electronic and written records, were reviewed to investigate 
for any instance of febrile episodes or , for the duration of any fever/infection, and for 
the duration of hospital stay until the patient was afebrile for 48 hours (table 16).  
4.3.4.13.3 Other data 
Other relevant information, including the type of nutritional support, analgesia and 
duration of hospital stay was taken from clinical records. Data collected were 
anonymised and stored on data collection forms. 
4.3.4.14 Data analysis 
4.3.4.14.1  Statistical analysis 
Data were entered into a secure, local, anonymised database and analysed using 
descriptive statistics, Student's t-test, Mann–Whitney U-test, and χ2 tests, for 
comparative, normal, non-normal, and categorical data respectively. Where possible, 
appropriate subgroup analysis was to be undertaken. 
4.3.4.15 Evaluation of the MaCROS study 
The MaCROS study evaluated: 
 The feasibility of undertaking a large, adequately powered RCT  
 The safety of MaCROS (use of probiotics/placebo and reporting of unexpected 
serious adverse events) 
This study was evaluated using both quantitative and qualitative methods. Data relating 
to the timing of the return of patient diaries, department referral rate, recruitment rate 
and numbers lost to follow-up was recorded. Acceptability and tolerability of the 
treatment intervention was assessed through the completion rate of the 
probiotic/placebo course, use of the patient diaries, and exploration of the 
patient’s/parent’s study participation via interview. 
4.3.4.15.1 Indications to consider stopping the feasibility study 
 The occurrence of an unexpected serious adverse reaction that is attributed to the 
probiotic or placebo 
4.3.4.15.2  Indications to consider not progressing to a full RCT (RED) 
 Inability to recruit 10 participants within 6 months of the study opening 
 Poor compliance with recording and returning patient diaries (less than 50%) 
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 Serious concerns identified during the qualitative analysis of participant’s/legal 
guardian’s interview 
4.3.4.15.3 Indications to consider modifying the study (AMBER) 
 Poor recruitment: fewer than 20 participants recruited 
 Poor identification of eligible patients 
 Problems with delivery/compliance (50-80% of intervention or placebo delivered) 
 Poor compliance with recording and returning patient diaries (less than 80%) 
4.3.4.15.4 Indications to continue the study without modification (GREEN) 
 No issues implementing the study protocol 
 An adequate number of participants identified and recruited within the 6-month 
period 
 100% compliance with the delivery of the intervention/placebo 
 Greater than 80% compliance of recording and returning of patient diaries 
4.3.4.16 Evaluation of participant/parent experience  
As part of the MaCROS study evaluation, a section was planned in which participants 
and/or parents were invited to discuss their experiences of participation in the trials. It 
was planned that participants who agreed to take part could be interviewed over the 
phone or in-person (depending on preference) and the interview audio could be 
recorded. The interview included questions regarding recruitment, the process of 
gaining consent and randomisation, and experiences using the probiotic/placebo and 
patient diary. The effect of these experiences on adhering to the study protocol was 
considered. Information was collected using a recording audio device, transcribed, and 
evaluated using the framework approach(113). The information was planned to be 
used in the development of any future RCT. 
Unfortunately, despite the planning, it was not possible to carry out this section as it 
was not possible to successfully recruit enough participants for this part of the study.  
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Table 11: Summary of the ‘traffic light’ approach for evaluating the MaCROS 
study. 
      
Identifying serious concerns 
during the qualitative 
analysis of the participant’s 
or legal guardian’s interview. 
Poor identification of eligible 
patients. 
No issues implementing the 
study protocol. 
 
Inability to recruit 10 
participants within 6 months 
of the study opening. 
Poor recruitment- e.g. fewer 
than 20 participants 
recruited. 
An adequate number of 
participants identified and 
recruited within the 6-month 
period. 
 Problems with 
delivery/compliance (50-
80% of intervention or 
placebo delivered). 
100% compliance with the 
delivery of the 
intervention/placebo. 
Poor compliance with 
recording and returning 
patient diaries (less than 
50%). 
Poor compliance with 
recording and returning 
patient diaries (less than 
80%). 
Greater than 80%  
compliance of recording and 
returning the patient diaries. 
 
4.3.4.17 Safety reporting  
The research team were responsible for identifying any adverse events. Serious 
Adverse Events (SAEs) were to be reported to REC using the safety reporting form 
recommended by the Health Research Authority 
(http://www.hra.nhs.uk/resources/during-and-after-your-study/progress-and-safety-
reporting).  
Because this feasibility study was classified as a non-CTIMP study, the only reports 
that were considered as SAEs were:  
• Related to the study (i.e. as a result of administering the Symprove or placebo) 
• Unexpected (i.e. not listed in the protocol as an expected occurrence) 
Serious Adverse Reactions (SARs) are: An adverse event that is both serious and, in 
the opinion of the reporting investigator, reasonably believed to be caused by the trial 
treatments based on the information provided. 
The strategies in place for safety reporting and a list of expected and unexpected SARs 
are summarised in the study protocol enclosed in appendix 2.1.  
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4.4 Part 3: Results  
4.4.1 Introduction to the MaCROS study results 
This section will include: 
 The evaluation of the study  
 Quantitative results 
 Qualitative findings 
Between May 2019 and November 2019, 39 children and young people were identified 
as eligible (diagnosed with cancer and at risk of developing mucositis).34 of these were 
approached to take part in the MaCROS study. 10 children (29.4% of those 
approached) were recruited. The ages of the participants recruited ranged from 1 year 
and 7 months to 15 years of age. The mean age of children recruited was 8 years and 
7 months. Of these 10 participants, nine were diagnosed with solid tumours and one 
with acute myeloid leukaemia. Two of these nine participants received an autologous 
stem cell rescue for the delivery of high dose chemotherapy. Demographics are 
summarised in table 13. 
Two participants (one placebo, one probiotic) chose not to continue participating 
because of the taste of the probiotic/placebo, and a change in desire to take the 
intervention/placebo. One of these participants submitted a partially completed diary 
and the other did not submit a diary upon completion. 
Of these 10 participants, four were randomly allocated to the intervention group, and 
six were randomly allocated to the control group. Eight participants managed to 
complete greater than 80% of the total course of probiotic/placebo. The only reason 
documented that participants omitted a dose of probiotic/placebo whilst actively 
participating was being requested as ‘nil by mouth’ by clinicians. A consort diagram of 








- 109 - 
 











- 110 - 
 
4.4.2 MaCROS study evaluation 
4.4.2.1 Setting up the study 
Setting up the study was a multi-step process.  This included: 
 Developing the study protocol 
 Identifying and communicating with the company Symprove who supplied the 
probiotic and placebo 
 Liaising with the study sponsors and legal departments at the University of Leeds 
 Liaising with the research pharmacy team to register the study, establish how 
blinding and how randomisation of the probiotic/placebo will take place 
 Applying to the NHS REC, NIHR portfolio, HRA and LTHT R&D department 
 Attending an NHS REC research ethics committee review 
 Delivering a presentation regarding the MaCROS study to health care professionals 
within the local department involved in the study, alongside regional, national and 
international presentations 
4.4.2.1.1 Facilitators to setting up the study 
The HRA, Yorkshire REC and Portfolio application have been streamlined to ensure 
the duplication of an application does not occur. The submission of the MaCROS study 
was approved by REC and HRA following minor amendments (appendices 2.10 and 
2.13). This demonstrates that this study is feasible to set up at both a local and national 
level. 
4.4.2.1.2 Barriers to setting up the study 
The application submitted to the Yorkshire REC and HRA for the MaCROS study took 
a significant amount of time to be reviewed and processed. Because LTHT R&D were 
unable to review the study until HRA had approved it, the pharmacy research team 
were unable to authorise the delivery of the probiotic/placebo by Symprove and thus 
undertake their required quality checks for dispensing. This resulted in the MaCROS 
study opening later than anticipated. Whilst the study was ultimately set up, the lengthy 
multi-step procedure was a barrier to setting up a future multi-centre study in a timely 
manner.  
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4.4.3 Primary outcomes 
4.4.3.1 Identification 
Between May and November 2019, there were 39 patients who met the eligibility 
criteria, of which 37 were screened, 34 participants were approached, and 10 were 
randomised. 
Participants were identified in the following ways: 
 New patients who were added to department’s weekly MDT meetings 
 Patient clinic lists 
 Inpatients 
 From recommendation by research nurses 
 Word of mouth- e.g. consultant identifying a participant 
Staff (doctors, nurses and allied healthcare professionals) within the department were 
informed of the MaCROS study through educational sessions delivered at 
departmental meetings, and one-on-one conversations. This was undertaken to 
increase awareness within the department, such that they could answer questions from 
eligible participants and families. 
Five patients were eligible to participate, but were not approached for the following 
reasons: 
 We were unable to communicate with the parents without an interpreter. 
Unfortunately, the parents were unable to read English PILs and consent forms. 
 A child had relapsed, and the parents were highly distressed (an HCP decision 
made not to approach). 
 Eligibility was discovered by an alternative route from that described above (and 
therefore did not meet the eligibility criteria because of the delay). 
4.4.3.2   Declining participation 
24 out of 34 eligible participants who were approached declined to participate. Of 
these, some were approached only once and others multiple times depending on their 
unique circumstances and their desires to have further time to consider joining. 
Families were approached more than once if they gave their consent to being re-
approached. Reasons for deciding to decline are summarised in table 12. 
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Parents/carers who declined participation were given the opportunity to fill in an 
anonymous questionnaire (appendix 2.17) as described in the methodology section, in 
their own time. This questionnaire was developed and included in the MaCROS study 
to help the evaluation of a possible RCT. Struggling to recruit enough children and 
young people in paediatric cancer trials is recognised as a barrier for achieving an 
adequately powered RCT. It was intended that the anonymous questionnaire would 
help identify barriers that may have prevented recruitment in the MaCROS study, and 
may prevent participation in a future study. 
No one completed the questionnaire. Reasons for this included:  
 Being too busy 
 Forgetting to complete the form 
 Losing the form 
 Changing their mind about completing it 
Eligible participants appeared to prefer giving opportunistic verbal feedback. In future 
feasibility studies, this information could be more routinely captured by developing the 
‘decline’ questionnaires, and having the researcher complete that after the discussion 
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Table 12  Verbal reasons why participation in the study was declined. 
 Reasons for declining after being 
approached once 
Reasons for declining after being 
approached two or more times  
“Worried about experiencing nausea” Parents were unable to convince child to 
participate. 
“Too much to deal with right now” Parent felt that their child already had too many 
medications. 
Worried about risk of probiotic-
associated infection. 
Initially overwhelmed with the new diagnosis. 
Asked researcher to return later, and then 
declined. 
Struggling to persuade the child to take 
any oral medicines. 
Child too unwell. 
Child dislikes the taste of milk/yoghurts. Mother wanting to participate, father not happy 
to. 
Doesn’t want to take ‘gamble’ of 
potentially receiving the placebo. 
Heard from another parent that the 
probiotic/placebo doesn’t taste nice. 
 
4.4.4 Included participants 
Ten eligible patients agreed to participate in the MaCROS study. Of these, 9 were 
diagnosed with solid tumours, and 1 was diagnosed with a malignant haematological 
condition. Two patients diagnosed with neuroblastoma were undergoing autologous 
stem cell rescue for high dose chemotherapy. Details of the anonymised demographic 
information is summarised in table 13. 
4.4.5 Patients who withdrew participation 
Two participants aged 12 (placebo) and 15 years (probiotic) respectively withdrew 
participation after one day. Both reported a dislike for the taste of probiotic/placebo and 
stated they were unable to continue with the full 14-day course. One participant 
returned the diary after completing the first page, and the other participant did not wish 
to complete any of the diary. 
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Diagnosis Cycle/day Consent Date 
commenced  
Paper/diary  Stopped further 
participation in 
MaCROS study 
1 12 years F Ewing’s Sarcoma Last 
cycle 
10/06/2019 10/06/2019 Paper 13/06/2019 
2 13 years F Osteosarcoma Cycle 6 02-Jul 04-Jul Web-app  
3 7 years F Undifferentiated sarcoma Cycle 2 02/07/2019 02/07/2019 Not completed  
4  12 
years 
F HR NBL- HD 
chemotherapy and stem 
cell rescue 
Day 0 04/07/2019 04/07/2019 Not completed  
5 1 year, 7 
months 
M HR NBL Day 20 04/07/2019 04/07/2019 Paper  
6 1 year, 7 
months 
F HR NBL- HD 
chemotherapy  and stem 
cell rescue 
Day 0 04/07/2019 11/07/2019 Web-app  
7 14 years M AML Cycle 1 04/09/2019 05/09/2019 Web-app  
8 3 years M NHL Cycle 2 05/09/2019 09/09/2019 Paper  
9 15 years M Metastatic relapsed 
osteosarcoma 
Cycle 1 09/07/2019 10/09/2019 Paper 11/9/19 
10 8 years M Osteosarcoma Cycle 3 19/11/2019 19/11/2019 Paper  
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4.4.5.1 Facilitators to recruitment 
87% of eligible participants were correctly identified in a timely manner using the 
methods described previously. 94% of those identified were happy to be approached 
for a brief introduction and discussion regarding participation in the MaCROS study. 
Most families showed initial interest in participating in the study. 
4.4.5.2 Barriers to recruitment 
4.4.5.2.1 Identification 
The previous methods described did not identify 100% of eligible participants. Two 
participants were not appropriately identified in a timely manner, for the following 
reasons: 
 Participants were not identified via review of MDTs and clinic patient lists 
 Participants were not identified and conveyed to the research team 
 Participants were not identified at the right time in their program of treatment, i.e. 
prior to the start of their next or final course of chemotherapy. 
Specific reasons for not being identified at the right time include changes/delays to their 
start of treatment. For example, a number of those who were not appropriately 
identified were those undergoing allogeneic HSCT. This was because the HSCT may 
have been delayed (due to the child being too unwell) and the research team were not 
aware of the new date. 
The responsibility of recruitment, and subsequently consent, was mostly undertaken by 
one member of the research team (but by two persons in total). This could have limited 
the number of eligible patients being identified in a timely manner. Delivering training to 
the broader medical team on the topics of recruitment, consent and prescribing of the 
probiotic/placebo could ensure a higher proportion of eligible participants are recruited 
in future studies. 
4.4.5.2.2 Selection bias 
Several eligible patients who were identified in a timely manner were not approached 
or re-approached due to explicit decisions made by the clinicians involved in their care. 
Whilst the reasons to not approach (or re-approach) patients may arguably be justified, 
it may have altered the sample of participants who were successfully recruited. 
Examples include: 
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 Not approaching patients because they have relapsed with incurable disease 
(although it is worth noting that a patient with a relapsed incurable disease was 
successfully recruited) 
 Not approaching patients because their families are visibly upset (due to 
relapse/disease-progression/ severity of treatment-related morbidity) 
 Not approaching patients who were newly diagnosed because clinicians felt 
patients and their family required space to process information 
It was noted early in the study that patients who were eligible shortly after diagnosis 
(e.g. a patient diagnosed with B-ALL who is due to start induction) tended to decline 
participation because they felt distressed, overwhelmed, wanted to prioritise essential 
interventions for their child, or had already been approached to participate in a number 
of research studies and felt they had been ‘overloaded’ with requests. Therefore, a 
decision was made one month into the MaCROS study to not approach patients who 
were recently diagnosed with cancer. 
These factors may have contributed to the recruitment of a greater number of patients 
experiencing fewer treatment-related morbidity side effects (i.e. those diagnosed with 
solid tumours vs those diagnosed with malignant haematological conditions). 
4.4.5.3 Consent  
Once patients and their families verbally consented to take part in the study, they then 
signed a consent form. Some families consented to participate in the MaCROS study 
but declined consent to participate in an interview to discuss their experience of 
participating in the study. Several parents mentioned they were only interested in 
taking the probiotic/placebo and did not have the time to take part in an interview. Five 
participants agreed to participate in an interview at the time of consent, but none were 
undertaken. Four participants did not reply to telephone enquiries to set a date. Date 
and time were agreed for one participant; however, they were not able to commit closer 
to the time. No teenage participant expressed a desire to sign the assent form. Formal 
consenting by parents was straight forward following a verbal agreement to participate. 
4.4.5.3.1 Facilitators to the consent process  
Patient information leaflets (PILs) were positively received. Most patients/guardians did 
not have any questions prior to consent because they felt the PILs clearly explained the 
risks, benefits and processes of the MaCROS study. 
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4.4.5.3.2 Barriers to consent 
There were no barriers to the consenting process. In some instances, parents 
consented and expressed a desire to participate in the MaCROS study, but their 
teenage child did not. In these situations, the patient was not recruited. One particular 
case involved non-married cohabiting parents, where the father was not on the birth 
certificate. Whilst the mother was keen for her child to take part in the MaCROS studies 
the father was not. Following a discussion with the child’s mother, a decision was made 
to respect the father’s wishes (even though it was not required legally). 
4.4.5.4 Prescribing, randomisation, allocation, concealment and dispensing 
Prescribing of the probiotic/placebo occurred once written consent was obtained by a 
prescriber. This was a two-step process, including: 
 Completing and submitting a form issued by the pharmacy team containing patient 
demographics, identification numbers, weight and allergies. Doses were calculated 
according to that specified in the protocol and the number of bottles that would be 
required. Only those with signatories on the MaCROS study delegation log were 
able to complete this form. 
 Prescribing an anonymised clinical trials medicine on Emeds, the electronic 
prescribing system used at LTHT. This could be completed by any prescriber. 
Simple randomisation was undertaken by the research pharmacy team at Leeds. The 
LTHT lead trials pharmacist (P.S.) was responsible and undertook randomisation. 
None of the research or health care team had access to the randomisation code used.  
Symprove delivered the probiotics and placebos to the pharmacy department in boxes 
of unmarked 4x 500 mL bottles. Symprove and the pharmacy team liaised directly 
without input from the research teams to confirm which of the boxes contained the 
probiotic or placebo. Only the research pharmacy team knew allocation for each 
participant and ensured blinding took place. The probiotic/placebo was labelled as 
‘clinical trial medicine’. Those who dispensed the probiotic/placebo were not aware of 
which item the product contained. No member of the research team, healthcare 
professionals or participants were made aware of the allocation. The allocation was 
only revealed to the research team once the study had closed and the final patient had 
completed participating in the study. 
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4.4.5.4.1 Facilitators to prescribing, randomisation, allocation, concealment and 
dispensing 
The prescribing, randomisation, allocation, concealment and dispensing were quick 
and easy to undertake. A prescription form was given to the local pharmacist who 
delivered the form to the pharmacy research team. 
4.4.5.4.2 Barriers to prescribing, randomisation, allocation, concealment and 
dispensing 
Completion of the form could only be undertaken by those whose signatures were on 
the delegation log (H.H. and B.P.). This limited when prescribing was able to occur, as 
it could only be undertaken if either member was present on hospital premises. This 
issue could be avoided in future studies by allowing all GCP trained prescribers within 
the clinical team to place their signature in the delegation log. 
Submitting the prescription form, undertaking randomisation, and blinding allocation 
concealment could only occur during standard working hours by the research 
pharmacy team. If a patient was consented out of hours (evenings, weekends or bank 
holidays), delivery of the form could not take place until the next working day. Even if 
prescribing occurred in a timely manner, a delay in delivery of the prescription form 
could nullify the eligibility of the participant identified. However, this did not occur with 
the 10 participants who were recruited. 
For the feasibility study, it was possible to undertake simple randomisation due to the 
small number of participants recruited. However, in a future multi-centre randomised 
controlled trial, stratified randomisation undertaken by a statistician within a Clinical 
Trials Unit is likely to be required. 
4.4.5.5 Adherence to the probiotic/placebo 
Of the ten participants who were recruited to the MaCROS study, four participants were 
randomly allocated to the intervention group, and six participants were randomly 
allocated to the control group. In total, two participants withdrew from the study (one 
probiotic and one placebo) within 24 hours of participating in the study. 
4.4.5.5.1 Facilitators to adherence to the probiotic/placebo 
80% of participants adhered to the full course of probiotic/placebo. It was successfully 
administered orally and via nasogastric tubing consistently for the 14-day course. 
4.4.5.5.2 Barriers to adherence to the probiotic/placebo 
Two participants (one probiotic, one placebo) withdrew from the MaCROS study. Both 
participants chose to withdraw as they were not able to tolerate the taste. A further 
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teenage participant disliked the taste and stated it made them feel nauseous, but that 
they chose to complete the course, because they understood the importance of 
participating in research trials to help future children diagnosed with cancer.  
The volume of probiotic was mentioned by several parents who completed participation 
in the feedback given in the diaries. Some parents stated they struggled to deliver the 
volume required and that they felt using smaller volume and higher concentration 
would be easier to manage. One parent felt that distributing the volume throughout the 
day (e.g. twice a day instead of once a day) would be easier. 
4.4.5.6 Data capture 
Data was captured using paper and web-app diaries which were filled in by participants 
or their parents/carers. Seven participants opted to use the paper diary, and three 
opted to use the web-app (table 13). Only one participant chose to fill in the diary (web-
app) themselves, and the other nine were completed by their parents/carers. 
Three parents who chose to use the paper diary stated they would prefer to use the 
web-app but found the WiFi connection in the inpatient area unreliable. The other 
parents who chose to use the paper diary stated that the paper diary would be easier to 
use as they were not comfortable with technology. 
The clinical notes and electronic records were recorded during inpatient stay for all 10 
participants. Records were reviewed to identify and capture (i) information of febrile 
episodes, and (ii) infections, for (a) incidence and duration of fever/infection, and (b) 
duration of hospital stay.  
50% of data collected from the diaries and electronic records were reviewed and 
confirmed by a second reviewer (L.S). Out of the 10 participants, seven partially 
completed the diaries. Four out of seven (57%) submitted  paper diaries with partially 
completed data, and three out of three (100%) submitted partially completed data on 
the web-app. Three out of the seven participants who submitted data completed at 
least 80% of data for 14 days (duration of the course of probiotic/placebo). Only two 
participants completed 80% of the data required for the 21 days. No participant 
completed 100% of the information requested. 
4.4.5.6.1  Paper diary 
Four out of seven participants who chose to use the paper diary partially completed the 
questions and returned the diary. Two participants completed 80% or more data for 14 
days, and the other two partially completed the data. 
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Three participants did not return a paper diary. Of these, two stated they had misplaced 
the paper diary. The third person stated they would submit it on their next clinic 
appointment but forgot to do so. 
4.4.5.6.2  Web-app diary 
All participants who chose to use the web-app partially completed data. One participant 
completed 80% of the information for the 14-day course of the probiotic/placebo and 
the other two participants submitted a partially completed diary via the web-app. 
4.4.5.6.2.1  Facilitators for the capture of data (diaries) 
The paper diaries were easy to use and understand. Parents who gave verbal 
feedback all stated the questions were easy to understand. All participants who used 
the web-app stated it was easy to navigate. 
4.4.5.6.2.2  Barriers for the capture of data (diaries) 
Participants stated they forgot to complete the diary on a daily basis. Parents stated 
this typically occurred when they were busy, and therefore at times they would 
complete data for several days in one go.  
One parent gave feedback in their paper diary, stating they found it challenging to 
assess nausea and pain because their child was too young to communicate. Another 
parent stated they would have benefited from daily push notifications. However, 
participants/parents would have had to separately consent to be receiving reminders, 
and none of the three participants gave permission to do so. 30% of participants did not 
return their paper diaries. This is because they had either misplaced or forgot to return 
their diary. 
4.4.5.7 Clinical data 
100% of data was captured involving the inpatient stay using clinical information taken 
from written and electronic records into a pre-developed proforma, using a Microsoft 
excel spreadsheet. 50% of the data collected was verified by a second reviewer for 
accuracy.  
4.4.5.7.1 Facilitators to data collection 
Collecting data from written and electronic records and using the pre-developed 
proforma was undertaken with ease. 
4.4.5.7.2 Barriers to data collection 
Lack of documentation in clinical records was the main barrier involving data collection. 
For example, a repeat blood culture may have been undertaken, but the indication was 
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not specified. Therefore, whilst the proforma could capture the information as 
documented, it may not capture the full clinical picture.  
4.4.6 Summary of primary outcomes 
The MaCROS study protocol received ethical approval and successfully opened in May 
2019. Between May and November 2019, 10 participants were recruited out of 39 
eligible participants, of which 34 were approached. Simple randomisation, allocation 
concealment and double blinding successfully took place. Four participants were 
randomised to receive the probiotic and six participants received the placebo. Of these, 
eight participants (three probiotics, five placebo) completed the full course. Seven 
participants returned partially completed diaries (four paper, three web-app). No 
participant completed data for the full 21 days. Three out of seven participants (42.9%) 
completed 80% of the data for the duration of the 14-day course of probiotic. No patient 
who declined consent opted to fill the anonymous questionnaire, although many 
participants consented to give verbal feedback and discussion of their reasons. Five 
participants agreed to participate in an interview at the time of consent. However, four 
of these participants did not reply to enquiries. One participant agreed to a time and 
date but could not commit at the allocated time.  
No unexpected serious adverse events were reported. A summary of the evaluation of 
the MaCROS study, using the traffic light system demonstrated in table 11, is 
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Table 14: Findings from evaluating the MaCROS study using the traffic light 
system 
 
Aim Result Outcome 
Implementing protocol No issues Proceed 
Recruitment 10 participants recruited Modification required. 
Identification of eligible 
participants  
Adequate identification of 
eligible participants 
Proceed  
Problem with delivery of 
intervention/placebo 
No problems Proceed 
Adherence- 
probiotic/placebo 






Poor compliance with 
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4.4.7 MaCROS study evaluation: intended outcomes to be assessed for a 
future RCT 
4.4.7.1 Statistical findings 
Statistical analysis could have included, but was not limited to; the incidence, severity 
and duration of diarrhoea and infection, the incidence of nausea, vomiting and oral 
mucositis, use of analgesia, total parental nutrition (TPN) and evaluation of hospital 
stay. 
Incomplete data was a significant issue. Specific questions were left blank by patients 
even when responses were given for that day.  Because of this, a descriptive analysis 
was undertaken with no attempts to impute missing data, and results should be 
interpreted cautiously. 
It was anticipated that the MaCROS study could be used to calculate the sample size 
required for a future clinical trial at an appropriate power. Statistical power is defined as 
the probability that an outcome is not attributed to chance. To calculate the power of a 
study, three variables are required: 
 The acceptable possibility of a false positive (type 1 error) occurring (which is 
usually set at 0.05) 
 The magnitude and variability of effect in the population 
 The size of the sample 
Because the study had fewer than anticipated participants, and incomplete diary 
entries, it was not possible to reasonably calculate the standard deviation of symptom 
outcomes and estimate the possible magnitude and variability of effect. While historical 
data studies can be used to determine the treatment effect size, the systematic review 
and meta-analysis undertaken for this thesis identified significant heterogeneity 
between studies, meaning it is not possible to reasonably use these data Examples of 
heterogeneity identified included the type of probiotic used, outcomes investigated, and 
a lack of paediatric studies.  
4.4.7.2 Diary results 
Table 15 summarises the findings from the patient diaries. Seven out of 10 patients 
submitted partially completed diaries. The percentage of days filled (excluding those 
who did not return diaries) for the duration of the 21 days ranged from 4.8%- 90.5%. 
The median percentage of total diary completed was 46.9% (approximately 10 days of 
data). The participants were more likely to fill in the diary when taking the 
probiotic/placebo; the mean percentage of diary completed for the first 14 days was 
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64.2% (range 7.14-100%), and 5/7 (71%) participants who returned diaries completed 
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(21 days in 
total) 
Percentage of diary 
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*patient stopped participation 
1 * Probiotic 4.8% 7.14% 0 1 3 0 3 1 1 
2 Placebo 52.3% 78.5% 1 (0-5) 3 (1-5) 3 (1-5) 0 (0-0) 4 (0-5) 2 (1-4) 2 (1-4) 
3 Probiotic 0 0 NA NA NA NA NA NA NA 
4 Placebo 0 0 NA NA NA NA NA NA NA 
5 Probiotic 61.9% 92.9% 1 (0-3) 6 (4-7) Not 
document
ed 
1 (0-2) 1 (1-2) 1 (0-3) 1 (0-3) 
6 Probiotic 90.5% 100% 3 (0-10) 5 (4-7) 2 (1-3) 1 (0-3) 1 (0-3) 0 (0-2) 0 (0-2) 
7 Placebo 4.8% 7.14% 7 4 1 Not 
document
ed 
1 1 1 
8 Placebo 61.9% 92.9% 3 (0-7) 6 (6-7) 2 (1-3) 1 (0-3) 1 (1-3) 2 (1-4) 3 (0-4) 
9* Placebo 0 0 NA NA NA NA NA NA NA 
10 Placebo 52.3% 78.5% 1 (0-3) 4 (3-7) 2 (2-4) 1 (0-3) 1 (1-3) NA 2 (1-4) 
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4.4.7.3 Inpatient admissions  
Nine out of 10 participants had an in-patient stay. All data captured involving the 
inpatient stay was from clinical information, taken from written and electronic records, 
as previously described. 
4.4.7.4 Pyrexia and infection 
Table 17 presents a summary of the participants who were febrile (non-neutropenic), 
febrile (neutropenic) or had grown an organism from a blood culture without fever. Two 
of the three participants who were febrile but not neutropenic did not receive antibiotics. 
The participant who did was undergoing a high-risk procedure (autologous transplant). 
All three participants who developed febrile neutropenia received antibiotics. One 
participant who was not febrile received antibiotics following the recommendation from 
the microbiology team. 
4.4.7.5 Other supportive care interventions 
Table 18 summarises supportive care interventions delivered to the participants 
recruited to the MaCROS study. No participants were admitted to intensive care. 
Expected serious adverse events which occurred included a participant developing 
neutropenic enterocolitis, vaso-occlusive disease (VOD), post-transplant ileus and a 
C.difficile infection. 10 participants (100%) required antiemetics for nausea and seven 
participants (70%) required analgesia. Of these, two participants (two probiotics) 
required a Patient-controlled analgesia (PCAS). Four participants (40%, two probiotics, 
two placebos) required nasogastric tubes, and one participant in the placebo group 
required Total parental nutrition (TPN).
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1 * Probiotic 12 years Ewing’s 
Sarcoma 
Yes No No No N/A  
2 Placebo 13 years Osteosarcoma Yes Yes Yes No No  
3 Probiotic 7 years Undifferentiated 
sarcoma 
Yes No No No NA  
4 Placebo 12 years HR NBL-HD 
chemo and stem 
cell rescue 
Yes NA** Yes Yes No  
5 Probiotic 1 year, 7 
months 






6 Probiotic 1 year, 7 
months 
HR NBL- HD 
chemo and stem 
cell rescue 
Yes NA** Yes No Yes Gram negative 
bacilli 
 
7 Placebo 14 years AML Yes NA** Yes Yes No  
8 Placebo 3 years NHL Yes Yes Yes Yes No  
9* Placebo 15 years Metastatic 
relapsed 
No No No No NA  

















10 Placebo 8 years Osteosarcoma Yes Yes Yes No No  
*Withdrawn    ** Inpatient until count recovered 
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Organism Additional information 
2 Placebo 13 years. Osteosarcoma No Neut 10.5x10^9/L 
WCC 11.5  x10^9/L  
CRP 41 mg/L   
No  ? Temperature related to 
mifamurtide 
Not commenced on 
antibiotics 
4 Placebo 12 years. HR NBL Yes Neut 0.02  x10^9/L  
WCC 0.04  x10^9/L  
CRP 244  mg/L   
 
No  Treated for thrush (mouth 
swab Candida albicans) 




5 Probiotic 1 year 7 
months. 
HR NBL No Neut 0.63   x10^9/L 
WCC 2.26 x10^9/L   







CRP not checked until 
noted to have positive 
culture result 
 
Not febrile or neutropenic. 
Cultures taken after patient 
vomited on himself and 
requiring a change of 
central line smart sites and 
routine cultures being 
taken 
Treated with vancomycin 












Organism Additional information 
6 Probiotic 1 year, 7 
months 
HR NBL No Neut 0.68  x10^9/L  
WCC 0.71  x10^9/L  





Treated for neutropenic 
sepsis, neutropenic 
enterocolitis and VOD  
Unable to fully identify 
organism 97% similarity to 
proposed genus 
Anaeromassillibacillus 
Treated with tazocin and 
tobramycin then switched 
to Meropenem 
7 Placebo 14 years. AML Yes Neut 0.03  x10^9/L 
WCC 0.71 x10^9/L   
CRP 52  mg/L   
No  No possible focus 
documented. 
Treated with Tazocin 
 
8 Placebo 3 years. NHL Yes Neut 0.09  x10^9/L  
WCC 0.14  x10^9/L  
CRP 21  mg/L   
 
No C. diff toxin 
positive stool 
Loose stools- moderate 
severity CDT score. 
Commenced metronidazole 
for CDI and meropenem 
(penicillin allergic) for FN 
10 Placebo 8 years. Osteosarcoma No Neut 5.38  x10^9/L  
WCC 7.3  x10^9/L 
 CRP 20  mg/L   
No  Coryzal, NPA negative not 
started on antibiotics 
Neut: Neutrophils     WCC: White cell count    CRP: C-reactive protein 
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IV fluids* Critical care 
admission 
Antiemetics Analgesia Location 
of pain 
1 * Probiotic 12 years. Ewing’s 
Sarcoma 
No  Yes No Yes PCAS Mouth 
Stomach 
2 Placebo 13 years. Osteosarcoma No  No No Yes No NA 
3 Probiotic 7 years. Undifferentiated 
sarcoma 
Yes  No No Yes Dihydrocodeine Not 
known 
4 Placebo 12 years. HR NBL Yes Yes Yes No Yes PCAS Mouth, 
stomach 
5 Probiotic 1 year 7 
months. 
HR NBL Yes  No No Yes Dihydrocodeine Not 
known 
6 Probiotic 1 year 7 
months. 
HR NBL No  Yes No Yes Oramorph Not 
known 
7 Placebo 14 years. AML No  No No Yes Dihydrocodeine  Not 
known 
8 Placebo 3 years. NHL Yes  Yes No Yes Oramorph Mouth, 
Throat 









IV fluids* Critical care 
admission 




9* Placebo 15 years. Metastatic 
Osteosarcoma 
No  No No Yes No NA 
10 Placebo 8 years. Osteosarcoma No  No No Yes No NA 
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4.4.7.6 Qualitative evaluation- feedback from the diary 
Four participants recorded feedback in the paper diaries. Some feedback related to 
adherence with the probiotic/placebo and use of the patient diary. Table 19 
summarises this feedback, which has been anonymised and paraphrased for 
confidentiality.  
Table 19: Feedback delivered in diaries (both paper and web-app) 
Probiotic/placebo Feedback 
Probiotic “X found it difficult to drink the sample as the smell is quite off-
putting, we did get it down but I’m sure if it had a better smell 
the task would be easier” 
 
“From an adults’ point of view, all the chemo and extra meds 
the kids have to then take another product that has such a bad 
smell and taste is hard for them” 
Probiotic “Y stopped eating-not sure if its due to feeling sick or not eating 
because of mucositis” 
 
“I don’t think she had the trial medicine today as she had to 
stop any oral intake (bowels slowing down)” 
 
“Trial med not given as no oral/NG tube allowed” 
Placebo “Dose taken an hour later as Z had yoghurt with food at the 
time dose was due” 
“Being a baby, it is difficult to say how sickly Z feels so it’s all a 
best guess” 
“Would be helpful to have reminders” 
Placebo “20 mL is too much to put down an NG tube in a small child” 
“Not eaten for a while” 
“Again 20 mL is too much volume, it makes him retch as you 
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put it down” 
 
4.4.7.7 Economic evaluation 
4.4.7.7.1 Study set up 
No research costs other than funding for the author of this thesis was required to set up 
the MaCROS study. This study received NIHR portfolio funding, and this enabled direct 
access and support, from research nurses who work within the department, at no extra 
cost. A research nurse directly communicated with some participants, approached 
eligible participants to participate in the study, supplied PILS and collected diaries from 
participants upon completion.    
The company Symprove supplied the probiotic and placebo to the MaCROS study free 
of charge and donated costs to the development of the web-app. 
4.4.7.7.2 Inpatient stay 
Due to the limited number of participants in the study, it was not possible to undertake 
formal economic evaluation (cost/benefit analysis). However, there were no 
unexpected serious adverse events and no prolonged hospital admissions due to the 
probiotic. 
4.5 Summary 
The MaCROS study protocol received NIHR portfolio status (appendix 2.15), ethical 
approval from the HRA (appendix 2.13), Yorkshire REC (appendix 2.11) and LTHT 
R&D (appendix 2.14) and opened to recruitment 23rd May 2019. Between May and 
November 2019, 39 eligible participants were found to be eligible, of which 34 were 
approached and 10 were recruited to the study. Simple randomisation, allocation 
concealment and double blinding were successfully implemented. Four participants 
were randomised to receive the probiotic and six participants received the placebo. Of 
these, eight participants (three probiotics, five placebo) completed the full course. 
Seven participants returned partially completed diaries (four paper diaries, three web-
app). Of these, no participants completed data for the full 21 days. Three out of the 
seven participants (42.9%) completed 80% of the data for the duration of the 14-day 
course of probiotics. No patient who declined consent opted to fill the anonymous 
questionnaire, although verbal feedback was given at the time. Five participants agreed 
to participate in an interview at the time of consent, but no interviews occurred. Four 
participants gave feedback on the study in the supplied diaries. 
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Missing data was a significant issue. Select questions were left blank even when 
responses were given for that day.  
Data was captured from clinical and electronic records for all participants recruited to 
the MaCROS study. Seven of these participants either developed pyrexia or were 
noted to have a positive blood culture result. Six participants (one probiotic group, five 
placebos) developed pyrexia. Three of these participants also had febrile neutropenia 
(three placebos) who were also classified as high-risk febrile neutropenia. Two 
participants (two probiotics) had positive culture results. One of these participants was 
noted to have a positive culture from a routine check despite not being febrile or febrile 
neutropenic. Organisms reported include an unidentified organism, Streptococcus 
mitis/oralis, Streptococcus vestibularis and Streptococcus parasangui. A participant in 
the placebo group with febrile neutropenia was also treated for oral thrush. A further 
participant in the placebo group developed a C. difficile infection (positive toxin) which 
required treatment with oral metronidazole. 
There were no deaths, and no participants were admitted to intensive care. Expected 
serious adverse events which occurred included a participant developing neutropenic 
enterocolitis, vaso-occlusive disease (VOD), post-transplant ileus and a C,difficile 
infection. Ten participants (100%) required antiemetics for nausea, seven participants 
(70%) required analgesia. Of these, two participants (two probiotics) required a patient-
controlled analgesia (PCAS). Four participants (40%, 2 probiotics, 2 placebos) required 
nasogastric tubes and one participant in the placebo group required total parental 
nutrition (TPN). 
Four participants recorded feedback in the submitted diaries. The feedback related to 
adhering to the schedule for taking the probiotic/placebo and use of the patient diary. 
There were generally negative opinions recorded on the taste and volume of probiotic, 
and the challenges in completing the diary daily, especially when judging the degree of 
nausea experienced by very small children. No additional research costs (apart from 
funding for the author of this thesis) were required to set up the MaCROS study. This 
study received NIHR portfolio funding. This enabled direct access and support from 





- 137 - 
4.6 Conclusion 
The MaCROS study, a double-blind randomised control feasibility study, was 
successfully developed, opened and completed on the basis of information reported in 
this thesis.  10 participants were recruited during a six-month period. Whilst the primary 
outcome of recruiting 20-40 participants was not achieved, significant barriers were 
noted, providing guidance for future studies. In conclusion, we propose applying 
revisions to the MaCROS study protocol and extending the study to reassess findings. 
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5 Evaluation of the MaCROS study 
 
5.1 Introduction 
The MaCROS study evaluated the feasibility of undertaking an RCT to investigate the 
efficacy of liquid probiotics to prevent or reduce mucositis and infection in children 
diagnosed with cancers. In general, the research protocol was successfully 
implemented. The MaCROS study demonstrated that health care professionals and 
researchers were able to comply with the protocol. The main barriers to compliance 
with the protocol were (i) identifying and approaching all eligible participants, (ii) 
adherence to completion of diaries, (iii) recruitment to the face to face interviews and 
(iv) completion of anonymous questionnaires. 
5.2 Summary of the MaCROS study 
The MaCROS study demonstrated that it is feasible to undertake a future RCT. Ten 
participants were recruited into this study, and no unexpected severe adverse events 
were reported. Children and young people of a range of ages diagnosed with malignant 
haematological and solid tumours were successfully recruited. 
Strengths of the study included ensuring the protocol was developed with patients and 
families in mind. The probiotic and placebo were delivered in liquid form, ensuring they 
could be given orally or via nasogastric tubing, as some children struggle to take 
tablets. Patient information leaflets and diaries were designed to be easy to understand 
and complete. Participants and their families were able to choose from a paper and 
web-app version of the diary to address the preferred options for data capture.   
Diaries, leaflets and consent forms developed for patients and families were designed 
for different age groups and were developed in conjunction with patients, families, and 
other health care professionals. In particular, the ‘chemo’ duck leaflet was positively 
received by families and health care professionals. 
The MaCROS study was awarded portfolio status by the National Institute of Health 
Research, enabling additional support including access to the department’s research 
nurses. Symprove kindly donated the probiotic and placebo free of charge and 
provided a donation for the development of the web-app. Other than the funding of the 
PhD fellowship, no additional funding was required for this study. 
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5.3 Learning from the MaCROS study 
This section discusses the lessons learned from undertaking the MaCROS study. It 
identifies (i) specific barriers  to achieving particular objectives, (ii) which areas of the 
protocol would benefit from revision, and (iii) potential strategies to overcome barriers 
in future studies. 
5.3.1 Recruitment 
Evaluation of the MaCROS study identified that recruiting a sample of 20-40 
participants over a six month period was an ambitious estimate. This sample was 
calculated on the assumption that two new patients would present to the department 
every week resulting in 50 potential participants over six months. However, this 
estimation did not consider that some of these patients would not meet the eligibility 
criteria, e.g. children under the age of 1, and children who are on chemotherapy 
regimens unlikely to cause mucositis.  
At the start of recruitment to the study, there was a reduction in the presentation of new 
patients, which is a common phenomenon seen in a rare disease speciality. On 
average, 2-3 new participants are diagnosed weekly, but in the four weeks after the 
MaCROS study opened, there were just two new patients who presented with a new 
diagnosis. The week to week variability in patients who presented during this period 
impacted the recruitment of new patients. Patients who were already receiving 
chemotherapy treatment while the MaCROS study was open were also considered. 
Allowing this enabled identification of 10 potential participants, one of which was not 
approached due to a language barrier. Three (33%) of these 9 ‘ongoing treatment’ 
patients were recruited to the MaCROS study. Seven of 30 (23.3%) newly diagnosed 
eligible participants were recruited. 
Studies have reported that 50-70% of children and 30% of young people enrol onto 
therapeutic clinical trials (114). Recalculating the recruitment target using the 39 
eligible participants during the six months it was open, 10-20 participants 
(approximately 26%-50%) appears to be a more reasonable target. However, even 
though the MaCROS study did achieve the lower goal of recruiting 10 participants, 
further barriers have been identified.  
5.3.2 Difficulties for health care professionals  
Five eligible participants were not approached because either (i) they were not 
identified at the appropriate time, (ii) there were significant language barriers, or (iii) 
because health care professionals involved felt it was not appropriate to contact the 
family.  
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Recruitment to clinical trials is often reliant on health care professionals who act as 
'gatekeepers' by screening patients, and at times obtaining consent on behalf of the 
research team. 
How gatekeepers impact recruitment is poorly understood, though it is believed they 
can influence the willingness to participate. Newington et al reported that Patients 
approached by their usual doctor, rather than someone unfamiliar to them, are more 
likely to participate in a study (115). Gatekeepers may consider multiple factors before 
deciding to approach an eligible patient such as engagement, the patient's health 
status and their attitude towards research. Gatekeepers are believed to be more likely 
to contact a participant if they believe the benefits outweigh the risks of taking part in 
the study (116). However, there is a lack of research exploring how to overcome the 
barriers health care professionals (HCPs) face when approaching a cancer patient or 
their  parents/carers.  
Other factors that can impact recruitment include how HCPs perceive a family, such as 
assuming which parents aremore likely to decline participation. Such perceptions come 
about because of the HCPs’ previous interactions with families in a clinical setting. 
When considering approaching an eligible patient, HCPs worry about the reaction of 
the child or young person, or their family, and how this might affect the HCP-patient 
relationship. 
In the MaCROS study, some health care professionals felt there were too many 
competing demands to consider when contacting the parents or guardians of individual 
eligible patients, and for this reason chose not to approach them. It was noted on a 
number of occasions that health care professionals felt it was not appropriate to 
approach a family, because the family were still coming to terms with  difficult news or 
a new diagnosis. 
Organisational barriers were also recognised as a barrier for health care professionals 
to approaching eligible participants and their families. Health care professionals (apart 
from the PI of the study) were required to identify and contact families during their 
clinical duties. Dealing with the necessary clinical tasks while discussing the MaCROS 
study with a family was, at times difficult, mainly when dealing with multiple stressful 
situations. There were times when the intensity of workload, levels of sickness and 
critical illness on the ward, and in outpatient settings, resulted in senior medical staff 
being unable to give patient recruitment the priority it required. 
Figure 9 summarises the complex multifactorial barriers which may influence a health 
care professional’s decision to approach an eligible patient or their family about 
participation in the MaCROS study.  
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Barriers toa, and facilitators of, recruitment to trials have been examined extensively in 
the past. A systematic review of 37 studies undertaken by Caldwell et al (117) 
assessed 4 recruitment strategies, focussing on increasing potential participants’ 
awareness of trials. The review focused on: (i) novel trial designs, (ii) recruiter 
differences, (iii) provisions of trial information, (iv) and incentives. Meta-analysis 
suggested that using interactive programmes, videos or educational sessions, and 
monetary incentives, improved recruitment. Increasing patients understanding of the 
trial process, but using different methods of randomisation and consent did not. 
However, whilst thirteen of the thirty-nine studies included in the systematic review 
focused on cancer conditions, none of these 13 studies included paediatric patients.   
A review by McDonald et al (118) reviewed recruitment in RCTs that were funded by 
the UK Medical Research Council and the Health Technology Assessment Programme 
between 1994 and 2002. It reported that studies which had simple trial designs, 
support from trials units, or were drug intervention trials were more likely to be 
associated with successful recruitment. The MaCROS study had a simple trial design 
but did not receive support from a trials unit. The review by McDonald et al (118)  also 
stated that using newsletters and posters to inform clinical staff and patients, regular 
site visits, amending the inclusion criteria/protocols, and delivering presentations and 
workshops to site staff / appropriate groups were successful strategies to increase 
recruitment. However, the odds ratios reported were associated with wide confidence 
intervals (CIs), highlighting the uncertainty of these findings. Furthermore the review 
did not include any paediatric studies.  
The recognised barriers associated with recruitment in RCTs has led to the 
development of  interventions targeting recruitment. A study by Rooshenat et al 
evaluated the impact of  the  QuinteT recruitment intervention on 5 RCTs (119). The 
aim of this intervention was to identify recruitment difficulties and implement actions to 
address these issues. 4 out of the 5 RCTs encountered recruitment challenges and 3 
of these improved following interventions implemented. Four of these RCTs were 
feasibility studies and two of these included adult participants diagnosed with cancer. 
Both cancer studies were for surgical interventions and had recruitment periods (12 
and 21 months) which were considerably longer than the recruitment period in the 
MaCROS study (6 months) and involved multiple centres. 
A Cochrane systematic review undertaken by Treweek et al reviewed strategies for 
improving the recruitment of participants to RCTs  for a wide range of diseases (120). It 
identified 68 trials (totalling over 74,000 participants) that implemented recruitment 
interventions. The interventions focused on trial design, trial conduct changes, 
modifying the consent processes and information delivery to participants, interventions 
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aimed at recruiters, and incentives. However, only 2 studies that demonstrated an 
increase in recruitment were supported by high certainty evidence. The interventions 
implemented in these 2 studies were (i) using non-blinded rather than blinded placebo 
trials, and (ii) telephone reminders for people who do not respond to postal enquiries. 
Using a bespoke participant information leaflet, which is user-tested, was supported by 
high certainty evidence but demonstrated little to no effect. Treweek et Al suggested 
focusing on improving evidence based  current strategies rather than developing new 
ones. They suggested using Studies Within a Trial (SWAT) for evaluation of 
recruitment (121), and contacting Trial Forge (www.trialforge.org) about intended 
recruitment evaluation, to ensure better coordination and dissemination of intentions. 
However, these interventions focused on studies of adult participants, and a paucity of 
strategies which target paediatric studies was noted. The review by Treweek et al also 
highlighted the lack of studies targeting interventions at paediatric recruitment and only 
one study included children (120). Whilst interventions such as the QuinteT recruitment 
intervention could be applied to paediatric studies, it would have required modification 
to factor in proxy parental consent, and would have needed analysis by those 
experienced in clinical trials involving children.  
Strategies which could be used to increase recruitment in a future RCT, based on the 
barriers identified in the MaCROS study, are summarised in table 20. As large-scale 
recruitment appears to be a significant barrier in many paediatric RCTs, it is clear 
further research is needed to develop and validate interventions and create a 
framework which can help increase recruitment in future studies. 
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Figure 9: Summary of factors which can influence a health care professional decision to approach a patient. 
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Table 20: Strategies to overcome barriers which impacted recruitment in a future RCT 
 
Barrier Strategy 
Organisational       Revise eligibility criteria – consider greater flexibility on the start date of probiotic/placebo. 
Extra support- i.e. the initial enquiry is delivered by health care professional known to the family (e.g. named 
consultant) with research nurse- who can then complete the rest of the consenting process. 
Predeveloped research packs (including PILS, consent and prescribing forms) to reduce the burden on the health care 
professional. 
      Increase recruitment period (i.e. 12 months or longer) 
      Use SWAT analysis and consider involving Trial Forge 
 
Interpersonal        Having the named consultant/health care professional who has an established rapport 
       with the family approach initially 
       Approach 
Parental         Consider strategies to help support families during stressful situations. 
        Increase the awareness of research from diagnosis, e.g. have a research nurse 
        join the consultant and Macmillan nurse.  
        Having a named research nurse for each family who will approach the family for all potential studies,  
        thereby establishing rapport 
        Have someone who has already established a rapport with the family initially approach (e.g. named consultant). 
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Barrier Strategy 
Not fluent in 
written and 
spoken English 
         Patient information leaflets in commonly used languages (e.g. Urdu) and access to interpreters 
Clinical           Enhanced training of health care professionals using presentations, multimedia and group sessions.  
         Consent and randomisation to take place in advance (e.g. completed in cycle two but prescribe at the start of  
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5.3.3 Barriers impacting patients and families 
Whilst many families expressed interest in the MaCROS study, and 10 participants 
were successfully recruited, some parents chose to decline participation. A breadth of 
parental opinions and decisions impacted their choice. 
At times patients and families chose not to participate in the MaCROS study without 
reading the patient information leaflets or further discussion. Being diagnosed with 
cancer as a child or young person is a challenging and life-changing experience. 
Patients and their families may be experience feelings of overwhelming sadness, 
hopelessness, anger or despair. Because of this, they may experience difficulty 
processing their thoughts and feelings, and may not be able to focus on matters which 
they do not feel are critical for the current situation. In the weeks following a diagnosis, 
some parents/guardians stated that they felt too overwhelmed and did not want to 
consider the MaCROS study further. An example of this is a discussion that occurred 
after the MaCROS study closed with a parent of a child diagnosed with Non-Hodgkin’s 
lymphoma. The following text is paraphrased anonymised: 
“When you approached me about the MaCROS study nearer to X's diagnosis, I was 
devastated and overwhelmed. My child was diagnosed with cancer, could potentially 
die, and I had to manage this while looking after X's younger siblings and everything 
else... I said no because I felt I had too much on and couldn’t deal with another thing to 
think about…however, seeing X develop mucositis and how much he suffered. 
Knowing what I know now, I would have considered it".  
This theme has been highlighted in other paediatric cancer trials. Parents of children 
diagnosed with a life-limiting brain tumour, a diffuse intrinsic brain stem glioma (DIPG), 
consented to post-mortem biopsies for research purposes. Parents cited that an 
optional biopsy at diagnosis was a challenging decision to make, but after their child’s 
death, they wanted to help make a difference in the future management of other 
children diagnosed with DIPG (122). 
The role of proxy consent from a parent on behalf of their child may also impact their 
decision to participate in a clinical trial and this affects recruitment (123). One study 
reported that parents felt deciding on behalf of their child was harder than deciding to 
consent for themselves  (124). Another study reported how some parents felt that 
whilst they could accept certain research risks for themselves, they were much less 
certain about accepting these risks for their child (125). These parents also reported 
that they would be prepared to take greater risks in treatment for their child for the hope 
of cure (126). 
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 ‘Research fatigue’ was another theme noted. A number of families expressed a desire 
not to be approached about the MaCROS study because they have already been 
contacted about other research trials and felt ‘saturated’ by the requests. Patients and 
families have a fixed amount of available time and resources. They need to use this to 
manage their illness, health, stress, social and family circles and self-care etc., and this 
may impact or influence their decision to participate.  Kenten et al. (127) explored some 
of the barriers that occurred in recruiting young people to the observational 
BRIGHTLIGHT study, which intended to ask all young people newly diagnosed with a 
malignancy, between 2012 and 2015, to describe their treatment journey and 
emotional/psychological response. It identified how patients needing treatment felt they 
should prioritise their time, and that engaging in research was an additional burden. 
Therefore, strategies to minimise the burden on families should be considered in future 
studies. Strategies could include focused interventions on relieving the pressure felt by 
families, by, for example, having a research nurse sit with a family and assist the 
completion of  questionnaires/diaries etc. 
Recruitment may have also been impacted by the relationship patients and their family 
have with the health care professional who first enquired about participation in the 
MaCROS study. Studies have previously reported how families may be more likely to 
participate in a trial when approached by a professional they have already established 
rapport and confidence with (128-130). In the MaCROS study, a number of 
professionals initially approached patients and families. This included named 
consultants, the PI and PhD fellow (HH - who was a paediatric registrar within the 
department) and research nurses. HH worked within the department at weekends on 
an ad-hoc basis as a junior member of the clinical team and was present on the wards 
and clinics with other clinicians. Whilst HH established rapport with some families; at 
other times HH had to approach families without previous contact. This may have 
impacted negatively upon recruitment. A strategy to overcome this in future studies is 
having the patients’ named consultant approach the patient or family about 
participation. An alternative strategy includes changing the way research nurses are 
allocated to trials. Currently, at LTHT haematology and oncology department, research 
nurses are typically designated responsibility for a particular study. Therefore, a family 
may be approached by various research nurses about different trials. The relationship 
between research nurses and families could be strengthened by allocating a specific 
research nurse to the family. Allocating one research nurse to the same family could 
help increase the success of establishing rapport. However, this strategy would need 
further consideration of the impact on practicalities and cost. 
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Patients or parents may also be more likely to engage with a discussion about a clinical 
trial if they feel it has value, i.e. a patient may be more likely to consider a trial which 
has potential curative intent. Alternatively, they may be more likely to engage with a 
clinical trial if it requires less ‘effort’. For example, patients and families may agree to 
participate in a study which involves taking a blood sample for research purposes 
alongside other necessary routine interventions. They may prefer not to participate in 
an interventional trial or qualitative studies, since these studies may or may not 
improve symptoms. Patients and families may feel that certain studies are more 
‘burdensome’ and therefore, a lower priority.  
Barriers that also appeared to impact a patient/their parents' decision to participate in 
the MaCROS study included the possibility of receiving a placebo or having to 
complete a patient diary. Some patients/parents disliked the option of receiving the 
placebo and felt the 'risk' was not worth it. Others stated they were interested in 
receiving the probiotic/placebo but were put off by having to complete a diary every day 
for 21 days. Some of these barriers are demonstrated in figure 10. 
A paraphrased statement which was mentioned a few times when declining to 
participate was: 
‘I don’t want to do it if there is a chance I will be in the placebo group'.  
Similar barriers have been previously explored in studies. A systematic review by 
Beasant et al (131), which included paediatric cancer studies, reported how parents 
may have a treatment preference which could impact participation in a randomised 
controlled trial. Beasant et al discuss the use of patient preference and comprehensive 
cohort trials - in which participants with a preference are offered their treatment of 
choice, and those without  are randomly allocated treatment. However, the use of non-
randomised studies reduces the robustness of their findings. An alternative option 
includes undertaking a cross-over clinical trial to ensure participants receive both the 
probiotic and placebo. However, it is not clear what the impact of chemotherapy and 
antibiotics on probiotics would be in a cross-over trial. 
Whilst studies have identified and explored factors which influenced parents’ choices in 
taking part in clinical trials, a lack of studies which focused on  interventions to 
overcome barriers to parent participation was noted. Further consideration of strategies 
targeting paediatric trials may help increase recruitment trials which have similar issues 
to those identified in the MaCROS study. 
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5.3.4 Other barriers that impacted recruitment 
Children and young people who were eligible for the MaCROS study may have also 
been eligible for other studies. As a consequence, trials may be in ‘competition’ with 
each other for the consent of a participant. A review of the literature identified research 
exploring competing clinical trials as a theme (132), highlighting how recruitment 
competition can impact studies. Exploration of competing clinical trials focusses on 
studies targeting specific patient populations and studies with similar outcomes, where 
the patient can enrol in only one of the studies. An example of such studies are phase 
1 studies exploring novel interventions for curative intent for children with relapsed 
high-risk neuroblastoma. There is a lack of research exploring competition between 
different types of trials (e.g. interventional vs observational), and what patients’ and 
parents’ views around this are. 
It is also worth mentioning that the MaCROS study was classified as a non-CTIMP 
study by the MHRA. However, the MHRA stated that recommendation would have to 
be reviewed before the undertaking of any future research. Being classified as a 
CTIMP study may have a profound impact on recruitment as participants are currently 
forbidden from enrolling from more than one CTIMP trial at a time.   Many patients who 
meet the eligibility criteria would, therefore, be excluded because they are on another 
larger, protocol driven CTIMP trial. This is something that would have to be considered 
or reviewed in future studies. 
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Figure 10: Summary of factors influencing a patient or their families decision to participate in the MaCROS study.  
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5.3.5 Barriers to patient diary completion  
Two major issues were identified in relation to the patient/symptom diaries. These were 
 Completion of the full information over the course of the 21 days 
 Return of the diaries 
Even though the patient diary was created to minimise the amount of effort and time 
needed to complete it, we were not able to achieve the intended outcome. This was 
despite giving participants and their parents the choice of using either a web-app or 
paper diary. Some parents expressed an interest in using the web-app, but stated that 
the poor WiFi connection in the hospital dissuaded them from this.  Therefore, a poor 
WiFi connection was identified as an organisational/system barrier which impacted how 
participants chose to collect data.  
The proportion of each diary completed appeared to decline at multiple points during 
the study; some participants did not return a diary or had only completed data for one 
or two days of the study. This may be because they had already received the 
probiotic/placebo, and completion of the diary was therefore viewed as a task which 
had little direct benefit to themselves. The diaries may have been considered to be 
burdensome - juggling complex family circumstances, an ill child and additional stress 
making it difficult to remember to complete the diary. A participant may also have been 
interrupted when completing the diary affecting their ‘flow’ and concentration or cause 
them to miss questions.  
Attrition in completion of the diary occurred a further time, at day 14,  when participants 
had completed the full course of probiotic/placebo. Only three participants completed 
any information beyond this point, and none completed information on all 21 days. We 
suspect this attrition occurred because the participants had finished their course of 
probiotic/placebo, and they had fewer incentives/reminders to complete the diary. 
As completing a diary was a time-consuming requirement of the study, strategies to 
reduce the burden on participants/and their families should be considered in future 
studies. A study by Okupa et al (133) explored the impact of the patient burden by 
comparing the use of daily diaries with retrospective questionnaires, for children and 
young people with asthma. The study reported that daily symptom diaries increased 
reporting of symptoms from the most recent two weeks, when compared with 
retrospective questionnaires. It suggested that diaries should not be used 
interchangeably with retrospective questionnaires and that the nature of the hypothesis 
should indicate what should be applied. Studies which require greater accuracy may 
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benefit from the use of diaries. It is worth noting Okupa et al (133) stated that the use 
of electronic web diaries might increase adherence. While there were a small number 
of MaCROS participants who chose to use the web-app, 3/3 returned a partially 
completed diary.  
The robustness of data vs. completeness of data need to be considered before further 
research, based on MaCROS, is undertaken. Future versions of the MaCROS study 
may benefit from an increased drive to use web-app diaries with a daily reminder. An 
alternative option could include a research professional (e.g. research nurse) 
telephoning participants every week during the three weeks, and completing a 
standardised form over the phone, regarding symptoms during the previous week. 
However, this is likely to result in recall bias, and as previously highlighted may not be 
beneficial in studies which are investigating outcomes requiring greater accuracy.   
Gifting or rewarding participants for returning diaries/taking part in questionnaires is 
also an option. The ethical implications of this have been extensively explored in 
previous studies (126, 134, 135) and the HRA have issued guidance on payments and 
incentives in research which states that this is acceptable, in certain circumstances, for 
adults (136). This HRA guidance also references the Medicines for Human Use 
(Clinical Trials) Regulations (2004) for payments to children in CTIMP trials, stating that 
financial incentives cannot be given for paediatric CTIMP trials. The Royal College of 
Paediatrics and Child Health have issued guidance for non-CTIMP studies (137). It 
reports that financial inducement should not be offered but that expenses should be 
paid. Expenses could be given to future participants for the time required to complete 
the patient diaries by asking them to complete an invoice. Participants can also be 
given pre-stamped envelopes to return diaries, daily reminders via text or email to 
complete information for both paper diaries and web-apps, or gifts/donations for 
returning diaries. This could include the gifting of vouchers or a monetary fee of 
reasonable value for the time estimated to complete the information. 
 
5.3.6 Barriers to study-procedure interviews and questionnaires 
The MaCROS study was initially designed to use ‘declining participant’ questionnaires 
and interviews with those who had completed the study. No participants opted to give 
feedback using interviews; no participants returned anonymous questionnaires or 
participated in the interview. Reasons for this appear to be the effort required/time 
commitment for participants and families while 'juggling' other requirements such as (i) 
family commitments, (ii) attending patient clinics, (iii) dealing with unexpected changes, 
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and (iv) unplanned additions to the treatment/care. However, because the MaCROS 
study was an underpowered study, these findings could have occurred by chance. 
Should further studies based on the MaCROS study wish to investigate the reasons for 
non-participation and  how to improve the practical implementation of the protocol,  it 
will be necessary to look at removing the burden of a time-intensive feedback process. 
For example, rather than ask patients, or their parents or guardians, to fill in an 
anonymous questionnaire explaining why they declined to participate, the 
researcher/responsible clinician could complete a proforma following a verbal 
discussion. This part of the feasibility study is not necessarily required in a future study 
and could be removed from the protocol, or used in a limited phase early on, as part of 
a QuinteT-style approach. Participants/families could be offered a range-methods to 
deliver feedback, i.e. returning feedback using a prepaid envelope, completing 
feedback online,  or requesting a meeting with a research assistant who can help them 
provide feedback. 
5.3.7 Completion rates of probiotic and placebo 
Eight participants (3 probiotics, 5 placebos) out of ten completed the full course of 
intervention. Two participants dropped out of the study after the first dose because they 
did not like the taste of the liquid (one from each arm). One participant had to omit 
several doses due to being nil by mouth. The MaCROS study demonstrated that even 
though a majority of participants completed the course of probiotic/ placebo, taste and 
mode of delivery can impact adherence. Modifications to the frequency, dose, and 
taste of the probiotic/ placebo may therefore improve compliance. Increasing the 
frequency of dosing would reduce the volume required for each dose. On the other 
hand, the increased burden of delivery could be an issue for some participants or their 
parents/caregivers.  
In an attempt to minimise the barrier to participant adherence and retention presented 
by poor taste, methods to mask the taste were explored. A healthy family (two parents, 
and two children aged 3 and 7) were asked to drink the Symprove probiotic in different 
combinations. The Symprove probiotic was added to a variety of drinks, including 
Lucozade, lemonade, sugar-free cordial (Robinsons), orange juice, and milkshake. The 
parents and their children stated that the probiotic tasted best in the sugar-free cordial. 
Therefore, for the remainder of the study participants were advised to mix the probiotic/ 
placebo with sugar-free cordial juice if they could not tolerate the taste. However, 
because the taste was only explored in a healthy family, it is unclear how 
chemotherapy could impact the taste experience by cancer patients receiving the 
probiotic. In undertaking a larger study, the palatability of probiotics must be thoroughly 
explored. 
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5.3.8 Preliminary health economic information 
Participation in the MaCROS study did not impact patient care. As recruitment, consent 
and randomisation occurred when participants were already in the hospital for routine 
patient care. There were no reported unexpected serious adverse events attributed to 
the probiotic or placebo. Patients’ hospital stays were not impacted, nor were 
supportive care strategies required.  
A cost/benefit analysis was submitted as part of the application to the HRA. No 
additional research costs (apart from funding for the author of this thesis) were required 
to set up the MaCROS study, and this study received NIHR portfolio funding. This 
enabled direct access and support from research nurses who work within the 
department at no extra cost. A research nurse communicated with participants, 
approached eligible participants to join the study, supplied PILS, and collected diaries 
from participants upon completion.  The company Symprove provided the probiotic and 
placebo to the MaCROS study free of charge, and donated costs to the development of 
the web-app. Evaluation of the study demonstrated that participation did not contribute 
to any additional clinical care, or incur any further cost. However, any future study 
would require external funding for it to continue, in particular if a multi-centre RCT is 
undertaken, since that would require more clinical and research staff as well as input 
from a clinical trials unit.  
 
5.4 Other considerations 
5.4.1 The microbiome 
Research has recently explored how the state of the microbiome before, during and 
following a cancer diagnosis can be linked to the development of toxicity (i.e. infection) 
and response to interventions (75). This dysbiosis (the disruption of the microbiome) 
can affect the health of an individual and may vary at different stages of a cancer 
patient’s journey, i.e. before diagnosis, during treatment, and at the end of treatment. 
Overall, there is a lack of research to understand the role of dysbiosis, particularly in 
children. 
As previously discussed in chapter one, the gut microbiome may affect drug 
metabolism and efficacy, and how an individual responds to chemotherapy (62). The 
gut microbiome is impacted during cancer treatment by a range of factors, including (i) 
diet, (ii) surgical intervention, (iii) supportive care interventions, i.e. antibiotics, and (iv) 
chemotherapy. Research by Panebianco et al (69) proposed that in mice bacterial 
translocation and T-helper 17 cell activation increases the efficacy of 
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cyclophosphamide in a  ‘healthy’ gut microbiome, when compared to mice raised in a 
sterile environment. Mice with a reduction of gram-positive bacteria, due to 
vancomycin, were found to have a reduced therapeutic response to 
cyclophosphamide, when compared to the control group. Lactobacillus johnsonii, 
Lactobacillus murinus, and Enterococcus hirae were found to stimulate an Th1 and 
Th17 immune response in the spleen and mesenteric lymph nodes, thereby improving 
the effectiveness of cyclophosphamide. The study authors Viaud et al (70) were unable 
to demonstrate this response in mice that received vancomycin. 
However, although this has been demonstrated in murine studies, the impact of 
intravenous antibiotics on the gut microbiome and how this affects the therapeutic 
response to cyclophosphamide in humans has not been investigated. 
A further recent study by Zieglar et al 2019 (72) evaluated the impact on the gut 
microbiome of a prophylactic antibiotic (levofloxacin) (prescribed to prevent febrile 
neutropenia). The study compared this to broad-spectrum beta-lactam (BSBL) 
antibiotics to treat episodes of fever. In both groups (totalling 60 patients) the patients 
had haematological malignancies (72). It was found that the gut microbiome of patients 
with BSBL exposure had significantly reduced diversity when compared to those 
without. This study proposes that the gut microbiome may interact with the delivery of 
chemotherapy and supportive care interventions, potentially impacting the toxicity 
experienced by a patient in their current and future courses of chemotherapy (72). This 
research stands alongside the work suggesting probiotics, delivered during a course of 
antibiotics, may reduce antibiotic-associated diarrhoea (43), and emphasises that how 
antibiotics and probiotics interact remains uncertain. 
There is still a lack of research which has fully explored the pharmacology, 
pharmacokinetics and pharmacodynamics of probiotics, particularly in 
immunocompromised patients and children. This sparseness of data meant it was not 
possible to use robust scientific evidence to justify  the commencement and duration of 
the course of probiotics in the MaCROS study. Through considerations of the practical 
delivery of the intervention, for the study we chose to supply the probiotic over a fixed 
period of fourteen days, rather than throughout treatment. Assessment of the 
microbiome, gut flora and bacterial colonisation could identify advantages or 
disadvantages of probiotic use and mucositis. It would enable understanding of the 
mechanism relating the bacterial composition of stool samples to outcomes. Further 
exploration of how probiotics may impact upon bacterial diversity could help guide how 
to dose probiotics, and for how long, in future clinical trials. 
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5.4.2 Biological sub-study 
 
Once the MaCROS study had opened, the need to research the biological component 
of using probiotics was identified. Therefore, a parallel biological feasibility sub-study 
was developed to be undertaken in conjunction with the MaCROS study. This sub-
study aimed to investigate the mechanism of action (or lack thereof) of probiotics in 
children with febrile mucositis, by investigating the presence of a biomarker (faecal 
calprotectin) and bacterial diversity in stool samples. 
Biomarkers are defined as “human or animal biological property whose in vitro 
measurement or identification is useful for the prevention, diagnosis, prognosis, 
treatment and follow-up of humans or animal diseases, and for their understanding 
(138)”.  
A review of the literature highlighted that biomarkers have been used to identify or 
stratify the risk of mucositis in adults (139, 140) .Ten biomarkers have been 
investigated in 4 paediatric studies (141) (142) (143) (144). These studies reported 
that: 
 Serum citrulline may be used to determine the severity of mucositis (143)  
 Faecal calprotectin may be used as a non-invasive biomarker for those with 
mucositis without neutropenia (141) 
 Serum procalcitonin may be able to distinguish fevers due to bacteria from 
those with mucositis who are febrile due to a systemic inflammatory response 
(144)  
 The C-Sucrose breath test is feasible to use in children with cancer (142) 
Whilst serum IL-8 is a potential biomarker in children with febrile neutropenia it may not 
be accurate for use in those who also have mucositis. 
The four trials were reported as prospective studies by research authors (including one 
randomised-control trial), however two of these studies reported on a subgroup of 
participants, of which samples were analysed retrospectively.  
All studies had small sample sizes and reporting of the studies was unclear. Significant 
biases were found in these studies, including selection bias (142) confounding bias (all 
studies) and outcome information bias (all studies). Reporting of statistical results did 
not include 95% confidence intervals. 
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The studies used different definitions and grading tools for mucositis. Gosselin KB et al 
(145) and Tooley KL (142) on oral mucositis only, WJFM van der Velden et al (143)  
included those with oral and gastrointestinal mucositis (using different grading tools), 
whilst KG Miedema et al (144) did not make any reference to oral mucositis. It is 
unclear from these studies whether oral, gastrointestinal or combined mucositis would 
impact the interpretation of biomarkers.   
This review highlighted the need for further robust studies to explore how biomarkers 
can be used to investigate the response probiotics may have on mucositis. Faecal 
calprotectin is a non-invasive biomarker with a relatively low cost to undertake analysis.  
One stool sample can be used to simultaneously analyze bacterial composition and 
biomarkers. This is less invasive and more convenient for participants then requiring to 
attend hospital for a blood test. 
Therefore, an amendment to the MaCROS study to include a biological sub-study was 
proposed. This would investigate the feasibility of testing stool samples for probiotic 
bacterial colonisation, and faecal calprotectin as a biomarker to explore the effect of 
probiotic consumption in children with mucositis. 
However, it was not possible to pursue the sub-study while the MaCROS study was 
open, due to challenges in submitting an amendment to the HRA, seeking permission 
from the LTHT REC and LTHT R&D, and setting up the trial with the local microbiology 
department,. The biological sub-study protocol developed is enclosed in appendix 2.19 
, and it is proposed that future versions of the MaCROS trial should include a parallel 
biological sub-study investigating the mechanism of probiotic response. 





5.4.3 Alternative strategies  
A number of options can be considered to improve on the limitations of incomplete data 
and recruitment that were identified in the feasibility study. These include: 
 Undertaking an RCT with patient public involvement to enhance recruitment 
and compliance (previously discussed in this chapter). 
 Undertaking a further feasibility study prior to undertaking an adequately 
powered RCT 
 Undertaking a pilot study which can be embedded into an RCT 
 
5.4.3.1 Undertaking a further feasibility study 
Undertaking a second feasibility study, prior to a RCT, would allow further evaluation of 
changes made to the study protocol with the aim of improving recruitment and 
adherence to data collection. This could reduce problems that still may occur in a future 
RCT. A future RCT may still be problematic despite this research identifying, and 
proposing solutions to, barriers to an RCT.  
Demonstrating how the proposed revisions to the protocol have resulted in an increase 
in recruitment and adherence to the capture of data would help researchers limit 
inefficiencies in a RCT, and increase confidence in researchers and health funders who 
invest time and funding into the trial. 
 However, there are also disadvantages to undertaking a further feasibility study, such 
as dedicating more time, effort, and costs to evaluating the study design and protocol. 
Table 14 demonstrated that 4 out of 6 objectives evaluated did not need further 
modification; undertaking a further feasibility study would result in unnecessary 
repetition of parts of the research protocol.. 
 
5.4.3.2  Undertaking a pilot study that is embedded in an RCT 
Undertaking a pilot study (a ‘preliminary study’) that is embedded in a future RCT is 
also an alternative option to undertaking a full RCT. Like a feasibility study, a pilot study 
can guide the design of a study, while allowing the opportunity for modifications to the 
protocol to take place prior to completion of the study. Whilst a feasibility study also 
evaluates the implementation of the protocol, its data cannot be used in an adequately 





powered RCT. Therefore, data from a feasibility study cannot be used to draw 
conclusions regarding efficacy. However, data from a pilot study can be included in the 
intended RCT whilst giving the opportunity to evaluate study design. 
Advantages of a pilot study over a further feasibility study are (i) a reduction of costs, 
and (ii) avoiding  unnecessary repetition and time wastage. It would enable further 
evaluation of  the revisions made to improve recruitment and data capture adherence, 
these improvements having been identified from the feasibility study. A pilot study 
would identify whether the proposed changes appear successful or require further 
revision. However, a pilot study would not guarantee success for an adequately 
powered randomised controlled trial. This risks loss of time, funding and effort. The 
impact of failure could be limited by instead undertaking a further RCT. 







This thesis has reported that the survival rate of children diagnosed with cancer has 
increased during recent decades, because of earlier diagnosis, and improved curative 
treatment and supportive care strategies. However, death attributed to treatment-
related mortality, particularly infection-related mortality from increased toxicity of 
intensive treatment strategies, remains a significant concern.  
This thesis identified how treatment-related mortality (TRM) is poorly defined and 
reported in studies. It then demonstrated how increasing the accuracy when reporting 
TRM vs infection-related mortality (IRM) would harmonise results. It was in turn 
demonstrated this would enable better comparisons of clinical trials, with knowledge 
gained applied to understanding the role of IRM in TRM.  
This thesis then demonstrated the usefulness of a validated classification tool and 
cause of death attribution system, which could guide future research and supportive 
care strategies. The thesis also highlighted the impact of infection and mucositis on 
treatment-related morbidity and mortality.  
From this, two critical areas of research were identified and proposed that required 
further exploration: 
1) The need for a uniform definition of TRM and disease-progression for the 
classification of death in children with cancer, applicable in high-income 
countries 
2) The need for preventative and treatment strategies to reduce TRM in children 
diagnosed with cancers, potentially through the modification of the microbiome 
to reduce mucositis, bacterial translocation, and bloodstream infection  
This led to the review of preventative supportive care strategies, which could potentially 
reduce the burden of mucositis and infection, and introduced the concept of using 
probiotics in people and children with cancers. A paucity of evidence was highlighted, 
and used to demonstrate that further research was required. 
 





6.2 Aims and data collected 
Based on these findings, the following research was undertaken to explore this in 
further detail: 
 A newly developed definition of TRM using a classification tool and cause of 
death attribution system was validated in a study undertaken at Leeds Teaching 
Hospital Trust, UK  
 An updated systematic review and meta-analysis was undertaken to explore the 
efficacy and safety of probiotics in people with cancer 
 A double-blind randomised control feasibility study was undertaken to 
investigate the feasibility of an RCT investigating the use of probiotics to 
prevent or reduce mucositis and infection in children with cancer  
A classification tool and cause of death attribution system was validated at LTHT, a 
hospital outside the country where it had been developed. Thirty medical records of the 
most recent deaths in children with cancer, 2 and 4 weeks prior to death, were 
anonymised and presented to the participants. Reviewers independently classified 
deaths as ‘treatment-related mortality’ or ‘not treatment-related’ according to the 
algorithm developed. When TRM occurred, reviewers applied the cause-of-death 
attribution system to identify the primary cause of death. Inter-relater reliability was 
assessed using the kappa statistic (k). 
Reliability of the classification was deemed ‘very good’ between CRA and consultants 
(k=0.86, 95% CI 0.72 to 0.97). Ten deaths were classified as TRM, of which infection 
was the most frequent cause identified. Reviewers disagreed on the primary cause of 
death (e.g., respiratory vs infection), in six cases, when applying the cause-of-death 
attribution system, and disagreed on the probable and possible causes in four cases. 
Out of the 10 patients who died from deaths due to TRM, 6 were attributed to infection. 
The study identified how the algorithm might not detect TRM in patients receiving non-
curative therapy.  
The findings led to the conclusion that further preventative strategies to reduce the 
burden of infection-reduced morbidity and mortality were required.  
A systematic review and meta-analysis were undertaken to explore the use of 
probiotics to reduce or prevent symptoms of mucositis and infection in people with 





cancer. Randomised control trials (RCTs), identified through screening multiple 
databases, were included for analysis of efficacy. Non-randomised control trials and 
case reports were included for safety analysis. Outcomes included a reduction in the 
incidence and severity of diarrhoea and adverse events. Where possible, data were 
combined for meta-analysis using a random-effects model. Planned subgroup analyses 
were not possible due to marked heterogeneity of study characteristics. 
The systematic review demonstrated that probiotics appear safe to use in this group of 
patients, and may reduce the incidence of diarrhoea and duration of fever, but that 
there is uncertainty regarding the risk of bias from included the studies (table 8, figure 
4), and therefore a lack of confidence in the studies’ conclusions. The review also 
highlighted a significant lack of paediatric studies investigating the use of probiotics in 
this group of patients. Twenty-one studies (N = 2982 participants) were included for 
assessment of efficacy. Probiotics may reduce the incidence of diarrhoea in patients 
with cancer [odds ratio (OR) = 0.52, 95% confidence interval (CI) 0.34-0.78, 95% 
prediction interval (PI) 0.3-0.92, I-sq 36.9%, 5 studies] and the duration of pyrexia 
[standardised mean difference 0.39 days, 95% CI 0.35-0.43, I-sq 0.01%, 5 studies]. 
The systematic review demonstrated that there are insufficient studies to assess the 
true effect of probiotics in people with cancer. Meta-analysis suggested probiotics may 
be beneficial, but further studies were required, particularly in children. 
Twenty-five studies (N = 2242) were included in the safety analysis. Five case reports 
showed probiotic-related bacteraemia/fungaemia/positive blood cultures. Definitions 
and reporting of adverse events were variable and inconsistent. It was identified that 
improved reporting of outcomes and adverse events in clinical trials are required to 
improve the accuracy of future studies and confidence in the conclusions drawn from 
them. 
This provided the rationale for developing a randomised control feasibility study, before 
undertaking an RCT, to investigate the efficacy of probiotics for reducing and 
preventing infection and mucositis in children with cancer. The MaCROS study 
recruited 10 participants between May and November 2019, from 34 who were 
approached and 39 who had been deemed eligible. 
Four participants were randomised to receive the probiotic and 6 participants received 
the placebo. Of these, 8 participants (3 probiotics, 5 placebo) completed the full course. 
Seven participants returned partially completed diaries (4 paper diaries, 3 web-app).No 





participants completed data for all 21 days. Three of the seven participants completed 
80% of the data for the duration of the 14-day course of probiotic. There were no 
deaths, and no participants were admitted to intensive care. Expected serious adverse 
events which occurred included one participant developing neutropenic enterocolitis, 
vaso-occlusive disease (VOD), post-transplant ileus and a C. difficile infection. Ten out 
of ten participants required antiemetics for nausea, 7/10 participants required 
analgesia. Of these, two participants in the probiotic arm required a patient-controlled 
analgesia system (PCAS) Four participants (2 probiotics, 2 placebos) required 
nasogastric tubes and one participant in the placebo group required total parental 
nutrition (TPN). 
No patient who declined consent opted to fill in the anonymous feedback questionnaire 
although verbal feedback was given at the time. No participants agreed to an interview 
regarding the study, but four participants gave feedback in the diaries supplied. 
Feedback received from participants and family was generally positive, and many 
families expressed interest in taking part in the MaCROS study. Those who received 
and reviewed the participant information leaflets stated that the leaflets were easy to 
read and understand, and that they covered all necessary information. The ‘chemo 
duck’ leaflet was particularly appreciated by children and families. 
Feedback documented in symptom diaries, from participants or their 
parents/guardians, identified aspects of the MaCROS study that require further 
consideration. These included (i) reviewing the taste and volume of probiotic delivered, 
(ii) improving adherence to the capture of data, and (iii) assessing symptoms in 
children who are unable to communicate their experiences. 
The MaCROS study demonstrated that an RCT is feasible, and no unexpected serious 
adverse events were reported. Modifications to the protocol will need to focus on 
recruitment strategies and adherence to data capture. More support for participants 
and their families to complete diaries is essential.  
 
 





6.3 Impact on children diagnosed with cancers 
6.3.1 Classification of death  
The findings from the TRM study support the hypothesis that the classification system 
can be implemented effectively in different health care settings, thereby improving the 
consistency and accuracy of outcome reporting in trials and clinical practice. The 
classification tool and cause of death attribution system can be used to guide local 
practice, and prompt guideline reviews to further improve supportive care interventions. 
Whilst these findings would not directly impact children diagnosed with cancers, 
implementing the classification tool and cause of death attribution system could 
improve the care for children subsequently diagnosed. Regular auditing of deaths using 
the classification tool and attribution system could consistently identify the cause of 
death within a department. Such findings can then be used to review local guidance or 
implement quality improvement projects. For example, an audit of TRM attributed to 
bleeding could prompt a review of platelet transfusions by increasing or decreasing the 
threshold for undertaking a platelet transfusion. Increasing the threshold for platelet 
transfusions, because a higher number of deaths are attributed to bleeding, could 
reduce the occurrence of spontaneous bleeds. Similarly lowering platelet thresholds, 
because an audit demonstrated a low incidence of TRM deaths attributed to bleeding, 
could result in the reduction of unnecessary delivery of blood products. 
6.3.2 Probiotics 
The systematic review undertaken to investigate the use of probiotics in people with 
cancer established that there is still insufficient evidence to conclude that probiotics are 
effective and safe in people with cancer. The meta-analysis demonstrated that 
probiotics might reduce (i) the incidence of diarrhoea, (ii) duration of pyrexia, and(iii) 
incidence of septicaemia and central line infection. It was not possible to perform 
subgroup analysis, particularly in children, to investigate this further. Probiotics may be 
a rare source of infection, but no deaths have been attributed to their consumption.   
Findings from the systematic review and meta-analysis could prompt local centres to 
review neutropenic guidelines, and allow children diagnosed with cancers to take 
probiotics. Whilst there is not sufficient scientific evidence to demonstrate the benefits 
of probiotics in children with cancers, it would give participants and their families the 
autonomy to make an informed decision about taking probiotics. 





6.3.2.1 Participation in feasibility studies 
The MaCROS study has identified the need for further strategies to improve 
recruitment, adherence to the probiotic dosing, and the adherence for completion of 
data. These findings can be used to improve the experiences of children and their 
families who participate in future RCTs. Findings can also be used to improve the 
participants experience in other feasibility studies - particularly those investigating the 
use of probiotics or studies which require capture of proxy or self-reported symptoms. 
6.4 Implications for national recommendations and guidelines 
6.4.1 Classification of Death 
The classification of death and cause of death attribution system can be used to guide 
national policies and agendas. This could include developing recommendations or 
identifying research needed to improve supportive care. Findings could be used to 
research curative strategies. 
6.4.2 Probiotics 
The findings from this systematic review could be used to support recommendations in 
adult guidelines. The Multinational Association of Supportive Care in Cancer (MASCC) 
2014 issued guidelines on the management of mucositis secondary to cancer therapy. 
This guideline advises that probiotics containing Lactobacillus species should be used 
to prevent diarrhoea in patients receiving chemotherapy and/or radiation therapy for a 
pelvic malignancy but has not referenced the evidence for this recommendation.  
In 2018 the European Society for Medical Oncology (EMSO) issued guidelines for the 
management of diarrhoea in adult patients with cancer (146), including the use of 
probiotics. The guideline discusses the conflicting evidence reviewed  for the use of 
probiotics (grade II B) and mentions how probiotics may reduce the incidence of 
diarrhoea, but that there is a higher risk of developing a severe infection in 
immunocompromised patients. The review undertaken for this PhD has demonstrated 
that probiotics may be a rare source of infection but that no deaths have been 
attributed to their consumption. The guideline could be revised based on the findings of 
this study. 
In the UK, neutropenic diet guidelines for haematology patients state that patients 
should avoid consuming foods or supplements with probiotic cultures. It states that 





Lactobacilli and Bifidobacteria do not have a more significant infection risk than strains 
found in the mouth, ileum and colon, and that reported infections are mostly limited to 
Saccharomyces boulardii/ cerevisiae, B Subtilis and Lactobacillus rhamnosus LGG. 
Findings from the neutropenic diet guidelines appear to be in keeping with our updated 
systematic review, although evidence to support this is limited.  
6.5 Limitations of this PhD 
The TRM study reported that although consultants were considered the gold-standard 
for classifying death, even experienced clinicians can disagree on the cause of death 
when using the algorithm. The differences identified highlight how the TRM 
classification tool would never have perfect agreement between reviewers, irrespective 
of experience, or clinical and scientific knowledge. Whilst the current TRM classification 
tool can be applied reliably, there still may be confusion as to what the definitions of 
treatment-related mortality and cancer-related death encompass. Suicide or unrelated 
accidents/illnesses lead to a lack of clarity in decisions. 
The study asked reviewers to attribute death to one primary probable, or possible, 
cause. Reviewers found it challenging to identify one cause of death, and to distinguish 
between probable and possible causes, indicating further consideration for future 
applicability. 
The systematic review reported how most domains at risk of bias were reported as 
unclear due to limited reporting of methods undertaken (table 8). The highest risk was 
identified when assessing selection and detection bias. Whilst aspects of these biases 
may not be relevant, e.g. whether participants were blinded to the episodes of 
diarrhoea, most studies did not report sufficient information about methods undertaken, 
e.g. whether personnel were blinded from allocation or randomisation. This may have 
undermined the randomisation process, resulting in biased and inflated effect 
estimates. It was not possible to perform subgroup analysis due to the high clinical and 
statistical heterogeneity. Studies had a variety of different strains, doses and duration 
of probiotics and  reported different outcomes. The significant heterogeneity reported 
indicated uncertainty in the findings reported. 
The Loke method for the quality assessment of safety of probiotics identified that 
studies are still unclear on definitions, measures, and reporting of adverse events. 
Currently, no consistent definitions are used in the reporting of adverse events and 





other outcomes.  It was unclear how many individuals sustained adverse events as 
reporting varied between studies. Some studies reported on individual events rather 
than people sustaining an adverse event, and it is unclear how this may overlap. For 
example, some studies reported on the incidence of septicaemia, incidence of 
pneumonia and UTIs. This made it challenging to identify the number of individuals, or 
indeed if the same episode of illness was counted in two categories. Some studies did 
not report on bacterial isolates from positive blood cultures identified in either the 
probiotic or control groups. Therefore, it cannot be concluded with confidence that 
there were no probiotic-associated infections, or that adverse events sustained cannot 
be attributed to probiotics consumed, due to the heterogeneity of malignancies and 
treatment regimens. As adverse events were also not clearly or uniformly defined in 
identified studies, it cannot be determined if all relevant data were appropriately 
identified, recorded or documented.  
Results from the MaCROS study was used to evaluate the future feasibility of an RCT 
and provide descriptive results. However, evaluation of the MaCROS study was 
impacted because of barriers to recruitment and adherence to data collection. Further 
consideration of how to improve issues of eligibility, recruitment, retention, and missing 
data is required for future studies.  Overcoming these barriers would increase the 
accuracy and quality of data reported, therefore increasing the accuracy of studies and 
confidence in the conclusions drawn. 
A number of strategies could be applied to improve issues of eligibility, local 
departmental effects and recruitment. These include revising eligibility criteria, for 
instance having greater flexibility on the start date of probiotic/placebo. Using 
predeveloped research packs (including PILS, consent and prescribing forms) to 
reduce the burden on the health care professional, increasing the recruitment period 
(i.e. 12 months or longer), using a SWAT analysis, and involving Trial Forge can 
improve issues identified. Further supportive strategies can also be applied to aid 
recruitment and retention. These include delivering extra support through familiarity, 
such as having the initial enquiry be delivered by a health care professional known to 
the family. This could be a named consultant or a research nurse, and this person can 
then complete the rest of the consenting process.  
Strategies to improve retention and missing data include further exploring the use of 
web-app diaries (with daily reminders) and using health care professionals (e.g. 





research nurse) to undertake some data collection. Another suggestion is telephoning 
participants every week during the three weeks and completing a standardised form 
over the phone regarding symptoms during the previous week. A further suggestion is 
paying expenses for the time taken to complete the diaries. 
Barriers that were identified could be reviewed prior to undertaking a RCT by involving 
PPI groups and engaging in further evaluation, or further research to address these 
issues. Options include revising the protocol prior to an RCT, undertaking a further 
feasibility study, or including changes in a pilot study that is embedded in an 
adequately powered study. 
A lack of research exploring the microbiome and dysbiosis in different aspects of a 
child’s cancer diagnosis was also identified. The unknown factors include how quickly 
the  probiotic takes effect,  and the relationship of the gastrointestinal microbiome with 
cancer, probiotics, and antibiotics in the paediatric population. Better understanding of 
these factors and how they interact would help guide the dosing and delivery of 
probiotics and help refine methodologies of future studies. 
An absence of research investigating the biological evidence for the use of probiotics in 
people with cancer was also found. The previously discussed systematic review and 
meta-analysis did not include a review of the bacterial compositions of the stool 
samples of included studies, because of the lack of data reported. Investigating the 
bacterial composition of stool samples would allow further exploration of how probiotics 
may impact bacterial diversity, particularly in patients who are also receiving 
intravenous antibiotics. 
During the undertaking of the MaCROS study, we identified this need to research the 
biological component of using probiotics and fully developed a parallel feasibility 
biological sub-study to investigate the mechanism of action (or lack of) of probiotics in 
children with febrile mucositis. However, due to the challenges noted in section x.x it 
was not possible to set up the biological sub-study. 
 
6.6 What was known prior to this thesis? 
The survival rate of children diagnosed with cancer has improved during recent 
decades. Earlier diagnoses, as well as improved curative treatment and supportive 





care strategies, have reduced overall mortality. However, death attributed to treatment-
related mortality, particularly infection-related mortality from increased toxicity of 
intensive treatment strategies, is still a significant concern. 
Treatment-related mortality (TRM) is poorly defined and reported in studies. Increased 
accuracy and reporting of TRM and infection-related mortality (IRM) would harmonise 
results, enabling better comparisons of clinical trials. 
Despite the recognised relationship between mucositis and febrile neutropenia, there 
are no widely used preventative or therapeutic interventions for febrile mucositis. 
Exploration of possible strategies to reduce IRM and TRM is required. 
6.7 What has this thesis contributed? 
The TRM study undertaken confirmed the reproducibility and criterion validity of the 
TRM classification system. This supports the hypothesis that the classification system 
can be implemented efficiently and effectively in different health care settings, thereby 
improving the consistency and accuracy of outcome reporting in clinical trials.  
The systematic review identified that there is still insufficient evidence to conclude that 
probiotics are effective and safe in people with cancer. The meta-analysis 
demonstrated that probiotics might reduce the incidence of diarrhoea, duration of 
pyrexia and may reduce the incidence of septicaemia and central line infection. 
Probiotics may be a rare source of infection, but no deaths have been attributed to their 
consumption.  
The MaCROS study demonstrated that it is feasible to undertake a double-blind 
randomised control clinical trial in this population of patients.  The main barriers 
identified in undertaking an RCT in the future were recruitment and adherence to data 
capture. 
6.8 Future research 
6.8.1 Classification of death 
Findings from this thesis can be used to guide future research on the reporting of 
treatment-related mortality and cause of death attribution system. Improved 
classification and attribution to cause of death would enable improved understanding of 





where future research strategies should be targeted to increase overall survival in 
children with cancer or supportive care strategies. 
The TRM study identified the need to refine the approach to categorising cause of 
death in cancer patients receiving care without intent to cure. This is particularly 
important if the system is applied in ‘routine’ settings, such as assessing deaths in a 
palliative setting, rather than in the original setting of use - a curative trial. Increasingly, 
individuals destined not to be cured are living for lengthier periods due to participation 
in clinical trials/studies. This group of patients currently have all deaths classified as 
“not treatment-related mortality” as clinicians would have specified either progressive 
disease or that cancer therapy has no curative intent. The algorithm in figure 1 may fail 
to identify a significant group of patients, who may die of causes amenable to better 
supportive care, whilst receiving palliative care. This could be addressed by modifying 
the algorithm for this type of use.  
Reviewers in the TRM did not agree on 6 out of 10 causes of death attributed to TRM.  
Further research should focus on the application of the cause of death attribution 
system, and on how agreement in outcome reporting could be improved. 
Understanding and interpretation of the system, as proposed for attribution of a specific 
mechanistic cause of death, could potentially be improved by dedicating more time 
during the presentations and using the newly developed web-based training tool.  
The author of this thesis has published findings from this study (147). Since this 
publication the classification tool and cause of death attribution system has been used 
to analyse data from two Dutch hospitals (21) and a population-based cohort (148). 
The use of the TRM classification system and cause of death attribution has been 
validated in centres  in high-income countries. Future research would ideally focus on 
its use in middle-income countries. This study can help guide future global strategies. 
6.8.2 Probiotics  
The author of this thesis has published this systematic review and meta-analysis (149). 
The updated systematic review identified twelve ongoing trials investigating the use of 
probiotics in people with cancer. An updated systematic review and meta-analysis 
should, therefore, be undertaken in 3-5 years’ time. 
As adverse events were also not clearly or uniformly defined in identified studies, it 
cannot be determined if all relevant data were appropriately identified, recorded or 





documented. However, the variability of definitions used and reporting of adverse 
events means conclusions cannot be drawn with confidence. Further harmonisation of 
reporting of clinical trials using strategies such as the COMET initiative and CONSORT 
checklist would enable greater precision and confidence in conclusions drawn.  
6.8.3 Paediatric feasibility studies 
The MaCROS study demonstrated the feasibility of undertaking an RCT, but that 
further research is needed to address barriers to success, specifically recruitment and 
the adherence to the capture of data. The evaluation of the MaCROS study identified a 
lack of evidence-based targeted interventions, such as the QuinteT intervention or 
SWAT analysis, to improve recruitment in paediatric studies. Further research should 
focus on implementing evidence-based targeted interventions in paediatric studies.  
The research undertaken in this thesis has identified a paucity of research exploring 
the biological evidence for the use of probiotics in people with cancer. Assessment of 
the microbiome, the gut flora, and any colonisation by probiotics observed may help in 
understanding the interactions between probiotic consumption and mucositis, be it 
beneficial or ineffective. Using a ‘biological tool’ to explore the severity of mucositis with 
the use of probiotics could enhance understanding of the aetiology, stratification and 
treatment of mucositis. Therefore, biomarkers may be a useful aid to investigate how 
probiotics may impact mucositis, and it would be beneficial to assess the feasibility of 
undertaking a parallel sub-study, in a future study, to further understand the biological 
impact of probiotics in children with febrile mucositis.  
6.9 Overall conclusion 
This thesis has validated a uniform definition of TRM and disease-progression for the 
classification of death in children with cancer, which has applicability in clinical trials 
and health care settings in high-income countries. Findings from this study were 
presented to the UK National Cancer Research Institute Clinical Studies Research 
Group. This was favourably received by the research group and is currently being 
considered at a national and European level. 
This thesis has also identified and investigated how probiotics can be used to reduce or 
prevent mucositis and infection in children diagnosed with cancers, potentially through 
the modification of the microbiome. Findings from the systematic review and meta-
analysis have been used to change recommendations at the Royal Victoria Hospital in 





Newcastle. Because of this study, children diagnosed with cancer can now take 
probiotics as part of their neutropenic diet. 
The results of the MaCROS study are currently being disseminated nationally and 
internationally. Evaluation of the MaCROS study and systematic review have been 
used to identify facilitators and barriers for undertaking a future randomised control trial 
and has also been used to develop a parallel biological sub-study. It is hoped this sub-
study will be included in a future study. 
It is hoped that outcomes from this thesis will shape future research and clinical 
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1.2 Participant information Leaflet  
Leeds institute of Cancer and Pathology 
 Version 2 
 
 
Part I: Participant Information Leaflet 
Validation of a system for classifying treatment-related mortality 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. Please ask us if there is 
anything that is not clear or if you would like more information. 
What is the purpose of the study? 
Cause of death in children with cancer may be attributed to the cancer and disease-
progression, or complications of treatment delivered. Death not directly due to the 
cancer has been termed “treatment-related mortality (TRM)” and includes infection, 
bleeding, and organ dysfunction. Appreciating differences between TRM and disease-
related death is critical in helping researchers and clinicians understand how to direct 
care and therapies to improve survival. A collaboration led by Lillian Sung from Toronto 
in Canada developed and validated a classification system for TRM intended for use by 
clinical research assistants (CRA), non-medically qualified professionals who work with 
clinical trial data capture and entry. Causes of death in identified patients’ notes were 
reviewed using the developed classification tool by two independent CRAs and 
compared with two consultants. This system requires validation in different centres, to 
assess if it can be applied consistently outside of the institution in which it was 
developed. This could potentially be used for international clinical trials enabling 
uniformity of outcomes reported. 
What is the aim of the study? 
The aim of this study is to validate the TRM classification at Leeds Teaching Hospital 
Trust (LTHT), by assessing the agreement of clinical consultants and CRAs. Two 
consultant paediatric haematologist or oncologists and two CRAs will review 30 
anonymised case notes of most recent deaths of patients with malignancy, or who 
received a haemopoetic stem cell transplant, while under the care of LTHT. The CRAs 
decisions will be a compared to those of the consultants. 
Leeds institute of Cancer and 






Why have I been asked to participate? 
You are either a consultant oncologist/haematologist or clinical research associate who 
meets the requirement required for participate who has been identified by the research 
team 
What will happen now? 
If you agree to participate in the study, we will ask you to attend a chosen location at 
Leeds Teaching Hospital Trust in the near future which is suitable for all participants. 
After signing written consent form you will receive training on how to use the 
classification tool which will be delivered in person by the research team alongside any 
relevant documentation required. You will then be placed in separate rooms (without 
any direct contact or communication with the other participants) and given 60 sets of 
anonymised case notes. You will then review the notes and classify death according to 
the algorithm. For the patients whose death you classify as TRM you will assign a 
probable cause of death according to a further schema. After a short break you will 
meet with the other participants to discuss your experiences of using the classification 
tool. Your participation should take approximately half a working day. 
Do I have to take part? 
You do not have to take part in the study. If you agree to participate we will ask you to 
sign a written consent form confirming your willingness to participate. 
Do I have the right to withdraw from the study? 
You have the right to withdraw from the study up to 2 weeks after completion of the 
study by contacting the study lead with your request. After two weeks you will not be 
able to withdraw your participation. 
Are there any disadvantages of taking part in this study? 
If you participate in the study, you will be reviewing notes of children with cancer who 
have died. This may cause you to become upset or distressed. If you feel you need 
further support the research team will be able to advise who to contact. 
Will my taking part in the study be kept confidential? 
Your participation and information supplied is entirely confidential and will not be 
disclosed to anyone outside the research team without your permission. We also ask 





that you keep all study information and discussions confidential also. All the information 
collected will be stored securely according to the Data Protection Act 1998. 
Who is organising and funding the research? 
The study is led by Dr Hadeel Hassan a paediatric trainee, and Clinical Research 
Fellow and PhD student at the University of Leeds under the supervision of Dr Bob 
Phillips consultant paediatric oncologist and senior academic, and Professor Sally 
Kinsey, Paediatric haematologist. Dr Hadeel Hassan’s Clinical Research Fellowship is 
funded by The Candlelighters Charity. 
Who has reviewed the study? 
This study has been reviewed by the University of Leeds, School of Medicine Research 
Ethics 
Committee (SoMREC), reference number MREC15-118.” 
 
 
Who do I contact for further information? 
For further information about the study please contact Dr Hadeel Hassan at the 
University of Leeds telephone number 0113 3432596 or Dr Bob Phillips at Leeds 
Teaching Hospital 0113 39 28779 (secretary). 
Do I have to take part? 
You do not have to take part in the study. If you agree to participate we will ask you to 
sign a written consent form confirming your willingness to participate. 
Do I have the right to withdraw from the study? 
You have the right to withdraw from the study up to 2 weeks after completion of the 
study by contacting the study lead with your request. After two weeks you will not be 
able to withdraw your participation. 
Are there any disadvantages of taking part in this study? 
If you participate in the study, you will be reviewing notes of children with cancer who 
have died. This may cause you to become upset or distressed. If you feel you need 
further support the research team will be able to advise who to contact. 





Will my taking part in the study be kept confidential? 
Your participation and information supplied is entirely confidential and will not be 
disclosed to anyone outside the research team without your permission. We also ask 
that you keep all study information and discussions confidential also. All the information 
collected will be stored securely according to the Data Protection Act 1998. 
Who is organising and funding the research? 
The study is led by Dr Hadeel Hassan a paediatric trainee, and Clinical Research 
Fellow and PhD student at the University of Leeds under the supervision of Dr Bob 
Phillips consultant paediatric oncologist and senior academic, and Professor Sally 
Kinsey, Paediatric haematologist. Dr Hadeel Hassan’s Clinical Research Fellowship is 
funded by The Candlelighters Charity. 
Who has reviewed the study? 
This study has been reviewed by the University of Leeds, School of Medicine Research 
Ethics 
Committee (SoMREC), reference number MREC15-118.” 
Who do I contact for further information? 
For further information about the study please contact Dr Hadeel Hassan at the 
University of Leeds telephone number 0113 3432596 or Dr Bob Phillips at Leeds 




1.3 Consent form 
 
Consent to take part in the Validation of a system for classifying treatment-
related mortality study 
 
 Add your initials next to 
the statements you agree 
with  
I confirm that I have read and understand the 
information sheet dated 29/7/16 explaining the 
above research project and I have had the 
opportunity to ask questions about the project. 
 
I agree for the data collected from me to be stored 
and used in relevant future research in an 
anonymised form.  
 
I understand that relevant sections of the data 
collected during the study, may be looked at by 
individuals from the University of Leeds or from 
regulatory authorities where it is relevant to my 
taking part in this research. I give permission for 
these individuals to have access to my records. 
 
I agree to take part in the above research project 
and will inform the lead researcher should my 
contact details change. 
 
I understand that I have the right to withdraw from 
the study up to 2 weeks after completion of the 
study by contacting the study lead with my request. 
After 2 weeks I will not be able to withdraw my 
 
























*To be signed and dated in the presence of the participant.  
 
 
Once this has been signed by all parties the participant should receive a copy of 
the signed and dated participant consent form, the letter/ pre-written script/ 
information sheet and any other written information provided to the participants. 
A copy of the signed and dated consent form should be kept with the project’s 
main documents which must be kept in a secure location.  
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Mucositis and infection reduction with liquid probiotics in children with cancer: a 
randomised-controlled feasibility study protocol 
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Table 21: Key trial contacts 
Chief Investigator 
Principal Investigator 
Dr Hadeel Hassan 
Room 9.86 
Level 9, Worsley Building  
University of Leeds 
Clarendon Way 
Leeds LS2 9NL 
Telephone: 07437319762 
Email: umhh@leeds.ac.uk, hadeelhassan@nhs.net 
Trial Co-ordinator Dr Hadeel Hassan 
Room 9.86 
Level 9, Worsley Building  
University of Leeds 
Clarendon Way 





Sponsor University of Leeds 
Clarendon Way 
Leeds LS2 9NL 




Funder(s) Candlelighters charity 
 
Key Protocol Contributors Dr Bob Phillips 
Centre for Reviews and Dissemination 
University of York 
01904 321040 
Bob.phillips@york.ac.uk 
Professor Sally Kinsey 
Leeds Institute of Cancer and Pathology 
University of Leeds 
0113 3928772 
Sally.kinsey@nhs.net 
Trials Pharmacist Caroline Bedford 
Medicines Management and Pharmacy Services 








Trial Title Mucositis and infection reduction with liquid 
probiotics: a randomised-controlled feasibility study  
 
Internal ref. no. (or short title) The MaCROS study  
Clinical Phase  Feasibility 
Trial Design Double-blind randomised-controlled trial (RCT) 
Trial Participants Patients treated on paediatric cancer protocols receiving 
chemotherapy on regimens likely to cause mucositis 
Planned Sample Size 20-40 participants 
Treatment duration 14 days 
Follow up duration 21 days 
Planned Trial Period 6 months 
 Objectives Outcome Measures 
Primary Evaluate the feasibility of an 




 efficacy of liquid probiotics 
(Symprove) to prevent or 
reduce mucositis and 
infection in children 
diagnosed with cancer 
undergoing treatment 
regimens likely to cause 
mucositis 
Completion rates of 
intervention/placebo 







Evaluation of the research 
protocol 
Compare outcomes detailed 
in both groups 
Explore participants and 
parents views of experiences 
The incidence, severity 
and duration of diarrhoea 
The incidence of nausea, 
vomiting, oral mucositis 
Recorded telephone or 
face to face interview of 
parents  
Use of analgesia and 
evaluation of hospital 
admission  
Investigational Product Symprove liquid probiotic dietary supplement 
 
 
Formulation, dose, route of 
Administration 
Symprove liquid probiotic which is available in 2 flavours-
Symprove original and mango and passion fruit. 
Placebo: similar appearance, taste and consistency. The 
placebo is an identical liquid in appearance and taste, 
containing distilled water (99.22%), mango and passion 
fruit natural flavour (0.50%), ascorbic acid (0.26%), and 
beta-carotene (0.02%). 
Formulation 
Taken NG orally, or nasogastric tubing or gastrostomy. 
Ages:  
<4 years of age:  20 mls 
4-8 years of age: 0.5mls/kg 






Trial flow chart 







The aim of this study is to evaluate the feasibility of an RCT to investigate the efficacy 
of liquid probiotics to prevent or reduce mucositis and infection in children diagnosed 
with cancer who are undergoing treatment with regimes likely to cause mucositis. 
Objectives 
The primary objectives of this study will therefore determine: 
Whether it is feasible to recruit children diagnosed with cancer who are at risk of 
developing mucositis 
The completion rates of participants taking the liquid probiotic/placebo for 2 weeks  
The completion rate of the symptom diary (paper/web-app) by participants/parental to 
record the symptoms of nausea, vomiting, diarrhoea, oral mucositis and abdominal 
pain from the start of chemotherapy for 21 days  
Preliminary health economic information surrounding the costs/benefits of the 
intervention. 
Secondary objectives will include: 
Evaluation of the research protocol 
Barriers to compliance with the protocol 
Evaluation of intended outcomes to be assessed if an RCT is undertaken. This will 
include, but is not limited to the incidence, severity and duration of diarrhoea and 
infection in both groups, the incidence of nausea, vomiting, oral mucositis, and use of 
analgesia and evaluation of hospital admissions. 
 
Background 
Probiotics are defined as “live micro-organisms which, when administered in adequate 
amounts, confer a health benefit on the host” according to the World Health 
Organisation and United Nations Food and Agriculture organization (FAO) (37). The 
most common strains belong to the genera Lactococcus and Bifidobacterium (38). 
Health benefits attributed to probiotics include the reduction of the severity of antibiotic 
associated diarrhoea in paediatric patients(42), necrotising enterocolitis in premature 
infants (150) and the incidence of radiation-induced diarrhoea (151). 
 
 
Chemotherapy and radiotherapy induced diarrhoea is a common adverse event and is 
associated in particular with fluorouracil, capecitabine and irinotecan-based treatment 
regimes. Radiotherapy is believed to potentially alter bacterial flora and affect the 
intestinal motility and vascular permeability of mucosal cells (44). Chemotherapy is 
thought to alter the composition of intestinal flora and therefore affect the metabolism 
of intestinal enzymes which is vital for gut integrity. Changes to the gut flora may 
impact the gut defence barrier, immune function and absorption of vital nutrients (45). It 
is estimated that 20-45% of all chemotherapy patients experience severe diarrhoea 
(30). Radiotherapy or chemotherapy induced diarrhoea may interrupt or even stop 
treatment, impair the quality of life and prolong hospital stay of patients with cancer, 
also potentially increasing health economic burdens (46).  
There have been multiple studies investigating the role of probiotics in reducing 
chemotherapy and radiotherapy associated diarrhoea. An updated systematic review 
and meta-analysis was undertaken (PROSPERO registration: CRD42016050252). 
Randomised controlled trials (RCT), identified through screening multiple databases 
were included for analyses of efficacy. Non-randomised controlled-trials and case 
reports were included for safety analysis. Outcomes included the reduction in the 
incidence and severity of diarrhoea, and adverse events. Where possible, data were 
combined for meta-analysis using a random-effects model.  
Twenty one studies (N = 2,982 participants) were included for assessment of efficacy. 
Results showed probiotics may reduce the incidence of diarrhoea in patients with 
cancer [odds ratio (OR) = 0.52, 95% confidence interval (CI) 0.34-0.78, 95% 
percentage prediction interval (PI) 0.3-0.92, I-sq 36.9%, 5 studies], duration of pyrexia 
[standardized mean difference 0.64 days, 95% CI 053-0.77, PI 0.64-0.64, I-sq 0.01%, 5 
studies] and possibly the severity of diarrhoea [for example Common Toxicity Criteria 
grade 3 and 4 diarrhoea [OR=0.51, 95% CI 0.12-2.2, PI 0.03-9.08, I-sq 92.5%, 4 
studies]. Twenty five studies (N = 2,242) were included in the safety analysis. Five 
case reports showed probiotic-related bacteraemia/fungaemia/ positive blood cultures. 
The definitions and reporting of adverse events were variable and inconsistent. It was 
not possible to undertake planned sub-group analyses, investigating age, strains and 
dosage of probiotic and patient characteristics through marked heterogeneity of study 
characteristics. 
The review demonstrated there were insufficient studies to assess the true effect of 
probiotics in people with cancer. Meta-analysis suggests probiotics may be beneficial 
but further studies are still required, particularly in children. 
 
 
We therefore propose a feasibility study to investigate whether it is possible to 
undertake a RCT investigating the use of probiotics compared with placebo for 
preventing and reducing mucositis and infection in children diagnosed with cancer. 
Data from this study will be used to inform and assess the feasibility of a pragmatic 
randomised controlled trial. Results will be reported according to the CONSORT 2010 
statement for feasibility and pilot studies (152). 
Methods 
Trial design 
This will be a single-centre double-blind randomised-controlled feasibility study.  
Study setting 
This study at Leeds Teaching Hospital Trust, Leeds UK between January to July 2019.  
Recruitment 
Participants will be recruited from the paediatric haematology and oncology department 
at Leeds Teaching Hospital Trust, Leeds, UK. 
Target recruitment 
The recruitment target is between 20 and 40 patients over a 6 month period. As this is 
a feasibility study, a power calculation is not required. 
Eligibility criteria for participants  
Patients between the ages of 1 and 18 treated on paediatric cancer protocols receiving 
chemotherapy on regimens likely to cause mucositis. These include the UK ALL 11 
(patients receiving delayed intensification therapy in regimen A and all participants 
receiving induction, post induction therapy and delayed intensification in regimen’s B 
and C) IntReALL SR 2010, Inter-B-NHL ritux 2010, Euro Ewings 2012, RMS 2005, 
SIOP Ependymoma II, Headstart III, SIOPEN HR Neuroblastoma study and 
Myechild01 protocols. Participants receiving myeloablative therapy will also be 
included; for example those receiving high dose chemotherapy with stem-cell rescue 
for high risk neuroblastoma.  
Exclusion criteria 
Patients who have already started the course of chemotherapy. 
Patients receiving radiotherapy or surgery alone. 
Patients diagnosed with an immunodeficiency (excluding IgA). 
 
 
Patients who have previously taken probiotics within the month prior to commencing 
the course of chemotherapy. 
Interventions 
Participants will be required to commence the blinded liquid probiotic (Symprove) or 
placebo on the first day of their chemotherapy/pre stem cell transplant chemotherapy 
conditioning and take this once daily for 14 days. The dose will be adjusted according 
to age.  
Symprove liquid probiotic 
Symprove (Symprove Ltd, Farnham, Surrey, UK) is a liquid probiotic that contains four 
strains of bacteria with a total of 109 colony forming units: (Lactobacillus rhamnosus 
NCIMB 30174, Lactobacillus plantarum NCIMB 30173, Lactobacillus acidophilus 
NCIMB 30175, and Enterococcus faecium NCIMB 30176) in a water-based suspension 
of barley extract. Symprove is classified as a food supplement under EU law (153). 
It is hypothesised that the barley extract suspension, provides acid protection and a 
nutrient source for the bacteria when compared to freeze-dried probiotic formulations, 
and a greater number of bacteria survives the transit of gastrointestinal system. This 
results in a higher number of probiotic bacteria to colonise in the colon (154). 
Colonisation of bacteria from a probiotic supplement is believed to increase the 
secretions of anti-inflammatory cytokine interleukins (IL) such as IL-10 and IL-8, T-
regulatory cells, and reduce interferons which inhibits the development of oral, 
intestinal inflammation and therefore mucositis (155).  
The use of Symprove in randomised-controlled trials has been investigated in 
conditions affecting the gastrointestinal system, including inflammatory bowel disease, 
irritable bowel disease and diverticular disease. 
Symprove in adults 
Data suggests that Symprove reduces intestinal inflammation in patients with ulcerative 
colitis (156), and frequency of diarrhoea and mucorrhea in patients with diverticular 
disease (13).  Another randomised controlled trial demonstrated that the use of 
Symprove resulted in lower symptom severity in participants with irritable bowel 
syndrome (IBS) when compared to placebo (mean difference −35.0 ,95% CI; −62.03, 
−7.87; P = 0.01) (157).  
Symprove in paediatrics 
The use of Symprove has been approved for use in children under EU law and 
Symprove encourages the use of the liquid probiotics in paediatrics. However, dose 
 
 
varies in the younger children (20mls for those under the age of 4 and 0.5mg/kg for 
children aged between 4-8). There have been no paediatric clinical investigating the 
use of Symprove and the MaCROS study will be the first trial exploring the use of 
Symprove in paediatrics and people with cancer. It is believed the liquid and flavoured 
formulations will improve compliance in children when compared to tabled/freeze dried 
formulations. As the use of Symprove has been investigated in other gastrointestinal 
disorders the study authors felt it would be an appropriate intervention to explore in 
children with cancer who are at risk of developing mucositis. 
Safety of Symprove 
Liquid probiotic has been reported as safe in previous studies undertaken and there 
have been no reports of serious adverse events attributed to Symprove (153, 158). 
However, consumption may be associated with nausea and reflux (159). As previously 
reported probiotics can rarely be associated with infections in immunocompromised 
patients. 
Randomisation: type 
Simple randomisation will be undertaken by the research pharmacist due to the small 
number of participants intended to be recruited. Ideally randomisation would be 
stratified according to type of malignancy (solid tumour/ leukaemia/ stem cell 
transplants - allogeneic or autologous), chemotherapy type (etoposide, doxorubicin or 
high dose methotrexate, SCT), age (dichotomised at 10 years and older).  
Randomisation: implementation 
Allocation concealment 
Health care professionals and participants will be blinded to the randomisation 
allocation. 
Blinding 
Patients, health care professionals (apart from the pharmacy department) and the 
research team will be blinded to the type of intervention delivered (intervention or 
placebo). The placebo and probiotic will be packaged in identical sealed boxes, 
identified by a trial batch/code as supplied by the Symprove company. 
Data collection 
Patient diary 
The diary will include questions to assess nausea, vomiting, diarrhoea, pain and oral 
mucositis (using a modified version of the Children’s International Mucositis Evaluation 
 
 
Scale (ChIMES) (103)). An example of the patient diary is supplied in the appendix. 
Either the participant or parent will fill in the diary on a daily basis for a minimum of 21 
days. If possible, the same person will be required to fill in the diary during the 21 days. 
Participants/parents/guardians will have the option of choosing to use a paper diary or 
a web-app diary. If participants/parents/guardians choose to use the web-app they will 
be given a link to download the web-app which they filly daily. They can also opt for 
daily reminders using their mobile number or email address. 
Investigation of febrile episodes/infection 
Clinical records including electronic and written records will be reviewed to investigate 
any febrile episodes and infections for incidence and duration of fever/infection and 
duration of hospital stay until afebrile for 48 hrs.  
Other data 
Other relevant information including type of nutritional support, analgesia and duration 
of hospital stay, will be taken from clinical records during any hospital stay. Data 
collected will be anonymised and stored on data collection forms. 
Evaluation of participant/parent experience  
Participants and/or parents will be invited to discuss their experiences of participation 
in the trials. Those agreeing to participate will be interviewed over the phone, or in 
person depending on preference, and the interviews audio recorded. This will include 
questions regarding recruitment, the process of gaining consent and randomisation, 
and experiences of adherence of the probiotic/placebo and patient diary and should not 
take longer then 45 minutes.  
Information will be collected using a recording audio device, transcribed and 
information will be evaluated using the framework approach [21] . The recording will be 
deleted as immediately after completion of transcribing. Interviewees will be asked not 
to refer to any names or patient identifiable information. Information will be used in 
conjunction with the development of any future RCT.  
Participants who chose to decline participation the MaCROS study will also be invited 
to fill an optional anonymous questionnaire explaining why they chose not to take part 
in the study. Consent will be implied by return of the questionnaire. 
Data management  
Information will be collected centrally in the NHS and stored anonymously at the 




Participant/parent to fill in diary daily.  
CI to collect diaries following completion of study and collect data of participants 
admitted to hospital using their clinical records.  
Data to be anonymised locally, with only the randomisation number issued by 
pharmacy will be available on forms.  
Any spreadsheet will be anonymised on a secure NHS computer before transfer and 
access and  on a secure password protected University of Leeds computer using the 
secure NHS email account. 
Data supplied on the web-app will only be linked to the participants randomisation 
number and stored on the secure cloud based Amazon web server. Web-app 
information will only be accessed on a secure NHS or university of Leeds computer 
and transferred to anonymised excel sheet which is only identifiable by the participants 
randomisation number which will be stored on a password protected University of 
Leeds M Drive. Once data has been stored on the M drive this will be deleted from the 
web-app server. 
Participants/parents/guardians who opt for daily reminders to fill in the app will have 
information stored on the secure cloud based Amazon web server reminder system. 
Once the diary has been completed their mobile number/email address will be deleted. 
Participants/parents/guardians who agree to participate in interviews will have this 
recorded using an NHS or university of Leeds encrypted audio recording. Once 
transcribing has finished the recording will be deleted. 
Personal data relating to study to be destroyed by PI or supervisor at end of storage 
period (10 years).  
Consent forms/diaries will be secured in locked filing cabinet in Martin Wing D floor at 
LTHT and destroyed after the 10 year period.  
Electronic database at the University of Leeds will be used to collect the pseudo 
anonymised data. 
Database to be stored on CI University M drive, a secure, password protected, 
University of Leeds server. 
CI or responsible person (e.g. Professor Kinsey) will be responsible for deleting data 








Statistical power is not required for this feasibility study. However, we believe recruiting 
between 20-40 participants will supply enough information to evaluate the feasibility of 
undertaking an RCT.  
Data will be entered into a secured local anonymised database and analysed using 
descriptive statistics, Student's t-test, Mann–Whitney U-test and χ2 tests for 
comparative normal, non-normal and categorical data respectively. Where possible 
appropriate subgroup analysis will be undertaken. 
Evaluation of the feasibility for undertaking a randomised-controlled trial 
The feasibility of undertaking an RCT will be evaluated using both quantitative and 
qualitative methods. Data relating to timing of the return of patient diaries, department 
referral rate, recruitment rate and numbers lost to follow-up will be recorded. 
Acceptability and tolerability of the treatment intervention will be assessed through 
completion rate of the probiotic/placebo course, use of the patient diaries and 
exploration of the patients/parents study participation via interview. 
 
Indications to consider stopping the study 
Unable to recruit a minimum of 20 patients within 6 months of the study opening 
The occurrence of an unexpected serious adverse reaction or event attributed to the 
probiotic or placebo 
Intentional non-compliance/deviation from the study protocol (e.g. patient un-blinded to 
intervention delivered without approval from a member of the research team) 
Indications to consider modifying the study 
Poor recruitment- e.g. fewer than 10 patients recruited within a 3 month period. 
Poor identification of eligible patients (less than 100%) 
Problems with delivery/compliance 50-80% of  intervention or placebo delivered 
 
 
Poor compliance with recording and returning patient diaries (less than 80%). 
Indications to continue the study without modification 
No issues implementing study protocol 
Adequate number of participants identified and recruited within the 6 month period 
100% compliance with the delivery of the intervention/placebo 
Greater than 80% compliance of recording and returning of patient diaries. 
Indications to not undertake a RCT 
Unable to recruit minimum of 20 patients within 6 months of the study opening 
Poor compliance with recording and returning patient diaries (less than 50%) 
Serious concerns identified during qualitative analysis of participants/parents interview. 
Safety reporting  
The research and clinical team are responsible for identifying any adverse event. Any 
serious adverse event (SAE) will be reported to REC using the safety reporting form 
recommended by the Health Research Authority 
(http://www.hra.nhs.uk/resources/during-and-after-your-study/progress-and-safety-
reporting).   
As this feasibility study has been classified as a non-CTIMP study, only reports of 
Serious Adverse reaction (SAE) that are:  
• Related to the study (ie resulted from administration of any of the 
Symprove/placebo)  
• Unexpected (i.e .not listed in the protocol as an expected occurrence) 
And Serious Adverse Reactions (SAR): 
• An adverse event that is both serious and, in the opinion of the reporting 
investigator, believed with reasonable probability to be due to one of the trial 
treatments, based on the information provided. 
Information should be submitted to the REC using the Non-CTIMP safety report 
(appendix 1). These should be sent within 15 days of the chief investigator becoming 
aware of the event. Reports of unexpected SAE/SARs should be unblinded.  
2) The University of Leeds sponsors should be notified of any unexpected SAE or 








Infections (not attributed to the probiotic) 
Haematological toxicity (e.g. low haemoglobin or platelets) 
Gut toxicity, mucositis, stomatitis (e.g. mouth ulcers, nausea, vomiting and diarrhoea) 





Hospitalisation, including prolonged stay (which is not attributed to the 
probiotic/placebo) 
Admission to the paediatric intensive care unit (which is not attributed to the 
probiotic/placebo) 
Disease-progression  
Expected death due to disease 
Dissemination 
The results of this feasibility study will inform the planning of a definitive RCT, by 
assessing rates of recruitment, retention, serious adverse events and data collection. 
The qualitative results will be used to further refine the protocol for a large RCT and 
presented to potential collaborators. Findings will be presented at relevant meetings as 




2.2 PILS for under 10 years 
Version 1 03/01/2019       Study Title: The MaCROS 
study 
Reference: IRAS no 246313 
 




Mucositis and infection reduction with probiotics in children with cancer: a 
randomised-controlled feasibility study 
 
Participant Information Leaflet for children 
 
Chemo Duck  







Hi, I’m Chemo Duck 
I finished the MaCROS study last week. 







When I came to hospital to have the medicine that makes me better, one of the 
nice doctors asked if I would take an extra medicine for 2 weeks. 
 
This extra medicine has friendly bugs called ‘bacteria’ which may help your 






It’s pretty cool because some of other chemo ducks took a different extra 
medicine. They took a ‘pretend’ probiotic medicine! 
 
I was told some chemo ducks had the ‘pretend’ probiotic medicine because the 
doctors don’t know if the probiotic really works so they need to do some 









Taking the medicine 
 
The extra medicine I took was a drink. It either had a fruity or plain taste. It 





I had to take it every day for 2 weeks.  
 
Every day for 3 weeks I had to answer questions about any tummy or mouth 
problems or if it was hurting anywhere in a diary. 
 
The doctor said that whoever looked after me at home (like mummy or daddy) 
could answer the questions if I didn’t want to, but I wanted to do it because there 









The detective work 
 





The doctor told me they will investigate my diary and hospital notes from when I 
had to go to the ward because I had a temperature. 
 
She said she will look at all the other chemo’s duck’s diaries and hospital notes.  
 
 
The doctor will collect the diaries and compare the secret groups to see if the 







The doctor told me that chemo ducks who took the probiotic may poo less.!  
 
The hospital and university may keep some of the information about you in the 
MaCROS study for up to 10 years after it finishes. If you want to find out more 





Well done for helping me. 
How did you find taking 







I hope it makes other 
chemo ducks better! 
 
 
2.3 PILS 10-16 years 
Mucositis and infection reduction with probiotics in children with cancer:  
a randomised-controlled feasibility study 
 
The MaCROS study 

















Will you receive chemo which may affect your gut? 
Would you be interested in taking part in a study which may reduce your symptoms 
AND help other kids or teenagers in the future? 
If so The MaCROS study maybe the study for you… 
What are probiotics? 
Probiotics are supplements which contain 
‘friendly bacteria’ which can help your gut. 
It is believed that taking probiotics may 
reduce some of the side effects of the 
chemo you are having.  
This includes:  
 







However, we don’t have enough proof to show this. Research (studies) is a way of 
trying to find answers to questions we don’t know the answer to. 
What will the MaCROS study investigate? 
The MaCROS study will explore if it is worth doing a large study called a ‘randomised-
controlled trial’ (RCT). This study will investigate how practical the study is and whether 
children and teenagers actually want to get involved. 
The study will also compare side effects described above in children and teenagers 
who take probiotics and those who take a ‘dummy probiotic’ called a placebo. 
 
Why have I been asked to take part? 
 
 
You have been asked to take part because you have cancer and receiving 
chemotherapy which can cause gut problems. You can help us find answers that will 
enable us to better understand if other children would be able to take part in the study 
in the future 
Did anyone else check the study is okay to do? 
This study has been checked by several people to make sure it is alright 
Do I have to take part? 
No you don’t. It is your choice whether you want to take part in the study and you can 
always change your mind. We will only collect information until the point you change 
your mind. 
What will I have to do if I get involved? 
A doctor will have a chat with you about the MaCROS study and answer any questions 
you may have. Once you have had time to think and if you decide to take part, yourself 
and a parent or guardian will be asked to sign a consent form. 
You will be asked to start taking the probiotic or the placebo on the first day of your 
course of chemo. No one apart from someone in pharmacy will know which type you 
are taking. 
You will need to take this every day for two weeks. 
You will also be given a symptom diary and will need to fill it in every day from the start 
of your course of chemo for three weeks. This can filled in using a paper diary or a 
web-app diary which can be downloaded using a link provided. If you decide to use the 
app you can also chose to have daily reminders. The diary should take no longer then 
15 minutes per day to fill in. 





 Poo problems 
One of the doctors (Dr Hadeel Hassan) will look at your hospital records if you end up 
developing a temperature and get admitted to hospital for antibiotics. 
 
 
Dr Hadeel will collect your diary when you have finished the diary. 
You may be invited to give your opinions on taking part of the study. This can be done 
on the phone or in person (whatever you prefer!) It shouldn’t take any longer than 45 
minutes. It will be recorded using a secure device. What is discussed will be 
transferred (anonymously) to a word document which will be kept on a password 
protected secured device. Once this has been done the audio recording will be deleted.  
What are the potential benefits of taking probiotics? 
You may have no benefit from taking the probiotic or placebo. 
However, there has been a lot of interest in probiotics in the medical world. 
It is already used to prevent infection in vulnerable premature babies. 
It has also be shown to reduce diarrhoea in children and teenagers taking antibiotics 






Are there any risks with taking probiotics? 
Probiotics have been reported to be very safe. 
25 studies were reviewed to investigate how safe it is for people with cancer to take 
probiotics. 
Side effects reported were bloating and sickness. 
In very very rare cases a person may get an infection 
which is caused by the friendly bacteria. The few who did 
get an infection made a full recovery with antibiotic 
treatment. 
What will happen when the research study stops? 
The research will be talked about and written down but no one will know that you took 
part. All identifiable information about you will be kept private. Non-identifiable 
 
 
information will be kept at the university of Leeds for up to 10 years on a secure 
computer. This non -identifiable information maybe used in future studies. 
The pharmacy team will also keep some identifiable information (i.e. name, NHS 
number and what you received). This will only be kept on a secure NHS computer for 
up to 10 years. 
What if something goes wrong? 
If there is a problem you can you can talk to your parents or guardians, or any of the 
researchers or health care team. If you don’t want to take part anymore then you can 
tell your parents/guardians or any of the researchers. You don’t need to give a reason. 
Who is paying for this study? 
 
The Candlelighters charity is paying Dr 
Hadeel’s university degree (called a PhD) 
and study costs.  
 
More information 
For further information you can email ask for Dr Hadeel via any staff member 
The NHS website also has some information about probiotics: 
https://www.nhs.uk/conditions/probiotics/ 
If you wish to make a complaint you can inform Dr Hadeel, any member of the health 
care team or contact PALS. 








2.4 PILS 16-18 yrs 
Mucositis and infection reduction with probiotics in children with cancer: a 
randomised-controlled feasibility study 
 
The MaCROS study 
Participant Information Leaflet for ages 16-18 
 
We would like to invite you to take part in a research study. Before you decide, you 
need to understand why this research is being done and what it would involve for you. 
Please take time to read the following information carefully and do not hesitate to ask 
any questions. 
Why probiotics? 
There has been a lot of interest regarding the use of probiotics (tablets or granules 
containing ‘friendly bacteria’) to improve the health of people with certain medical 
conditions. It is believed that probiotics can help change the type of bacteria that live in 
the gut to more ‘friendly’ types which are good for health. Clinical trials have shown that 
the use of probiotics may reduce antibiotic-associated diarrhoea in children, gut 
problems in people with chronic bowel conditions and prevent life threatening gut 
infections in premature babies. 
Certain studies have suggested that probiotics may also reduce side effects of 





mouth ulcers and infection. However, there have only been two small clinical trials in 
children and young people with cancer, and we are therefore not clear if probiotics will 
work for this group of patients.  
What is this study about? 
This study will investigate whether a large clinical trial (known as a randomised-
controlled trial) should take place. Patients taking part will be randomly allocated to 
receive the probiotic or a ‘dummy probiotic’ (known as a placebo). This has to be taken 
daily from the start of chemotherapy for 14 days. Patients will be asked to answer 
questions in a diary about problems which may affect the gut on a daily basis for 3 
weeks. We will also review records from any hospital admissions during this time to 
investigate any infections. This is called a feasibility study. 
Why is a feasibility study needed? 
It is important to do a feasibility study before undertaking a randomised-controlled trial 
as these types of studies are expensive, need a large number of patients, and involve 
significant time and effort to run. Researchers and health-care professionals may be 
interested in a particular question, but actually patients or parents may think that the 
question being asked is not important or actually useful. Sometimes it can be difficult to 
get patients to agree to take part in a study, take medications or fill in a diary. It is 
therefore important to identify any issues before the larger study. We will ‘trial’ the 
study on fewer patients than that required for the randomised-controlled trial. 
Information from this feasibility study will be used to guide whether we should proceed 
with the randomised-controlled trial, and to make the study more patient and family 
friendly. Essentially this feasibility study is a ‘mini randomised-controlled trial’ to check 
everything works and runs smoothly. 
Why have I been asked to participate? 
You have been diagnosed with cancer, and is receiving chemotherapy which may 
cause mouth ulcers, nausea, vomiting, pain and infections. 
What will happen now? 
If you agree to participate in the study, we will ask you to sign a written consent form. 
Before deciding you will also have the opportunity to ask the research team questions. 
Once you have agreed to take part, you will be randomised to receive the probiotic or 
placebo. This will be designed and packaged so that you or health care professionals 
will not be able to tell whether it is the probiotic or placebo. However, it will be labelled 
in a way that the research team will be able to identify what has been given. The 
 
 
reason why we are doing this is to try reduce any issues which could cause you, 
researchers and health care professionals to misinterpret results (in research this is 
known as bias). 
You should take the probiotic or placebo every day from the start of chemotherapy for 
14 days. If you find that you cannot take the probiotic or placebo, then please do inform 
a health care professional or a member of the research team. 
We also ask that you answer the questions in the diary (paper or web-app version) 
every day for 3 weeks once you start taking the probiotic or placebo. If you chose to 
use the web-app you will be given a web-app link to down load. You can log into the 
app using the identification number issued by pharmacy on your bottle of probiotic or 
placebo. You also have the optional choice of supplying your mobile number/email 
address to receive daily reminders to fill in the diary but you do not have to do this. 
You will also have the option to participate in an interview over the phone or in person. 
This will involve answering questions about your experiences. This should not take any 
longer than 45 minutes. The interview will be recorded using a secure audio device 
which will then be transferred to an anonymized word document. Once this has been 
completed the audio recording will be deleted.  
Anonymous quotes from interviews may be used during the analysis and reporting of 
the study (for example PhD thesis or journal papers).   
Taking part in the interview will help us understand how to improve the patient 
experience in any future study but you do not have to do this to take part in the 
MaCROS study. It is an optional part of the study. 
Why is it important to do this? 
You may develop side effects 10-14 days after taking chemotherapy. We have 
attempted to time the probiotic or placebo to fit in with this to see whether it could 
prevent or reduce any side effects. A randomised-controlled trial would investigate 
whether this is the correct time to give the probiotic, as well as the necessary duration 
of probiotic for any beneficial effect, and how easy or difficult it is to fill in the diary for 
21 days. The feasibility study will help us decide if this is a realistic thing to ask patients 
or parents to do.   
What are the benefits of taking part in this study? 
You may receive no benefit from taking part in this study. 
You will be contributing to a study which may improve the quality of life of children with 
cancer.  Whilst the main goal of this study is to investigate if we should undertake a 
 
 
randomised-controlled trial, you may benefit from fewer side effects including 
diarrhoea, pain, nausea, vomiting, mouth ulcers and infection. 
Do I have to take part? 
You do not have to take part in the study. If you agree to participate we will ask you 
and/or your parent to sign a written consent form confirming your willingness to 
participate. 
Can I change my mind after I have agreed to take part? 
You can withdraw at any point during the study. 
Are there any disadvantages of taking part in this study? 
As with any supplement or medicine there is a very small risk of developing side 
effects. Studies suggest that there are very few side-effects that can occur when a 
patient takes probiotics whilst receiving chemotherapy. There is a small risk of 
developing an infection which is caused by the ‘friendly bacteria’ in the probiotic. 
However, this is a very rare side effect. In a large review of 25 studies investigating the 
use of probiotics in people with cancer only 6 out of 1138 patients (0.5%) developed 
any probiotic-associated infection. All patients made a full recovery and the probiotic 
associated infections were successfully treated with antibiotics and supportive care. 
Other symptoms such as vomiting, bloating and diarrhoea were reported in both the 
probiotic and placebo groups. These symptoms are usually associated with the 
chemotherapy being used.  
While on the study you will receive the same clinical care as if you were not on the 
study. If you develop a temperature or became unwell you would be reviewed, 
investigated and treated as required for standard care. This would include attending 
hospital, being reviewed by health care professionals, having the usual investigations 
and receiving IV antibiotics or any other treatments required. In the unlikely 
development of a probiotic associated infection, appropriate antibiotics will be delivered 
following discussion with the microbiologists (doctors who give advice on antibiotics 
choice when targeting a particular bacteria). A safety and risk analysis will also be 
undertaken by the research team.    
Is this study insured? 







Will my taking part in the study be kept confidential? 
We will inform your GP that you are participating in the MaCROS study. Otherwise, 
participation and any information supplied is entirely confidential and will not be 
disclosed to anyone outside the research team without your permission.   
Your participation and any information supplied is entirely confidential and will not be 
disclosed to anyone outside the research team without your permission. We also ask 
that you keep all study information and discussions confidential too. All the information 
collected will be stored securely according to the Data Protection Act 2018. 
The university of Leeds will keep  non-identifiable information about you for 10 years. 
This data will be stored on a secure password protected computer and will only be 
accessible by a member of the research team responsible about data. Information may 
be used in future studies but only non-personalised and non-identifiable data will be 
supplied. 
The lead research pharmacist will also have your name and unique identifiable number 
on a database which is password protected on a secure NHS computer. This will be 
deleted after 10 years. 
Consent forms and paper diaries will be kept in a locked cabinet in the paediatric 
haematology and oncology office in Leeds General Infirmary. 
Will I be contacted about the results of the MaCROS study? 
If we receive your consent we can send you a letter reporting the outcome of the study 
once it has closed. 
Transparency 
The University of Leeds is the sponsor for this study based in the United Kingdom. We 
will be using information from your medical records in order to undertake this study and 
will act as the data controller for this study. This means that we are responsible for 
looking after your information and using it properly. The university of Leeds will keep 
identifiable information about you for the purpose of the study for up to 10 years after 
the study has finished. This information will be held by the Leeds Teaching Hospital 
Trust. 
Your rights to access, change or move your information are limited, as we need to 
manage your information in specific ways in order for the research to be reliable and 
 
 
accurate. If you withdraw from the study, we will keep the information about you that 
we have already obtained. To safeguard your rights, we will use the minimum 
personally-identifiable information possible. 
Leeds Teaching Hospital Trust will collect information from your medical records for 
this research study in accordance with our instructions. 
Leeds Teaching Hospital Trust (LTHT) will keep your name, NHS number and contact 
details. LTHT will not pass this information to the University of Leeds. LTHT will use 
this information as needed, to contact you about the research study, and make sure 
that relevant information about the study is recorded for your care, and to oversee the 
quality of the study. Certain individuals from the University of Leeds and regulatory 
organisations may look at your medical and research records to check the accuracy of 
the research study. The University of Leeds will only receive information without any 
identifying information. The people who analyse the information will not be able to 
identify you and will not be able to find out your name, NHS number and contact 
details. 
LTHT will keep identifiable information about you from this study for up to 10 years 
after the study has completed. 
You can find out more about how we use your information by contacting the University 
of Leeds data protection officer on DPO@leeds.ac.uk 
Who is organising and funding the research? 
The study is led by Dr Hadeel Hassan, a paediatric trainee and Clinical Research 
Fellow and PhD student at the University of Leeds under the supervision of Dr Bob 
Phillips, Consultant paediatric oncologist and senior academic, and Professor Sally 
Kinsey, Paediatric haematologist. Dr Hadeel Hassan’s Clinical Research Fellowship is 
funded by The Candlelighters Charity. 
Who has reviewed the study? 
The NHS Research Ethics service has reviewed this study to ensure to ensure your 
rights, safety, dignity and well-being are protected whilst facilitating research. 
Who do I contact for further information? For further information about the study 
please contact Dr Hadeel Hassan at the University of Leeds, telephone number 0113 
3432596, or Dr Bob Phillips at Leeds Teaching Hospital 0113 39 28779 (secretary). 














2.5 PILS parents/guardians 
 
Mucositis and infection reduction with probiotics in children with cancer: a 
randomised-controlled feasibility study 
 
 
The MaCROS study 
Participant Information Leaflet for person with parental/responsibility 
 
 
We would like to invite your child to take part in a research study. Before you decide, 
you need to understand why this research is being done and what it would involve for 
your child. Please take time to read the following information carefully and do not 
hesitate to ask any questions. 
Why probiotics? 
There has been a lot of interest regarding the use of probiotics (tablets or granules 
containing ‘friendly bacteria’) to improve the health of people with certain medical 
conditions. It is believed that probiotics can help change the type of bacteria that live in 
the gut to more ‘friendly’ types which are good for health. Clinical trials have shown that 
the use of probiotics may reduce antibiotic-associated diarrhea in children, gut 
 
 
problems in people with chronic bowel conditions and prevent life threatening gut 
infections in premature babies. 
Certain studies have suggested that probiotics may also reduce side effects of 
chemotherapy that can affect the gut. This includes diarrhoea, pain, nausea, vomiting, 
mouth ulcers and infection. However, there have only been two small clinical trials in 
children and young people with cancer, and we are therefore not clear if probiotics will 
work for this group of patients.  
What is this study about? 
This study will investigate whether a large clinical trial (known as a randomised-
controlled trial) should take place. Patients taking part will be randomly allocated to 
receive the probiotic or a ‘dummy probiotic’ (known as a placebo). This has to be taken 
daily from the start of chemotherapy for 14 days. Patients or those with parental 
responsibility will be asked to answer questions in a diary about problems which may 
affect the gut on a daily basis for 3 weeks. We will also review records from any 
hospital admissions during this time to investigate any infections. This is called a 
feasibility study. 
Why is a feasibility study needed? 
It is important to do a feasibility study before undertaking a randomised-controlled trial 
as these types of studies are expensive, need a large number of patients, and involve 
significant time and effort to run. Researchers and health-care professionals may be 
interested in a particular question, but actually patients or parents may think that the 
question being asked is not important or actually useful. Sometimes it can be difficult to 
get patients to agree to take part in a study, take medications or fill in a diary. It is 
therefore important to identify any issues before the larger study. We will ‘trial’ the 
study on fewer patients than that required for the randomised-controlled trial. 
Information from this feasibility study will be used to guide whether we should proceed 
with the randomised-controlled trial, and to make the study more patient and family 
friendly. Essentially this feasibility study is a ‘mini randomised-controlled trial’ to check 
everything works and runs smoothly. 
Why have I been asked to participate? 
Your child has been diagnosed with cancer, and is receiving chemotherapy which may 




What will happen now? 
If you agree for your child to participate in the study, we will ask you to sign a written 
consent form. Before deciding you will also have the opportunity to ask the research 
team questions. If your child is under the age of 16 they may also be asked to sign an 
assent form agreeing to their participation. 
Once you have agreed for your child to take part, your child will be randomised to 
receive the probiotic or placebo. This will be designed and packaged so that you or 
health care professionals will not be able to tell whether it is the probiotic or placebo. 
However, it will be labelled in a way that the pharmacist will be able to identify what has 
been given if there is any urgent need to know what is given . The reason why we are 
doing this is to try reduce any issues which could cause you, researchers and health 
care professionals to misinterpret results (in research this is known as bias). 
Your child should take the probiotic or placebo every day from the start of 
chemotherapy for 14 days. If you find that your child cannot take the probiotic or 
placebo, then please do inform a health care professional or a member of the research 
team. 
We also ask that you answer the questions about your child in the diary (paper or web-
app version) every day for 3 weeks once you start taking the probiotic or placebo. This 
should not take more than 10 minutes each day. If you chose to use the web-app you 
will be given a web-app link to download. You can log into the app using the 
identification number issued by pharmacy on your child’s bottle of probiotic or placebo. 
You also have the optional of receive daily push notifications to fill in the diary but you 
do not have to do this. 
You will also have the option to participate in an interview over the phone or in person. 
This will involve answering questions about yours and your child’s experiences. This 
should not take any longer than 45 minutes. The interview will be recorded using a 
secure audio device which will then be transferred to an anonymized word document. 
Once this has been completed the audio recording will be deleted.  
Anonymous quotes from interviews may be used during the analysis and reporting of 
the study (for example PhD thesis or journal papers).   
Taking part in the interview will help us understand how to improve the patient 
experience in any future study but your child does not have to do this to take part in the 
MaCROS study. It is an optional part of the study. 
Why is it important to do this? 
 
 
Your child may develop side effects 10-14 days after taking chemotherapy. We have 
attempted to time the probiotic or placebo to fit in with this to see whether it could 
prevent or reduce any side effects. A randomised-controlled trial would investigate 
whether this is the correct time to give the probiotic, as well as the necessary duration 
of probiotic for any beneficial effect, and how easy or difficult it is to fill in the diary for 
21 days. The feasibility study will help us decide if this is a realistic thing to ask patients 
or parents to do.   
What are the benefits for my child by taking part in this study? 
Your child may receive no benefit from taking part in this study. 
Your child will be contributing to a study which may improve the quality of life of 
children with cancer.  Whilst the main goal of this study is to investigate if we should 
undertake a randomised-controlled trial, your child may benefit from fewer side effects 
including diarrhoea, pain, nausea, vomiting, mouth ulcers and infection. 
Does my child have to take part? 
Your child does not have to take part in the MaCROS study. If you decide you would 
like to participate then we will ask you to sign a written consent form on behalf of your 
child. Your child may also be asked to sign an assent form. 
Can I change my mind after I have agreed to take part? 
You can withdraw your child at any point during the study. 
Are there any disadvantages for my child if we agree to take part in this study? 
As with any supplement or medicine there is a very small risk of developing side 
effects. Studies suggest that there are very few side-effects that can occur when a 
patient takes probiotics whilst receiving chemotherapy. There is a small risk of 
developing an infection which is caused by the ‘friendly bacteria’ in the probiotic. 
However, this is a very rare side effect. In a large review of 25 studies investigating the 
use of probiotics in people with cancer only 6 out of 1138 patients (0.5%) developed 
any probiotic-associated infection. All patients made a full recovery and the probiotic 
associated infections were successfully treated with antibiotics and supportive care. 
Other symptoms such as vomiting, bloating and diarrhoea were reported in both the 
probiotic and placebo groups. These symptoms are usually associated with the 





While on the study your child will receive the same clinical care as if they are not on the 
study. If your child develops a temperature or became unwell they would be reviewed, 
investigated and treated as required for standard care. This would include attending 
hospital, being reviewed by health care professionals, having the usual investigations 
and receiving IV antibiotics or any other treatments required. In the unlikely 
development of a probiotic associated infection, appropriate antibiotics will be delivered 
following discussion with the microbiologists (doctors who give advice on antibiotics 
choice when targeting a particular bacteria). A safety and risk analysis will also be 
undertaken by the research team.    
 
 
Will I be contacted about the results of the MaCROS study? 
If we receive your consent we can send you a letter reporting the outcome of the study 
once it has closed. 
Will my child’s participation in the study be kept confidential? 
We will inform your GP that your child is participating in the MaCROS study. Otherwise, 
participation and any information supplied is entirely confidential and will not be 
disclosed to anyone outside the research team without your permission.   
The university of Leeds will keep non-identifiable information about your child for 10 
years. This data will be stored on a secure password protected computer and will only 
be accessible by a member of the research team responsible about data. Information 
may be used in future studies but only non-personalised and non-identifiable data will 
be supplied. 
The lead research pharmacist will also have your childs name and unique identifiable 
number on a database which is password protected on a secure NHS computer. This 
will be deleted after 10 years. 
Consent forms and paper diaries will be kept in a locked cabinet in the paediatric 
haematology and oncology office in Leeds General Infirmary. 
We also ask that you keep all study information and discussions confidential too. All 
the information collected will be stored securely according to the Data Protection Act 
2018. 
Is this study insured? 




The University of Leeds is the sponsor for this study based in the United Kingdom. We 
will be using information from your child’s medical records in order to undertake this 
study and will act as the data controller for this study. This means that we are 
responsible for looking after your child’s information and using it properly. The 
university of Leeds will keep identifiable information about your child for the purpose of 
the study for up to 10 years after the study has finished. This information will be held by 
the Leeds Teaching Hospital Trust. 
Your rights to access, change or move your child’s information are limited, as we need 
to manage your information in specific ways in order for the research to be reliable and 
accurate. If you withdraw your child from the study, we will keep the information about 
your child that we have already obtained. To safeguard your child’s rights, we will use 
the minimum personally-identifiable information possible. 
Leeds Teaching Hospital Trust will collect information from your child’s medical records 
for this research study in accordance with our instructions. 
Leeds Teaching Hospital Trust (LTHT) will keep your child’s name, NHS number and 
contact details. LTHT will not pass this information to the University of Leeds. LTHT will 
use this information as needed, to contact you or your child about the research study, 
and make sure that relevant information about the study is recorded for your child’s 
care, and to oversee the quality of the study. Certain individuals from the University of 
Leeds and regulatory organisations may look at your child’s medical and research 
records to check the accuracy of the research study. The University of Leeds will only 
receive information without any identifying information. The people who analyse the 
information will not be able to identify your child and will not be able to find out their 
name, NHS number and contact details. 
LTHT will keep identifiable information about your child from this study for up to 10 
years after the study has completed. 
You can find out more about how we use your child’s information by contacting the 
University of Leeds data protection officer on DPO@leeds.ac.uk 
Who is organising and funding the research? 
The study is led by Dr Hadeel Hassan, a paediatric trainee and Clinical Research 
Fellow and PhD student at the University of Leeds under the supervision of Dr Bob 
Phillips, Consultant paediatric oncologist and senior academic, and Professor Sally 
 
 
Kinsey, Paediatric haematologist. Dr Hadeel Hassan’s Clinical Research Fellowship is 
funded by The Candlelighters Charity. 
Who has reviewed the study? 
The NHS Research Ethics service has reviewed this study to ensure to ensure your 
rights, safety, dignity and well-being are protected whilst facilitating research. 
Who do I contact for further information? For further information about the study 
please contact Dr Hadeel Hassan at the University of Leeds, telephone number 0113 
3432596, or Dr Bob Phillips at Leeds Teaching Hospital 0113 39 28779 (secretary). 



























2.6 Consent forms parents/guardians 
 
 Mucositis and infection reduction with probiotics in children with cancer: a 
randomised-controlled feasibility study protocol 
Consent form for those with parental responsibility 
Name:     
 Add your initials next to 
the statements you agree 
with  
I confirm that I have read and understand the 
information sheet version ………. dated ……..  
explaining the above research study I have had the 
opportunity to ask questions about the project. 
 
I understand that relevant anonymised quotes from 
myself or my child may be used in published works 
arising from this study 
 
I agree for the data collected from my child to be 
stored securely and used in relevant future research 
in an anonymised form.  
 
I understand that relevant sections of the data 
collected during the study, may be looked at by 
individuals from the University of Leeds or from 
regulatory authorities where it is relevant to my 
taking part in this research. I give permission for 
these individuals to have access to my child’s 
records. 
 
I understand that I have the right to withdraw my 
child from  the MaCROS study at any point 
 
I am happy for my child or myself to be approached 




interview about my experiences of participating in 
the MaCROS study.  
I understand that the interview will be recorded  on 
an audio device and deleted as soon as the 
interview has been transcribed to a word document.  
 
I am happy for my child’s GP to be informed of 
his/her participation in The MaCROS study. 
 
I would like to be contacted about the result of the 
MaCROS study by letter once it has closed 
 


















Once this has been signed by all parties the participant should receive a copy of 
the signed and dated participant consent form, the letter/ pre-written script/ 






information sheet and any other written information provided to the participants. 
A copy of the signed and dated consent form should be kept with the project’s 














2.7 Consent forms 16-18 yrs 
Mucositis and infection reduction with probiotics in children with cancer: a 
randomised-controlled feasibility study protocol  
Consent form for 16-18 yr olds 
Name: 
 Add your initials next to 
the statements you agree 
with  
I confirm that I have read and understand the 
information sheet version ………. dated ……..  
explaining the above research study I have had the 
opportunity to ask questions about the project. 
 
I understand that relevant anonymised quotes may 
be used in published works arising from this study 
 
I agree for the data collected from me to be stored 
securely and used in relevant future research in an 
anonymised form.  
 
I understand that relevant sections of the data 
collected during the study, may be looked at by 
individuals from the University of Leeds or from 
regulatory authorities where it is relevant to my 
taking part in this research. I give permission for 
these individuals to have access to my records. 
 
I understand that I have the right to withdraw from at 
any point 
 
I am happy to be approached about participating in 
a telephone/face to face interview about my 
experiences of participating in the MaCROS study.  
 
I understand that the interview will be recorded on 




interview has been transcribed to a word document.  
I am happy for my GP to be informed of my 
participation in The MaCROS study 
 
I consent to participating in the MaCROS study  
I would like to be contacted about the result of the 















Once this has been signed by all parties the participant should receive a copy of 
the signed and dated participant consent form, the letter/ pre-written script/ 
information sheet and any other written information provided to the participants. 
A copy of the signed and dated consent form should be kept with the project’s 
main documents which must be kept in a secure location.  
 















2.8 Assent form 
 
Mucositis and infection reduction with liquid probiotics in children with cancer: a 
randomised-controlled feasibility study protocol 
ASSENT FORM for children under the age of 16 
By responsible health care/research professional 
 Responsible health 
care/research 
professional initials next 
to the statements you 
agree with  
I have checked with the child understands that 
participation is voluntary 
 
I have checked with the child and they understand 
the procedures 
 
I have checked with the child and they understand 
the risks and discomforts 
 
I have checked with the child and they understand 




 Add your initials next to 
the statements you agree 
                                                                               
The MaCROS study version 1 03/1/2019  
ASSENT FORM for children under the 






I know that I can choose to be in the research study 
or choose not to be in the research study. I know 
that I can stop whenever I want. 
I have read this information ( or had the information 
read to me)  and I understand it.  
I have had my questions answered and know that I 
can ask questions later if I have them.   
I understand any changes to this will be discussed 
with me.  
I agree to take part in the research. 
 
I do not wish to take part in the research and I have 




Certificate of assent  


















Once this has been signed by all parties the participant should receive a copy of 
the signed and dated participant consent form, the letter/ pre-written script/ 
information sheet and any other written information provided to the participants. 
A copy of the signed and dated consent form should be kept with the project’s 










2.9 GP notification letter 
The MaCROS Study version 1 03/01/2019 
GP LETTER  
date  
Dear Dr ___________________________,  
RE: Patient’s Name: ________________________________   DOB: ____/____/___   
Address: _________________________________________________________  
_________________________________________________________________  
The MaCROS study 
IRAS Number: 246313 
This patient has consented to participate in the above clinical trial.  
The MaCROS is a randomised controlled feasibility study of probiotics vs placebo. The 
aim of the study is to evaluate the feasibility of a randomised controlled trial to 
investigate the efficacy of liquid probiotics to prevent or reduce mucositis and infection 
in children diagnosed with cancer who are undergoing treatment with regimes likely to 
cause mucositis. 
Patients will be randomised to receive the liquid probiotic or placebo on day 1 -14 of 
their chemotherapy. Patients, carers and healthcare professionals will be masked as to 
the allocation. Symptoms will be documented daily in a patient diary.  
Outcomes investigated will include analysis of the compliance of participants taking the 
probiotic on a daily basis and completion of patient diaries (using paper and web-app 
methods). Departmental referral and recruitment rates, numbers lost to follow up and 
evaluation of the participant/parent experience using telephone interviews will also be 
explored. Secondary outcomes investigated will include analysis of the incidence and 
severity of mucositis and infection, through the use of patient recorded diaries and 
review of clinical records. 
Findings of the completed study will be used to assess if it is feasible to undertake a 
RCT to investigate whether probiotics can reduce the incidence and severity of 
mucositis and infection in children with cancer 
A copy of the patient-information sheet is inclosed with this letter. 
Data protection  
 
 
Your patient will be followed up for a maximum of 3 weeks or until their discharge from 
hospital if admitted during the 3 weeks following completion of the probiotic course.  
Please keep the research team informed if the patient is hospitalised or in the event of 





Should you have any questions concerning the patient’s participation or their treatment, 
please contact myself, on:  
  
Tel  07437319762 or 01133928488 
  
Dr Hadeel Hassan, Paediatric registrar and Chief investigator 
Please ensure that a copy of this letter is kept in the patient’s file at your practice and 
that the patient is flagged as taking part in a clinical trial.  
  




Dr Hadeel Hassan 





















2.10 Diary: web-app 
Access the website URL: www.macrosstudy.com 
Access settings tab top right corner 
Select add to Home screen 































































































































2.16 Paper diary (Nb sample of cover and day 1. Days 2-21 are repeats of day 1) 
What is your User ID?  
Who filled in the diary? (please tick one): 
 ☐        Participant   
 ☐        Person with parental responsibility  
Day 1 
Which of these 7 pictures mostly describes your poo today? Tick the image that 
matches. 
 
How many times have you pooed today?  
Tick on 10, if more than 10 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Which of these faces describe how bad the nausea is today? Range from 1 (no 





How many times did you vomit today? 
Tick on 10, if more than 10 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 Did you feel pain? If so where did you feel it? 
Type your answer here: 
 
What medication have you taken today? 
 
 
☐ Pain, e.g. dihydrocodiene or oramorph 
☐ Sickness e.g. ondansetron or metoclopramide 
☐ Diarrhea e.g loperamide 



































2.18 Anon questionnaire 
 Mucositis and infection reduction with probiotics in children with cancer: a 
randomised-controlled feasibility study protocol 
 



























Leeds institute of Cancer and Pathology 














2.19 Interview template 
 




Primary aim  
1. Explore the participants or parents/guardians experience of participating in the 
MaCROS study 
2. Explore suggestions from participants or their parents/guardians to improve user 
experience in future studies. 
Sample size  
Up to 10 participants will be identified and invited to participate. The interview will be 
done using a telephone or face to face using a semi-structured interview format.  
 Selection criteria   
English speaking  
Be a participant/parent/guardian randomised in the MaCROS study OR willing to 







1.1. What involvement did you have in the MaCROS study? 
1.2. Why did you agree to participate? 
1.3. Why did you choose to decline participation? 
1.4. How did you find the experience of being approached to participate in the 
MaCROS study? 
Randomisation 
1.5 How did you find the randomisation process and receiving the probiotic/placebo? 
Taking the probiotic/placebo 
1.6 How easy or difficult was it to take the probiotic/placebo? 
1.7 Did you manage to take it every day? 
1.8 If not why? 
1.9 How did you or your child find the taste of the probiotic/placebo? 
Use of the web-app/paper diary 
1.10 Did you choose to use the web-app or paper diary? 
1.11. Why did you choose this? 
1.12. How did you find the experience of using the web-app/diary? 
1.13 What did you like about the diary? 
1.14 What didn’t you like about the diary? 
1.12 Do you have any suggestions to make the diary a better experience for future 
users? 
Communication 
1.13 How do you feel about the communication from the The MaCROS research team 
whilst taking part in the study? 
Overall experience 
1.14 What did you enjoy about the study? 
1.15 What didn’t you enjoy about the study 
 
 
1.16 Do you have any suggestions to improve the experience in a future study? 
1.17 Would you recommend this study to another person? 
1.18 Is there anything else you would like to mention? 
Notes for the Interviewer 
 
Inform the interviewees the session will be recorded. Have a fully charged voice 
recorder and back up available.  The interview can last up until 1 hour. 
Open ended questions with topic guides ` 
It is not necessary to stick to the exact line of questioning or order. The purpose is to 
be open and explorative. However, it is important, that the subject matters in the topic 
guides are explored and the style of questioning kept open and explorative. 
 







2.20 The MaCROS study biological substudy 
 
The MaCROS biological sub-study 
Introduction 
An ongoing randomised-controlled feasibility study investigating the use of liquid 
probiotics to reduce or prevent mucositis and infection in children with cancer (the 
MaCROS study) is currently open at Leeds Teaching Hospital Trust (ClinicalTrials.gov 
Identifier: NCT03785938 (active), IRAS PROJECT ID: 246313). It would also be 
beneficial to assess the feasibility of undertaking a parallel biological sub-study to 
investigate the mechanism of action (or lack of) of probiotics in children with febrile 
mucositis. Therefore, an amendment to the MaCROS study is proposed to include a 
parallel biological sub-study investigating the mechanism of probiotic response 




Mucositis is the inflammation and ulceration of the gastrointestinal mucosal lining which 
can occur in children diagnosed with cancer. It may be caused by radiotherapy or 
cytotoxic agents which affect DNA synthesis (particularly S-phase specific agents) 
including cytarabine, methotrexate and fluorouracil(160). 
Mucositis can occur in any part of gastrointestinal system from the mouth to the anus. 
Symptoms range from mild erythema to wide spread ulceration. Development of 
mucositis can therefore result in pain, nausea, malabsorption, malnutrition, diarrhoea 
and increased risk of local and systemic infections(161)  
Taking biopsies of the gastrointestinal mucosal lining is the gold standard test to 
confirm mucositis. However, children typically require an endoscopy under general 
anaesthesia for this investigation. This is associated with significant risk, particularly as 
children are immunosuppressed and susceptible to complications including severe 
infections and bleeding. Because of this, children with suspected mucositis are 
diagnosed clinically and graded according to the severity of reported symptoms using 
validated assessment scales such as the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE). 
The Sonis hypothesis proposes 5 stages of the pathogenesis of mucositis: 
 
 
Radiotherapy or cytoxic exposure to the mucosal lining resulting in DNA damage and 
release of free radicals 
Activation of transcription factors including NF-kb, which results in the upregulation of 
proinflammatory cytokines causing mucosal destruction 
Signal amplification which may exacerbate or prolong mucosal injury 
Ulceration  
Healing, and gradual restoration of the flora (162).  
The relationship between mucositis and febrile neutropenia is recognised and the term 
‘febrile mucositis’ has been proposed (161). Patients with mucositis are believed to be 
most vulnerable to bacterial translocation from the gastrointestinal tract during stage 4 
of the Sonis hypothesis(140), following damage to the epithelial lining of the mucosa 
and inflammatory amplification (140). 
A study of adult patients diagnosed with multiple myeloma or non-hodgkins lymphoma 
demonstrated that there was a higher incidence of fever with severe mucositis when 
compared to those with less severe or no mucositis (68% vs 47%, difference 21%, 
p=0.004 ) (161). However, studies investigating mucositis and infection in paediatric 
cancer patients are limited. A review of guidelines investigated the management of oral 
mucositis in children undergoing stem cell transplantation highlighted that the 
epidemiology of mucositis is poorly understood, and that further observational studies 
and consensus- based approaches are required to understand and develop 
appropriate risk stratification tools. It also reported that further studies are needed to 
investigate preventative strategies(161). Currently, management of mucositis involves 
supportive care strategies. This may include the use of analgesia, loperamide to 
reduce diarrhoea, and delivery of nutrition using both enteral and parental routes. 
There are no widespread preventative or therapeutic intervention for febrile mucositis. 
Recent studies have explored the role of probiotics as a preventative and therapeutic 
intervention for people with cancer and mucositis.  
 
Probiotics and gastro-intestinal bacterial colonisation 
Probiotics are defined as “live micro-organisms which, when administered in adequate 
amounts, confer a health benefit on the host” according to the World Health 
Organisation and United Nations Food and Agriculture organization (FAO) (37).  
A recent systematic review and meta-analysis investigated the use of probiotics in 
people with cancer(163). Twenty one studies (N = 2,982 participants) were identified 
 
 
for assessment of efficacy. Results showed probiotics may reduce the incidence of 
diarrhoea in patients with cancer [odds ratio (OR) = 0.52, 95% confidence interval (CI) 
0.34-0.78, 95% percentage prediction interval (PI) 0.3-0.92, I-sq 36.9%, 5 studies], 
duration of pyrexia [standardized mean difference 0.64 days, 95% CI 053-0.77, PI 
0.64-0.64, I-sq 0.01%, 5 studies] and possibly the severity of diarrhoea [for example 
Common Toxicity Criteria grade 3 and 4 diarrhoea [OR=0.51, 95% CI 0.12-2.2, PI 0.03-
9.08, I-sq 92.5%, 4 studies].  
A lack of paediatric patients, heterogeneity of study characteristics and unclear risk of 
bias reported in included studies highlighted the uncertainty of confidence from 
conclusions drawn. This review demonstrated that there were insufficient studies to 
assess the true effect of probiotics in people with cancer. Meta-analysis suggested that 
probiotics may be beneficial but further studies are still required, particularly in children.  
This has led to the development of a randomised-controlled feasibility study to 
investigate the use of liquid probiotics to reduce or prevent mucositis and infection in 
children with cancer (the MaCROS study) at Leeds Teaching Hospital Trust 
(ClinicalTrials.gov Identifier: NCT03785938 (active), IRAS PROJECT ID: 246313). 
Further review of the literature identified a paucity of information exploring the 
biological evidence for the use of probiotics in people with cancer. The systematic 
review and meta-analysis previously discussed (163) did not undertake a review of the 
bacterial composition in stool sample of included studies because of the lack of data 
reported. Investigating the bacterial composition of stool samples would allow further 
exploration of how probiotics may impact upon bacterial diversity. Assessment of the 
microbiome, the gut flora, and any colonisation by probiotics observed may help in 
understanding the interactions between probiotic consumption and mucositis, be it 
beneficial or ineffective 
Using a ‘biological tool’ to explore the severity of mucositis with the use of probiotics 
could enhance understanding of the etiology, stratification and treatment of mucositis. 
Therefore, biomarkers may be a useful aid to investigate how probiotics may impact 
mucositis. 
Biomarkers 
Biomarkers are defined as “human or animal biological property whose in vitro 
measurement or identification is useful for the prevention, diagnosis, prognosis, 




A review of the literature highlighted that biomarkers have been used to identify or 
stratify the risk of mucositis in adults(139, 140) .Ten biomarkers have been 
investigated in 4 paediatric studies. These studies reported that: 
Serum citrulline may be used to determine the severity of mucositis 
Faecal calprotectin maybe used as a non-invasive biomarker for those with mucositis 
without neutropenia 
Serum procalcitonin may be able to distinguish fevers due to bacteraemia from those 
with mucositis who are febrile due to a systemic inflammatory response 
The C-Sucrose breath test is feasible to use in children with cancer 
Whilst serum IL-8 is a potential biomarker in children with febrile neutropenia it may not 
be accurate for use in those who also have mucositis. 
The four trials were reported as prospective studies by research authors (including one 
randomised-controlled trial), however two of these studies reported on a subgroup of 
participants, of which samples were analysed retrospectively.  
All studies had small sample sizes and reporting of the studies were unclear. 
Significant biases were found in these studies including selection bias (Tooley KL et 
al), confounding bias (all studies) and outcome information bias (all studies). Reporting 
of statistical results did not include 95% confidence intervals. 
Studies used different definitions and grading tools for mucositis. Gosselin KB et al and 
Tooley KL focused on oral mucositis only, WJFM van der Velden et al included those 
with oral and gastrointestinal mucositis (using different grading tools), whilst KG 
Miedema et al did not make any reference to oral mucositis. It is unclear from these 
studies whether oral, gastrointestinal or combined mucositis would impact the 
interpretation of biomarkers.   
This review has highlighted the need for further robust studies to explore how 
biomarkers can be used to investigate the response probiotics may have on mucositis. 
Faecal calprotectin is a non-invasive biomarker with a relatively low cost to undertake 
analysis.  One stool sample can be used to simultaneously analyse bacterial 
composition and biomarkers. This is less invasive and more convenient for participants 
then requiring to attend hospital for a blood test. 
Therefore, an amendment to the MaCROS study to include a biological sub-study is 
proposed. This will investigate the feasibility of testing stool samples for probiotic 
bacterial colonisation, and faecal calprotectin as a biomarker to explore the effect 
probiotic consumption in children with mucositis.
 
 
Aims and Objectives 
Aim 
The aim of this biological sub-study is to 
Evaluate the feasibility of testing stool samples for probiotic bacterial colonisation 
Evaluate the feasibility of using faecal calprotectin as a biomarker explore the effect 
probiotics may have on mucositis 
Objectives 
The primary objectives of this sub-study will determine feasibility by recording: 
The proportion of participants who agree to participate in the study 
The proportion of participants complete the sub-study, including the completion rate of 
the stool samples returned prior to or on day 0 and days 7, 14, 21 and 28 days  
Preliminary health economic information surrounding the costs/benefits of the using 
biomarkers. 
Secondary objectives will include: 
Evaluation of the research sub-study protocol 
Barriers to compliance with the sub-study protocol 
Evaluation of intended outcomes to be assessed if an RCT substudy is undertaken. If 
sufficient data is available the correlation between faecal calprotectin and severity of 
mucositis (according to NCI CTCAE grading), mean differences of results between the 





This will be a biological substudy of a single-centre double-blind randomised-controlled 
feasibility study.  
Study setting 





Participants will be recruited from the paediatric haematology and oncology inpatient 
and outpatient departments at Leeds Teaching Hospital Trust, Leeds, UK. 
Participants will be invited to participate in the substudy when they consent to 
participate in the MaCROS study. 
Target recruitment 
The recruitment target is up to 10 patients. Recruitment will continue until the MaCROS 
study closes. As this is a feasibility study, a power calculation is not required. 
Eligibility criteria for participants  
Participants must be eligible and have agreed to participate in the MaCROS study. 
Exclusion criteria 
Patients who have already started the course of chemotherapy. Participants who have 
received IV antibiotics within 7 days of starting their course of chemotherapy. 
Methodology 
Participants will be randomised in the main study to take the liquid probiotic 
(Symprove) or placebo on the first day of their chemotherapy/pre-stem cell transplant 
chemotherapy conditioning and take this once daily for 14 days. The dose will be 
adjusted according to age.  
Additionally, participants will be asked to supply a stool sample prior to or on day 0 and 
days 7, 14, 21 and 28 days which will be analysed for probiotic bacterial colonisation 
(Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus acidophilus, and 
Enterococcus faecium) and faecal calprotectin. 
Data collection 
Stool samples will be collected in aliquots and transported to the LTHT microbiology 
laboratory at room temperature within 3 days following collection.  
Participants will be given the option to either submit samples to member of the clinical 
care team for transport or post samples in stamped and addressed packaging that 
complies with the Royal Mail packaging instruction 650 (e.g. the Safebox product). 
Samples will then be stored between −20°C and −70°C in the microbiology laboratory 
prior to analysis. Results will be issued to the research team (who are also clinicians) 




Data collected will be confidential according to NHS and University of Leeds data 
protection regulations.  Descriptive statistics (such as probiotic bacterial colonisation 
and reported faecal calprotectin level from stool samples taken prior to or day 0, and 
days 7,14,21 and 28) will be reported due to the small of number of participants 
targeted. If enough data is available outcomes investigated will also include: 
The correlation of faecal calprotectin and severity of mucositis (according to NCI 
CTCAE grading)  
Simple descriptive statistical or quantitative analysis 
The feasibility of undertaking a biological sub-study will be evaluated using both 
quantitative and qualitative methods. Data relating to timing of stools submitted, 
identification of eligible participants, recruitment rate and participants who discontinue 
the sub-study will be recorded. Acceptability and tolerability of the intervention will be 
assessed through completion rate of the delivery of stool samples on prior to or on day 
0 and days 7 , 14 , 21 and 28 will be explored. Exploration of the patients/parents study 
participation via interview will be explored as discussed in the MaCROS study protocol. 
A ‘traffic light system’ will be used to evaluate the biological sub-study (Table 1). 
Indications to consider stopping the sub-study 
The occurrence of an unexpected serious adverse event attributed to the biological 
sub-study. E.g. leakage of stool in transit. 
Indications to continue the study without modification 
No issues implementing study protocol 
Adequate number of participants identified and recruited during the MaCROS study 
100% compliance with the delivery of stool samples 
No problems undertaking bacterial analysis and faecal calprotectin of stool samples. 
Indications to not undertake this biological sub-study within an RCT 
Unable to recruit a minimum of 5 participants once the MaCROS study has closed 
The occurrence of an unexpected serious adverse event attributed to the biological 
sub-study. e.g. leakage of stool in transit. 
Serious concerns identified when undertaking bacterial composition analysis and 
measuring faecal calprotectin of stool 
 
 
Serious concerns identified during qualitative analysis of participants/parents interview. 
 
Table 1: Table summarising the traffic light system used to evaluate the 
biological sub-study  
To not proceed Modify  Proceed 
Less than 5 participants 
recruited 
Difficulty following the 
protocol e.g. identifying 
eligible participants  
No issues implementing 
protocol 
Occurrence of unexpected 
serious adverse event 
Poor compliance with the 
delivery of stool samples 
Adequate recruitment  
Serious concerns identified 
with faecal bacterial and 
calprotectin analysis 
Concerns identified with the 
faecal bacterial and 
calprotectin analysis 
100% compliance with the 
delivery of stool samples 
Serious concerns identified 
during qualitative analysis of 
participants/parents  
Concerns identified during 
qualitative analysis of 
participants/parents  
No concerns undertaking 
bacterial analysis and faecal 





The results of this feasibility biological sub-study will inform the planning of a definitive biological 
study alongside the development of a randomised-controlled trial within the evaluatiopn of the 
MaCROS study. Quantitive and qualitative results will be used to further refine the protocol for 
biological sub-study to be undertaken alongside large RCT. Findings will be presented at relevant 
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